

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 2392664 T3**

-
- (51) Int.Cl.: **C 12 P 7/64 (2006.01)** **C 12 N 9/02 (2006.01)** **C 12 P 7/00 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2016-05-09**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2016-02-10**
- (86) Europæisk ansøgning nr.: **11154995.2**
- (86) Europæisk indleveringsdag: **2004-05-07**
- (87) Den europæiske ansøgnings publiceringsdag: **2011-12-07**
- (30) Prioritet: **2003-05-07 US 468677 P**
- (62) Stamansøgningsnr: **04751769.3**
- (84) Designerede stater: **DE DK FR GB IT NL**
- (73) Patenthaver: **E. I. du Pont de Nemours and Company, Chestnut Run Plaza , 974 Center Road , P.O. Box 2915, Wilmington, DE 19805, USA**
- (72) Opfinder: **Picataggio, Stephen, K, 17 Meadow Wood Lane, Landenberg, PA PA 19350, USA**
Zhu, Quinn, Qun, 544 Revere Road, West Chester, PA PA 19382, USA
Yadav, Narendra, S., 3704 Knole Lane, Chadds Ford, PA PA 19348, USA
- (74) Fuldmægtig i Danmark: **Marks & Clerk (Luxembourg) LLP, 44 rue de la Vallée, B.P. 1775, L-1017 Luxembourg, Luxembourg**
- (54) Benævnelse: **FREMSTILLING AF POLYUMÆTTEDE FEDTSYRER I OLIEHOLDIG GÆR**
- (56) Fremdragne publikationer:
WO-A1-98/46763
US-A- 4 677 072
Guo,: "Screening for Yeasts Incorporating the Exogenous Eicosapentaenoic and Docosahexaenoic Acids from Crude Fish Oil", JOURNAL OF BIOSCIENCE AND BIOENGINEERING, 1 January 1999 (1999-01-01), pages 184-188., XP055009864, Retrieved from the Internet: URL:http://www.sciencedirect.com/science?_ob=MiamiImageURL&_cid=272249&_user=987766&_pii=S1389172399890106&_check=y&_origin=&_coverDate=31-Dec-1999&view=c&wchp=dGLzVBA-zSkzV&md5=bcec2cb398ea6dbb752eb13b836c071b/1-s2.0-S1389172399890106-main.pdf [retrieved on 2011-10-18]
SERAPHIM PAPANIKOLAOU ET AL: "Accumulation of a Cocoa-Butter-Like Lipid by Yarrowia lipolytica Cultivated on Agro-Industrial Residues", CURRENT MICROBIOLOGY, vol. 46, no. 2, 1 February 2003 (2003-02-01), pages 124-130, XP055009483, ISSN: 0343-8651, DOI: 10.1007/s00284-002-3833-3
SAKURADANI E ET AL: "IDENTIFICATION OF DELTA 12-FATTY ACID DESATURASE FROM ARACHIDONIC ACID-PRODUCING MORTIERELLA FUNGUS BY HETEROLOGOUS EXPRESSION IN THE YEAST SACCHAROMYCES CEREVISIAE AND THE FUNGUS ASPERGILLUS ORYZAE", EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, vol. 261, no. 3, 1 January 1999 (1999-01-01), pages 812-820, XP000906848, ISSN: 0014-2956
MARAZ ANNA: "From yeast genetics to biotechnology", ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA, AKADEMIAI KIADO, BUDAPEST, HU, vol. 49, no. 4, 1 January 2002 (2002-01-01), pages 483-491,

Fortsættes ...

XP009072932, ISSN: 1217-8950

HUANG Y S ET AL: "CLONING OF 12- AND 6-DESATURASES FROM MORTIERELLA ALPINA AND RECOMBINANT PRODUCTION OF GAMMA-LINOLENIC ACID IN SACCHAROMYCES CEREVISIAE", LIPIDS, SPRINGER, US, vol. 34, no. 7, 1 July 1999 (1999-07-01), pages 649-659, XP000908862, ISSN: 0024-4201, DOI: 10.1007/S11745-999-0410-8

JURETZEK T ET AL: "VECTORS FOR GENE EXPRESSION AND AMPLIFICATION IN THE YEAST XARROWIA LIPOLYTICA", YEAST, JOHN WILEY & SONS LTD, GB, vol. 18, no. 2, 30 January 2001 (2001-01-30), pages 97-113, XP008025954, ISSN: 0749-503X

MEESAPYODSUK D ET AL: "Substrate specificity, regioselectivity and cryptoregiochemistry of plant and animal omega-3 fatty acid desaturases", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 28, no. 6, December 2000 (2000-12), pages 632-635, XP002497849, ISSN: 0300-5127

DESCRIPTION

[0001] This application claims the benefit of U.S. Provisional Application No. 60/468677, filed May 7, 2003.

FIELD OF THE INVENTION

[0002] This invention is in the field of biotechnology. More specifically, this invention pertains to the production of long chain polyunsaturated fatty acids (PUFAs) in oleaginous yeasts.

BACKGROUND OF THE INVENTION

[0003] It has long been recognized that certain polyunsaturated fatty acids, or PUFAs, are important biological components of healthy cells. For example, such PUFAs are recognized as:

- "Essential" fatty acids that can not be synthesized *de novo* in mammals and instead must be obtained either in the diet or derived by further desaturation and elongation of linoleic acid (LA) or α -linolenic acid (ALA);
- Constituents of plasma membranes of cells, where they may be found in such forms as phospholipids or triglycerides;
- Necessary for proper development, particularly in the developing infant brain, and for tissue formation and repair; and,
- Precursors to several biologically active eicosanoids of importance in mammals, including prostacyclins, eicosanoids, leukotrienes and prostaglandins.

[0004] In the 1970's, observations of Greenland Eskimos linked a low incidence of heart disease and a high intake of long-chain ω -3 PUFAs (Dyerberg, J. et al., *Amer. J. Clin Nutr.* 28:958-966 (1975); Dyerberg, J. et al., *Lancet* 2(8081):117-119 (July 15, 1978)). More recent studies have confirmed the cardiovascular protective effects of ω -3 PUFAs (Shimokawa, H., *World Rev Nutr Diet*, 88:100-108 (2001); von Schacky, C., and Dyerberg, J., *World Rev Nutr Diet*, 88:90-99 (2001)). Further, it has been discovered that several disorders respond to treatment with ω -3 fatty acids, such as the rate of restenosis after angioplasty, symptoms of inflammation and rheumatoid arthritis, asthma, psoriasis and eczema. γ -linolenic acid (GLA, an ω -6 PUFA) has been shown to reduce increases in blood pressure associated with stress and to improve performance on arithmetic tests. GLA and dihomo- γ -linolenic acid (DGLA, another ω -6 PUFA) have been shown to inhibit platelet aggregation, cause vasodilation, lower cholesterol levels and inhibit proliferation of vessel wall smooth muscle and fibrous tissue (Brenner et al., *Adv. Exp. Med. Biol.* 83:85-101 (1976)). Administration of GLA or DGLA, alone or in combination with eicosapentaenoic acid (EPA, an ω -3 PUFA), has been shown to reduce or prevent gastrointestinal bleeding and other side effects caused by non-steroidal anti-inflammatory drugs (U.S. 4,666,701). Further, GLA and DGLA have been shown to prevent or treat endometriosis and premenstrual syndrome (U.S. 4,758,592) and to treat myalgic encephalomyelitis and chronic fatigue after viral infections (U.S. 5,116,871). Other evidence indicates that PUFAs may be involved in the regulation of calcium metabolism, suggesting that they may be useful in the treatment or prevention of osteoporosis and kidney or urinary tract stones. Finally, PUFAs can be used in the treatment of cancer and diabetes (U.S. 4,826,877; Horrobin et al., *Am. J. Clin. Nutr.* 57 (Suppl.): 732S-737S (1993)).

[0005] PUFAs are generally divided into two major classes (consisting of the ω -6 and the ω -3 fatty acids) that are derived by desaturation and elongation of the essential fatty acids, linoleic acid (LA) and α -linolenic acid (ALA), respectively. Despite this common derivation from "essential" fatty acids, it is becoming increasingly apparent that the ratio of ω -6 to ω -3 fatty acids in the diet is important for maintenance of good health. Due to changes in human dietary habits, the current ratio of ω -6 to ω -3 fatty acids is approximately 10:1, whereas the preferred ratio is 2:1 (Kris-Etherton, P.M. et al., *Am. J. Clin. Nutr.* 71(1 Suppl.):179S-88S (2000); Simopoulos, A. P. et al., *Ann. Nutr. Metab.* 43:127-130 (1999); Krauss, R. M. et al. *AHA Circulation* 102:2284-2299 (2000)).

[0006] The main sources of ω -6 fatty acids are vegetable oils (e.g., corn oil, soy oil) that contain high amounts of LA. GLA is found in the seeds of a number of plants, including evening primrose (*Oenothera biennis*), borage (*Borago officinalis*) and black currants (*Ribes nigrum*). Microorganisms in the genera *Mortierella* (filamentous fungus), *Entomophthora*, *Pythium* and *Porphyridium* (red alga) can be used for commercial production of the ω -6 fatty acid, arachidonic acid (ARA). The fungus *Mortierella alpina*, for example, is used to produce an oil containing ARA, while U.S. 5,658,767 (Martek Corporation) teaches a method for the production of an oil containing ARA comprising cultivating *Pythium insidiosum* in a culture medium containing a carbon and nitrogen source.

[0007] The ω -3 PUFAs of importance include EPA and docosahexaenoic acid (DHA), both of which are found in different types of fish oil and marine plankton. U.S. 5,244,921 (Martek Corporation) describes a process for producing an edible oil containing EPA by cultivating heterotrophic diatoms in a fermentor, specifically *Cyclotella* sp. and *Nitzschia* sp. DHA can be obtained from cold water marine fish, egg yolk fractions and by cultivation of certain heterotrophic microalgae of the class Dinophyceae, specifically, *Cryptothecodinium* sp. such as *C. cohnii* (U.S. 5,492,938 and U.S. 5,407,957). Stearidonic acid (STA), a precursor to EPA and DHA, can be found in marine oils and plant seeds; its commercial sources include production in the genera *Trichodesma* and *Echium*. Other sources of ω -3 acids are found in flaxseed oil and walnut oil, each containing predominantly ALA.

[0008] Despite a variety of commercial sources of PUFAs from natural sources, there are several disadvantages associated with these methods of production. First, natural sources such as fish and plants tend to have highly heterogeneous oil compositions. The oils obtained from these sources therefore can require extensive purification to separate or enrich one or more of the desired PUFAs. Fish oils commonly have unpleasant tastes and odors, which may be impossible to separate economically from the desired product and can render such products unacceptable as food supplements. Unpleasant tastes and odors can make medical regimens based on ingestion of high dosages undesirable, and may inhibit compliance by the patient. Furthermore, fish may accumulate environmental pollutants and ingestion of fish oil capsules as a dietary supplement may result in ingestion of undesired contaminants. Natural sources are also subject to uncontrollable fluctuations in availability (e.g., due to weather, disease, or over-fishing in the case of fish stocks); and, crops that produce PUFAs often are not competitive economically with hybrid crops developed for food production. Large-scale fermentation of some organisms that naturally produce PUFAs (e.g., *Porphyridium*, *Mortierella*) can also be expensive and/or difficult to cultivate on a commercial scale.

[0009] As a result of the limitations described above, extensive work has been conducted toward: 1.) the development of recombinant sources of PUFAs that are easy to produce commercially; and 2.) modification of fatty acid biosynthetic pathways, to enable production of desired PUFAs.

[0010] Advances in the isolation, cloning and manipulation of fatty acid desaturase and elongase genes from various organisms have been made over the last several years. Knowledge of these gene sequences offers the prospect of producing a desired fatty acid and/or fatty acid composition in novel host organisms that do not naturally produce PUFAs. The literature reports a number of examples in *Saccharomyces cerevisiae*, such as:

1. 1. Domergue, F. et al. (Eur. J. Biochem. 269:4105-4113 (2002)), wherein two desaturases from the marine diatom *Phaeodactylum tricornutum* were cloned into *S. cerevisiae*, leading to the production of EPA;
2. 2. Beaudoin F., et al. (Proc. Natl. Acad. Sci. U.S.A. 97(12):6421-6 (2000)), wherein the ω -3 and ω -6 PUFA biosynthetic pathways were reconstituted in *S. cerevisiae*, using genes from *Caenorhabditis elegans*;
3. 3. Dyer, J.M. et al. (Appl. Environ. Microbiol., 59:224-230 (2002)), wherein plant fatty acid desaturases (*FAD2* and *FAD3*) were expressed in *S. cerevisiae*, leading to the production of ALA; and
4. 4. U.S. 6,136,574 (Knutzon et al., Abbott Laboratories), wherein one desaturase from *Brassica napus* and two desaturases from the fungus *Mortierella alpina* were cloned into *S. cerevisiae*, leading to the production of LA, GLA, ALA and STA.

There remains a need, however, for an appropriate microbial system in which these types of genes can be expressed to provide for economical production of commercial quantities of one or more PUFAs. Additionally, a need exists for oils enriched in specific PUFAs, notably EPA and DHA.

[0011] Many microorganisms (including algae, bacteria, molds and yeasts) can synthesize oils in the ordinary course of cellular metabolism. Thus, oil production involves cultivating the microorganism in a suitable culture medium to allow for oil synthesis, followed by separation of the microorganism from the fermentation medium and treatment for recovery of the intracellular oil. Attempts have been made to optimize production of fatty acids by fermentive means involving varying such parameters as microorganisms used, media and conditions that permit oil production. However, these efforts have proved largely unsuccessful in improving yield of oil or the ability to control the characteristics of the oil composition produced.

[0012] One class of microorganisms that has not been previously examined as a production platform for PUFAs, however, are the oleaginous yeasts. These organisms can accumulate oil up to 80% of their dry cell weight. The technology for growing oleaginous yeast with high oil content is well developed (for example, see EP 0 005 277B1; Ratledge, C., Prog. Ind. Microbiol. 16:119-206 (1982)), and may offer a cost advantage compared to commercial micro-algae fermentation for production of ω -3 or ω -6 PUFAs. Whole yeast cells may also represent a convenient way of encapsulating ω -3 or ω -6 PUFA-enriched oils for use in functional foods and animal feed supplements.

[0013] Despite the advantages noted above, oleaginous yeast are naturally deficient in ω -6 and ω -3 PUFAs, since naturally

produced PUFAs in these organisms are limited to 18:2 fatty acids (and less commonly, 18:3 fatty acids). Thus, the problem to be solved is to develop an oleaginous yeast that accumulates oils enriched in ω -3 and/or ω -6 fatty acids. Toward this end, it is necessary to introduce desaturases and elongases that allow for the synthesis and accumulation of ω -3 and/or ω -6 fatty acids in oleaginous yeasts. Although advances in the art of genetic engineering have been made, such techniques have not been developed for oleaginous yeasts. Thus, one must overcome problems associated with the use of these particular host organisms for the production of PUFAs.

[0014] Applicants have solved the stated problem by demonstrating production of PUFAs in the host *Yarrowia lipolytica*, following the introduction of a heterologous ω -6 and/or ω -3 biosynthetic pathway. Specifically, ARA (representative of ω -6 fatty acids) and EPA (representative of ω -3 fatty acids) were produced herein, to exemplify the techniques of the invention.

SUMMARY OF THE INVENTION

[0015] The present invention provides methods for the expression of enzymes comprising the ω -3 fatty acid biosynthetic pathway in an oleaginous yeast host for the production of ω -3 fatty acids. Accordingly, the invention provides a transformed oleaginous yeast comprising heterologous genes encoding enzymes of the ω -3 fatty acid biosynthetic pathway, wherein the yeast is an oleaginous *Yarrowia lipolytica* that accumulates at least 25% of its dry cell weight as oil, wherein the heterologous genes encode Δ 17 desaturase, Δ 5 desaturase and elongase enzymes of the ω -3 fatty acid biosynthetic pathway wherein the oleaginous *Yarrowia lipolytica* produces substrates for the enzymes, and wherein said yeast is capable of producing ω -3 polyunsaturated fatty acids that are not naturally produced by said yeast.

[0016] Production of specific ω -6 fatty acids such as linoleic acid (LA), γ -linolenic acid (GLA), dihomo- γ -linoleic acid (DGLA) and arachidonic acid (ARA) may be by *de novo* biosynthesis or single step enzymatic reactions from the appropriate precursors. The present invention allows for the production of specific ω -3 fatty acids such as α -linoleic acid (ALA), stearidonic acid (STA), eicosatetraenoic acid (ETA), eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA) and docosahexaenoic acid by single step enzymatic reactions from the appropriate precursors.

BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE DESCRIPTIONS

[0017]

Figure 1 shows a schematic illustration of the biochemical mechanism for lipid accumulation in oleaginous yeast.

Figure 2 illustrates the ω -3/ ω -6 fatty acid biosynthetic pathway.

Figure 3 illustrates the construction of plasmid vector pY5 for gene expression in *Yarrowia lipolytica*.

Figure 4 illustrates the construction of plasmid vectors pY5-4 and pY5-13 for gene expression in *Y. lipolytica*.

Figure 5 is a schematic presentation of the construction of intermediate vector pYZM5CHPPA.

Figure 6 show a comparison between the DNA sequence of the *Saprolegnia diclina* Δ 17 desaturase gene and the synthetic gene codon-optimized for expression in *Y. lipolytica*.

Figure 7 illustrates the favored consensus sequences around the translation initiation codon 'ATG' in *Y. lipolytica*.

Figure 8 illustrates the strategy utilized for *in vitro* synthesis of the codon-optimized Δ 17 desaturase gene.

Figure 9 shows plasmids for expression of the synthetic codon-optimized and wildtype Δ 17 desaturase genes in *Y. lipolytica*.

Figures 10A and 10B show the results of gas chromatographic analysis of fatty acids produced in *Y. lipolytica* transformed with the wildtype and synthetic codon-optimized Δ 17 desaturase genes, respectively.

Figure 11 is a schematic presentation of the construction of intermediate vector pY24-4.

Figure 12 is a schematic presentation of the construction of intermediate vector pYZV16.

Figure 13 is a schematic presentation of the construction of integration vector pYZM5EL6.

Figure 14 is a schematic presentation of the construction of integration vectors pYZV5EL6 and pYZV5EL6/17.

Figure 15 is a chromatogram illustrating the production of ARA from an engineered *Y. lipolytica*.

Figure 16 is a chromatogram illustrating the production of EPA from an engineered *Y. lipolytica*.

[0018] The invention can be more fully understood from the following detailed description and the accompanying sequence descriptions, which form a part of this application.

[0019] The following sequences comply with 37 C.F.R. §1.821-1.825 ("Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures - the Sequence Rules") and are consistent with World Intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the EPO and PCT (Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administrative Instructions). The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

[0020] SEQ ID NO:1 shows the DNA sequence of the *Mortierella alpina* Δ6 desaturase gene, while SEQ ID NO:2 shows the amino acid sequence of the *M. alpina* Δ6 desaturase.

[0021] SEQ ID NO:3 shows the DNA sequence of the *Mortierella alpina* Δ5 desaturase gene, while SEQ ID NO:4 shows the amino acid sequence of the *M. alpina* Δ5 desaturase.

[0022] SEQ ID NO:5 shows the DNA sequence of the *Saprolegnia diclina* Δ17 desaturase gene, while SEQ ID NO:6 shows the corresponding amino acid sequence of the *S. diclina* Δ17 desaturase.

[0023] SEQ ID NO:7 shows the DNA sequence of the *Mortierella alpina* high affinity elongase gene, while SEQ ID NO:8 shows the amino acid sequence of the *M. alpina* high affinity elongase.

[0024] SEQ ID NO:9 shows the DNA sequence of the synthetic Δ17 desaturase gene codon-optimized for expression in *Yarrowia lipolytica*.

[0025] SEQ ID NOs:10-31 correspond to the 11 pairs of oligonucleotides that together comprise the entire codon-optimized coding region of the *S. diclina* Δ17 desaturase gene (e.g., D17-1A, D17-1B, D17-2A, D17-2B, D17-3A, D17-3B, D17-4A, D17-4B, D17-5A, D17-5B, D17-6A, D17-6B, D17-7A, D17-7B, D17-8A, D17-8B, D17-9A, D17-9B, D17-10A, D17-10B, D17-11A and D17-11B, respectively).

[0026] SEQ ID NOs:32-37 correspond to primers D17-1, D17-4R, D17-5, D17-8D, D17-8U and D17-11, respectively, used for PCR amplification during synthesis of the codon-optimized Δ17 desaturase gene.

[0027] SEQ ID NOs:38 and 39 correspond to primers TEF5' and TEF3', respectively, used to isolate the TEF promoter.

[0028] SEQ ID NOs:40 and 41 correspond to primers XPR5' and XPR3', respectively, used to isolate the XPR2 transcriptional terminator.

[0029] SEQ ID NOs:42 and 43 correspond to primers YL21A and YL22, used for amplifying the wild type Δ17 desaturase gene of *S. diclina* from plasmid pRSP19.

[0030] SEQ ID NOs:44 and 45 correspond to primers YL53 and YL54, respectively, used for site-directed mutagenesis to generate pYSD17M.

[0031] SEQ ID NOs:46 and 47 correspond to primers KU5 and KU3, respectively, used for amplifying a 1.7 kB DNA fragment (SEQ ID NO:48; amino acid sequence provided as SEQ ID NO:49) containing the *Yarrowia* URA3 gene.

[0032] SEQ ID NOs:50 and 51 correspond to primers KI5 and KI3, respectively, used for amplifying a 1.1 kB DNA fragment (SEQ ID NO:52; amino acid sequence provided as SEQ ID NO:53) containing the conjugase gene of *Impatiens balsama*.

[0033] SEQ ID NOs:54 and 55 correspond to primers KTI5 and KTI3, respectively, used for amplifying a 1.7 kB DNA fragment (SEQ ID NO:56; amino acid sequence provided as SEQ ID NO:57) containing a TEF::conjugase::XPR chimeric gene.

[0034] SEQ ID NOs:58 and 59 correspond to primers KH5 and KH3, respectively, used for amplifying a 1 kB DNA fragment (SEQ ID NO:60; amino acid sequence provided as SEQ ID NO:61) containing the *E. coli* hygromycin resistance gene.

[0035] SEQ ID NOs:62 and 63 correspond to primers KTH5 and KTH3, respectively, used for amplifying a 1.6 kB DNA fragment (SEQ ID NO:64; amino acid sequence provided as SEQ ID NO:65) containing the TEF::HPT::XPR fusion gene.

[0036] SEQ ID NOs:66 and 67 correspond to the 401 bp of 5'-sequence and 568 bp of 3'-sequence of the *Yarrowia lipolytica* URA3 gene, respectively, used to direct integration of expression cassettes into the Ura loci of the *Yarrowia* genome.

[0037] SEQ ID NOs:68-71 correspond to primers YL63, YL64, YL65 and YL66, respectively, used for site-directed mutagenesis to generate pY24-4.

[0038] SEQ ID NOs:72 and 73 correspond to primers YL11 and YL12, respectively, used for amplifying the *M. alpina* $\Delta 5$ desaturase.

[0039] SEQ ID NOs:74-77 correspond to primers YL81, YL82, YL83 and YL84, respectively, used for site-directed mutagenesis to generate pYZM5CH.

[0040] SEQ ID NOs:78 and 79 correspond to primers YL105 and YL106, respectively, used for site-directed mutagenesis to generate pYZM5CHPP.

[0041] SEQ ID NOs:80 and 81 correspond to primers YL119 and YL120, respectively, used for site-directed mutagenesis to generate pYZM5CHPPA.

[0042] SEQ ID NOs:82 and 83 correspond to primers YL121 and YL122, respectively, used for amplifying 440 bp of '-non-coding DNA sequence (SEQ ID NO:84) upstream from the *Y. lipolytica* URA3 gene.

[0043] SEQ ID NOs:85 and 86 correspond to primers YL114 and YL115, respectively, used for site-directed mutagenesis to generate pYZV5 and pYZV5P.

[0044] SEQ ID NO:87 corresponds to a 5.2 kB DNA fragment suitable for integration and expression of the *M. alpina* $\Delta 5$ desaturase gene in the *Yarrowia lipolytica* genome.

[0045] SEQ ID NOs:88-91 correspond to primers YL61, YL62, YL69 and YL70, respectively, used for site-directed mutagenesis to generate pY58BH.

[0046] SEQ ID NOs:92-95 correspond to primers YL77, YL78, YL79A and YL80A, respectively, used for site-directed mutagenesis to generate pY54PC.

[0047] SEQ ID NO:96 corresponds to a 8.9 kB DNA fragment suitable for integration and coordinate expression of the *M. alpina* $\Delta 6$ desaturase, *M. alpina* elongase and *M. alpina* $\Delta 5$ desaturase genes in the *Yarrowia lipolytica* genome.

[0048] SEQ ID NOs:97-100 correspond to primers YL101, YL102, YL103 and YL104, respectively, used for site-directed mutagenesis to generate pYSD17SPC.

[0049] SEQ ID NO: 101 corresponds to a 10.3 kB DNA fragment suitable for integration and coordinate expression of the *M. alpina* $\Delta 6$ desaturase, *M. alpina* elongase, *M. alpina* $\Delta 5$ desaturase and codon-optimized $\Delta 17$ desaturase genes in the *Yarrowia lipolytica* genome.

[0050] SEQ ID NOs:102-113 correspond to primers YL1, YL2, YL3, YL4, YL5, YL6, YL7, YL8, YL9, YL10, YL23 and YL24, respectively, used for plasmid construction.

[0051] SEQ ID NO:114 shows the DNA sequence of the *Saprolegnia diclina* $\Delta 5$ desaturase gene, while SEQ ID NO:115 shows the amino acid sequence of the *S. diclina* $\Delta 5$ desaturase.

[0052] SEQ ID NOs:116, 117, 120, 121, 124 and 125 correspond to primers YL13A, YL14, YL19A, YL20, YL15 and YL16B, respectively, used for cloning various $\Delta 5$ desaturases.

[0053] SEQ ID NO:118 shows the DNA sequence of the *Isochrysis galbana* $\Delta 5$ desaturase gene, while SEQ ID NO:119 shows the amino acid sequence of the *I. galbana* $\Delta 5$ desaturase.

[0054] SEQ ID NO: 122 shows the DNA sequence of the *Thraustochytrium aureum* $\Delta 5$ desaturase gene, while SEQ ID NO:123 shows the amino acid sequence of the *T. aureum* $\Delta 5$ desaturase.

[0055] SEQ ID NO:126 corresponds to the codon-optimized translation initiation site for genes optimally expressed in *Yarrowia sp.*

DETAILED DESCRIPTION OF THE INVENTION

[0056] In accordance with the subject invention, Applicants provide a transformed oleaginous yeast for the production of ω -3 fatty acids. Specifically, Applicants provide a transformed oleaginous yeast for production of eicosatetraenoic acid, eicosapentaenoic acid, docosapentaenoic acid and docosahexaenoic acid. In general, functional ω -3/ ω -6 fatty acid biosynthetic pathways encoded by genes conferring $\Delta 17$ desaturase, $\Delta 6$ desaturase, $\Delta 5$ desaturase, $\Delta 9$ desaturase, $\Delta 12$ desaturase, $\Delta 15$ desaturase, $\Delta 4$ desaturase and elongase activities can be introduced into oleaginous yeast hosts for recombinant expression. Thus, oleaginous yeasts can be engineered to enable production of any PUFA composition that is desired.

[0057] The subject invention finds many applications. PUFAs, or derivatives thereof, made by the methodology disclosed herein can be used as dietary substitutes, or supplements, particularly infant formulas, for patients undergoing intravenous feeding or for preventing or treating malnutrition. Alternatively, the purified PUFAs (or derivatives thereof) may be incorporated into cooking oils, fats or margarines formulated so that in normal use the recipient would receive the desired amount for dietary supplementation. The PUFAs may also be incorporated into infant formulas, nutritional supplements or other food products and may find use as anti-inflammatory or cholesterol lowering agents. Optionally, the compositions may be used for pharmaceutical use (human or veterinary). In this case, the PUFAs are generally administered orally but can be administered by any route by which they may be successfully absorbed, e.g., parenterally (e.g., subcutaneously, intramuscularly or intravenously), rectally, vaginally or topically (e.g., as a skin ointment or lotion).

[0058] Supplementation of humans or animals with PUFAs produced by recombinant means can result in increased levels of the added PUFAs, as well as their metabolic progeny. For example, treatment with arachidonic acid (ARA) can result not only in increased levels of ARA, but also downstream products of ARA such as prostaglandins. Complex regulatory mechanisms can make it desirable to combine various PUFAs, or add different conjugates of PUFAs, in order to prevent, control or overcome such mechanisms to achieve the desired levels of specific PUFAs in an individual.

Definitions

[0059] In this disclosure, a number of terms and abbreviations are used. The following definitions are provided.

[0060] "Open reading frame" is abbreviated ORF.

[0061] "Polymerase chain reaction" is abbreviated PCR.

[0062] "American Type Culture Collection" is abbreviated ATCC. "Polyunsaturated fatty acid(s)" is abbreviated PUFA(s).

[0063] The term "fatty acids" refers to long chain aliphatic acids (alkanoic acids) of varying chain lengths, from about C₁₂ to C₂₂ (although both longer and shorter chain-length acids are known). The predominant chain lengths are between C₁₆ and C₂₂. The structure of a fatty acid is represented by a simple notation system of "X:Y", where X is the total number of carbon (C) atoms and Y is the number of double bonds.

[0064] Generally, fatty acids are classified as saturated or unsaturated. The term "saturated fatty acids" refers to those fatty acids that have no "double bonds" between their carbon backbone. In contrast, "unsaturated fatty acids" are *cis-isomers* that have "double bonds" along their carbon backbones. "Monounsaturated fatty acids" have only one "double bond" along the carbon backbone (e.g., usually between the 9th and 10th carbon atom as for palmitoleic acid (16:1) and oleic acid (18:1)), while

"polyunsaturated fatty acids" (or "PUFAs") have at least two double bonds along the carbon backbone (e.g., between the 9th and 10th, and 12th and 13th carbon atoms for linoleic acid (18:2); and between the 9th and 10th, 12th and 13th, and 15th and 16th for α -linolenic acid (18:3)).

[0065] "PUFAs" can be classified into two major families (depending on the position (n) of the first double bond nearest the methyl end of the fatty acid carbon chain). Thus, the " ω -6 fatty acids" (ω -6 or *n*-6) have the first unsaturated double bond six carbon atoms from the omega (methyl) end of the molecule and additionally have a total of two or more double bonds, with each subsequent unsaturation occurring 3 additional carbon atoms toward the carboxyl end of the molecule. In contrast, the " ω -3 fatty acids" (ω -3 or *n*-3) have the first unsaturated double bond three carbon atoms away from the omega end of the molecule and additionally have a total of three or more double bonds, with each subsequent unsaturation occurring 3 additional carbon atoms toward the carboxyl end of the molecule.

[0066] For the purposes of the present disclosure, the omega-reference system will be used to indicate the number of carbons, the number of double bonds and the position of the double bond closest to the omega carbon, counting from the omega carbon (which is numbered 1 for this purpose). This nomenclature is shown below in Table 1, in the column titled "Shorthand Notation". The remainder of the Table summarizes the common names of ω -3 and ω -6 fatty acids, the abbreviations that will be used throughout the specification and each compounds' chemical name.

Table 1

Nomenclature of Polyunsaturated Fatty Acids			
Common Name	Abbreviation	Chemical Name	Shorthand Notation
Linoleic	LA	<i>cis</i> -9,12-octadecadienoic	18:2 ω -6
γ -Linoleic	GLA	<i>cis</i> -6, 9, 12-octadecatrienoic	18:3 ω -6
Dihomo- γ -Linoleic	DGLA	<i>cis</i> -8, 11, 14-eicosatrienoic	20:3 ω -6
Arachidonic	ARA	<i>cis</i> -5, 8, 11, 14-eicosatetraenoic	20:4 ω -6
α -Linolenic	ALA	<i>cis</i> -9, 12, 15-octadecatrienoic	18:3 ω -3
Stearidonic	STA	<i>cis</i> -6, 9, 12, 15-octadecatetraenoic	18:4 ω -3
Eicosatetraenoic	ETA	<i>cis</i> -8, 11, 14, 17-eicosatetraenoic	20:4 ω -3
Eicosapentaenoic	EPA	<i>cis</i> -5, 8, 11, 14, 17-eicosapentaenoic	20:5 ω -3
Docosapentaenoic	DPA	<i>cis</i> -7, 10, 13, 16, 19-docosapentaenoic	22:5 ω -3
Docosahexaenoic	DHA	<i>cis</i> -4, 7, 10, 13, 16, 19-docosahexaenoic	22:6 ω -3

[0067] The term "essential fatty acid" refers to a particular PUFA that an organism must ingest in order to survive, being unable to synthesize the particular essential fatty acid *de novo*. For example, mammals can not synthesize the essential fatty acid LA (18:2, ω -6). Other essential fatty acids include GLA (ω -6), DGLA (ω -6), ARA (ω -6), EPA (ω -3) and DHA (ω -3).

[0068] The term "fat" refers to a lipid substance that is solid at 25 °C and usually saturated.

[0069] The term "oil" refers to a lipid substance that is liquid at 25 °C and usually polyunsaturated. PUFAs are found in the oils of some algae, oleaginous yeasts and filamentous fungi. "Microbial oils" or "single cell oils" are those oils naturally produced by microorganisms during their lifespan. Such oils can contain long chain PUFAs.

[0070] The term "PUFA biosynthetic pathway enzyme" refers to any of the following enzymes (and genes which encode said enzymes) associated with the biosynthesis of a PUFA, including: a Δ 4 desaturase, a Δ 5 desaturase, a Δ 6 desaturase, a Δ 12 desaturase, a Δ 15 desaturase, a Δ 17 desaturase, a Δ 9 desaturase and/or an elongase.

[0071] The term " ω -3/ ω -6 fatty acid biosynthetic pathway" refers to a set of genes which, when expressed under the appropriate conditions encode enzymes that catalyze the production of either or both ω -3 and ω -6 fatty acids. Typically the genes involved in the ω -3/ ω -6 fatty acid biosynthetic pathway encode some or all of the following enzymes: Δ 12 desaturase, Δ 6 desaturase, elongase, Δ 5 desaturase, Δ 17 desaturase, Δ 15 desaturase, Δ 9 desaturase and Δ 4 desaturase. A representative pathway is illustrated in Figure 2, which demonstrates how both ω -3 and ω -6 fatty acids may be produced from a common source. The term "functional" as used herein in context with the ω -3/ ω -6 fatty acid biosynthetic pathway means that some or all of the genes in the pathway express active enzymes. It should be understood that " ω -3/ ω -6 fatty acid biosynthetic pathway" or "functional ω -3/ ω -6

fatty acid biosynthetic pathway" does not imply that all the genes listed in this paragraph are required as a number of fatty acid products will only require the expression of a subset of the genes of this pathway.

[0072] The term "desaturase" refers to a polypeptide component of a multi-enzyme complex that can desaturate one or more fatty acids to produce a mono- or polyunsaturated fatty acid or precursor of interest. Despite use of the omega-reference system throughout the specification to refer to specific fatty acids, it is more convenient to indicate the activity of a desaturase by counting from the carboxyl end of the substrate using the delta-system. Of particular interest herein are: 1.) $\Delta 17$ desaturases that desaturate a fatty acid between the 17th and 18th carbon atom numbered from the carboxyl-terminal end of the molecule and which, for example, catalyze the conversion of ARA to EPA and/or DGLA to ETA; 2.) $\Delta 6$ desaturases that catalyze the conversion of LA to GLA and/or ALA to STA; 3.) $\Delta 5$ desaturases that catalyze the conversion of DGLA to ARA and/or ETA to EPA; 4.) $\Delta 4$ desaturases that catalyze the conversion of DPA to DHA; 5.) $\Delta 12$ desaturases that catalyze the conversion of oleic acid to LA; 6.) $\Delta 15$ desaturases that catalyze the conversion of LA to ALA; and 7.) $\Delta 9$ desaturases that catalyze the conversion of palmitate to palmitoleic acid (16:1) and/or stearate to oleic acid (18:1).

[0073] The term "elongase" refers to a polypeptide component of a multi-enzyme complex that can elongate a fatty acid carbon chain to produce a mono- or polyunsaturated fatty acid that is 2 carbons longer than the fatty acid substrate that the elongase acts upon. This process of elongation occurs in a multi-step mechanism in association with fatty acid synthase, whereby CoA is the acyl carrier (Lassner et al., *The Plant Cell* 8:281-292 (1996)). Briefly, malonyl-CoA is condensed with a long-chain acyl-CoA to yield CO₂ and a β -ketoacyl-CoA (where the acyl moiety has been elongated by two carbon atoms). Subsequent reactions include reduction to β -hydroxyacyl-CoA, dehydration to an enoyl-CoA and a second reduction to yield the elongated acyl-CoA. Examples of reactions catalyzed by elongases are the conversion of GLA to DGLA, STA to ETA and EPA to DPA. Accordingly, elongases can have different specificities (e.g., a C_{16/18} elongase will prefer a C₁₆ substrate, a C_{18/20} elongase will prefer a C₁₈ substrate and a C_{20/22} elongase will prefer a C₂₀ substrate).

[0074] The term "high affinity elongase" refers to an elongase whose substrate specificity is preferably for GLA (with DGLA as a product of the elongase reaction). One such elongase is described in WO 00/12720.

[0075] The terms "conversion efficiency" and "percent substrate conversion" refer to the efficiency by which a particular enzyme (e.g., a desaturase or elongase) can convert substrate to product. The conversion efficiency is measured according to the following formula:

$$([product]/[substrate+product])*100$$
, where 'product' includes the

where 'product' includes the immediate product and all products in the pathway derived from it.

[0076] The term "oleaginous" refers to those organisms that tend to store their energy source in the form of lipid (Weete, In: *Fungal Lipid Biochemistry*, 2nd Ed., Plenum, 1980). Generally, the cellular PUFA content of these microorganisms follows a sigmoid curve, wherein the concentration of lipid increases until it reaches a maximum at the late logarithmic or early stationary growth phase and then gradually decreases during the late stationary and death phases (Yongmanitchai and Ward, *Appl. Environ. Microbiol.* 57:419-25 (1991)).

[0077] The term "oleaginous yeast" refers to those microorganisms classified as yeasts that can accumulate at least 25% of their dry cell weight as oil. Examples of oleaginous yeast include, but are not limited to, the following genera: *Yarrowia*, *Candida*, *Rhodotorula*, *Rhodospiridium*, *Cryptococcus*, *Trichosporon* and *Lipomyces*.

[0078] The term "fermentable carbon source" means a carbon source that a microorganism will metabolize to derive energy. Typical carbon sources for use in the invention include, but are not limited to: monosaccharides, oligosaccharides, polysaccharides, alkanes, fatty acids, esters of fatty acids, monoglycerides, diglycerides, triglycerides, carbon dioxide, methanol, formaldehyde, formate and carbon-containing amines.

[0079] As used herein, an "isolated nucleic acid fragment" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.

[0080] A "substantial portion" of an amino acid or nucleotide sequence is that portion comprising enough of the amino acid sequence of a polypeptide or the nucleotide sequence of a gene to putatively identify that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., *J. Mol. Biol.* 215:403-410 (1993)). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to identify putatively a

polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 20-30 contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12-15 bases may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises enough of the sequence to specifically identify and/or isolate a nucleic acid fragment comprising the sequence.

[0081] The term "complementary" is used to describe the relationship between nucleotide bases that are capable of hybridizing to one another. For example, with respect to DNA, adenosine is complementary to thymine and cytosine is complementary to guanine.

[0082] "Codon degeneracy" refers to the nature in the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

[0083] "Chemically synthesized", as related to a sequence of DNA, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of DNA may be accomplished using well-established procedures; or, automated chemical synthesis can be performed using one of a number of commercially available machines. "Synthetic genes" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form gene segments that are then enzymatically assembled to construct the entire gene. Accordingly, the genes can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell, where sequence information is available.

[0084] "Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure. A "codon-optimized gene" is a gene having its frequency of codon usage designed to mimic the frequency of preferred codon usage of the host cell.

[0085] "Coding sequence" refers to a DNA sequence that codes for a specific amino acid sequence. "Suitable regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, polyadenylation recognition sequences, RNA processing sites, effector binding sites and stem-loop structures.

[0086] "Promoter" refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters that cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.

[0087] The term "3' non-coding sequences" or "transcription terminator" refers to DNA sequences located downstream of a coding sequence. This includes polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The 3' region can influence the transcription, RNA

processing or stability, or translation of the associated coding sequence.

[0088] "RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from post-transcriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA" or "mRNA" refers to the RNA that is without introns and that can be translated into protein by the cell. "cDNA" refers to a double-stranded DNA that is complementary to, and derived from, mRNA. "Sense" RNA refers to RNA transcript that includes the mRNA and so can be translated into protein by the cell. "Antisense RNA" refers to a RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. 5,107,065; WO 99/28508). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, or the coding sequence. "Functional RNA" refers to antisense RNA, ribozyme RNA, or other RNA that is not translated and yet has an effect on cellular processes.

[0089] The term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

[0090] The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragments of the invention. Expression may also refer to translation of mRNA into a polypeptide.

[0091] "Transformation" refers to the transfer of a nucleic acid molecule into a host organism, resulting in genetically stable inheritance. The nucleic acid molecule may be a plasmid that replicates autonomously, for example; or, it may integrate into the genome of the host organism. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" or "recombinant" or "transformed" organisms.

[0092] The terms "plasmid", "vector" and "cassette" refer to an extra chromosomal element often carrying genes that are not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA fragments. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitates transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.

[0093] The term "sequence analysis software" refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences. "Sequence analysis software" may be commercially available or independently developed. Typical sequence analysis software will include, but is not limited to: 1.) the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, WI); 2.) BLASTP, BLASTN, BLASTX (Altschul et al., J. Mol. Biol. 215:403-410 (1990)); 3.) DNASTAR (DNASTAR, Inc. Madison, WI); 4.) Sequencher (Gene Codes Corporation, Ann Arbor, MI); and 5.) the FASTA program incorporating the Smith-Waterman algorithm (W. R. Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Plenum: New York, NY). Within the context of this application it will be understood that where sequence analysis software is used for analysis, that the results of the analysis will be based on the "default values" of the program referenced, unless otherwise specified. As used herein "default values" will mean any set of values or parameters that originally load with the software when first initialized.

[0094] Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described by Sambrook, J., Fritsch, E. F. and Maniatis, T., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory: Cold Spring Harbor, NY (1989) (hereinafter "Maniatis"); by Silhavy, T. J., Bannan, M. L. and Enquist, L. W., Experiments with Gene Fusions, Cold Spring Harbor Laboratory: Cold Spring Harbor, NY (1984); and by Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience (1987).

Microbial Biosynthesis Of Fatty Acids

[0095] In general, lipid accumulation in oleaginous microorganisms is triggered in response to the overall carbon to nitrogen ratio present in the growth medium (Figure 1). When cells have exhausted available nitrogen supplies (e.g., when the carbon to nitrogen ratio is greater than about 40), the depletion of cellular adenosine monophosphate (AMP) leads to the cessation of AMP-dependent isocitrate dehydrogenase activity in the mitochondria and the accumulation of citrate, transport of citrate into the cytosol and subsequent cleavage of the citrate by ATP-citrate lyase to yield acetyl-CoA and oxaloacetate. Acetyl-CoA is the principle building block for *de novo* biosynthesis of fatty acids. Although any compound that can effectively be metabolized to produce acetyl-CoA can serve as a precursor of fatty acids, glucose is the primary source of carbon in this type of reaction (Figure 1). Glucose is converted to pyruvate via glycolysis and pyruvate is then transported into the mitochondria where it can be converted to acetyl-CoA by pyruvate dehydrogenase ("PD"). Since acetyl-CoA cannot be transported directly across the mitochondrial membrane into the cytoplasm, the two carbons from acetyl-CoA condense with oxaloacetate to yield citrate (catalyzed by citrate synthase). Citrate is transported directly into the cytoplasm, where it is cleaved by ATP-citrate lyase to regenerate acetyl-CoA and oxaloacetate. The oxaloacetate reenters the tricarboxylic acid cycle, via conversion to malate.

[0096] The synthesis of malonyl-CoA is the first committed step of fatty acid biosynthesis, which takes place in the cytoplasm. Malonyl-CoA is produced via carboxylation of acetyl-CoA by acetyl-CoA carboxylase ("ACC"). Fatty acid synthesis is catalyzed by a multi-enzyme fatty acid synthase complex ("FAS") and occurs by the condensation of eight two-carbon fragments (acetyl groups from acetyl-CoA) to form a 16-carbon saturated fatty acid, palmitate. More specifically, FAS catalyzes a series of 7 reactions, which involve the following (Smith, S. FASEB J., 8(15):1248-59 (1994)):

1. 1. Acetyl-CoA and malonyl-CoA are transferred to the acyl carrier peptide (ACP) of FAS. The acetyl group is then transferred to the malonyl group, forming β -ketobutyryl-ACP and releasing CO₂.
2. 2. The β -ketobutyryl-ACP undergoes reduction (via β -ketoacyl reductase) and dehydration (via β -hydroxyacyl dehydratase) to form a *trans*-monounsaturated fatty acyl group.
3. 3. The double bond is reduced by NADPH, yielding a saturated fatty-acyl group two carbons longer than the initial one. The butyryl-group's ability to condense with a new malonyl group and repeat the elongation process is then regenerated.
4. 4. When the fatty acyl group becomes 16 carbons long, a thioesterase activity hydrolyses it, releasing free palmitate.

[0097] Palmitate (16:0) is the precursor of longer chain saturated and unsaturated fatty acids (e.g., stearic (18:0), palmitoleic (16:1) and oleic (18:1) acids) through the action of elongases and desaturases present in the endoplasmic reticulum membrane. Palmitate and stearate are converted to their unsaturated derivatives, palmitoleic (16:1) and oleic (18:1) acids, respectively, by the action of a $\Delta 9$ desaturase.

[0098] Triacylglycerols (the primary storage unit for fatty acids) are formed by the esterification of two molecules of acyl-CoA to glycerol-3-phosphate to yield 1,2-diacylglycerol phosphate (commonly identified as phosphatidic acid) (Figure 1). The phosphate is then removed, by phosphatidic acid phosphatase, to yield 1,2-diacylglycerol. Triacylglycerol is formed upon the addition of a third fatty acid by the action of a diacylglycerol-acyl transferase.

Biosynthesis Of Omega-3 And Omega-6 Fatty Acids

[0099] Simplistically, the metabolic process that converts LA to GLA, DGLA and ARA (the ω -6 pathway) and ALA to STA, ETA, EPA and DHA (the ω -3 pathway) involves elongation of the carbon chain through the addition of carbon atoms and desaturation of the molecule through the addition of double bonds (Figure 2). This requires a series of special desaturation and elongation enzymes present in the endoplasmic reticulum membrane.

ω -6 Fatty Acids

[0100] Oleic acid is converted to LA (18:2), the first of the ω -6 fatty acids, by the action of a $\Delta 12$ desaturase. Subsequent ω -6 fatty acids are produced as follows: 1.) LA is converted to GLA by the activity of a $\Delta 6$ desaturase; 2.) GLA is converted to DGLA by the action of an elongase; and 3.) DGLA is converted to ARA by the action of a $\Delta 5$ desaturase.

ω -3 Fatty Acids

[0101] Linoleic acid (LA) is converted to ALA, the first of the ω -3 fatty acids, by the action of a Δ 15 desaturase. Subsequent ω -3 fatty acids are produced in a series of steps similar to that for the ω -6 fatty acids. Specifically: 1.) ALA is converted to STA by the activity of a Δ 6 desaturase; 2.) STA is converted to ETA by the activity of an elongase; and 3.) ETA is converted to EPA by the activity of a Δ 5 desaturase. Alternatively, ETA and EPA can be produced from DGLA and ARA, respectively, by the activity of a Δ 17 desaturase. EPA can be further converted to DHA by the activity of an elongase and a Δ 4 desaturase.

Genes Involved In Omega Fatty Acid Production

[0102] Many microorganisms, including algae, bacteria, molds and yeasts, can synthesize PUFAs and omega fatty acids in the ordinary course of cellular metabolism. Particularly well-studied are fungi including *Schizochytrium aggregatum*, species of the genus *Thraustochytrium* and *Mortierella alpina*. Additionally, many dinoflagellates (Dinophyceae) naturally produce high concentrations of PUFAs. As such, a variety of genes involved in oil production have been identified through genetic means and the DNA sequences of some of these genes are publicly available (non-limiting examples are shown below in Table 2):

Table 2

<u>Some Publicly Available Genes Involved In PUFA Production</u>	
Genbank Accession No.	Description
AY131238	<i>Argania spinosa</i> Δ 6 desaturase
Y055118	<i>Echium pitardii</i> var. <i>pitardii</i> Δ 6 desaturase
AY055117	<i>Echium gentianoides</i> Δ 6 desaturase
AF296076	<i>Mucor rouxii</i> Δ 6 desaturase
AF007561	<i>Borago officinalis</i> Δ 6 desaturase
L11421	<i>Synechocystis</i> sp. Δ 6 desaturase
NM_031344	<i>Rattus norvegicus</i> Δ 6 fatty acid desaturase
AF465283, AF465281, AF110510	<i>Mortierella alpina</i> Δ 6 fatty acid desaturase
AF465282	<i>Mortierella isabellina</i> Δ 6 fatty acid desaturase
AF419296	<i>Pythium irregulare</i> Δ 6 fatty acid desaturase
AB052086	<i>Mucor circinelloides</i> D6d mRNA for Δ 6 fatty acid desaturase
AJ250735	<i>Ceratodon purpureus</i> mRNA for Δ 6 fatty acid desaturase
A126799	<i>Homo sapiens</i> Δ 6 fatty acid desaturase
A126798	<i>Mus musculus</i> Δ 6 fatty acid desaturase
A199596, AF226273	<i>Homo sapiens</i> Δ 5 desaturase
AF320509	<i>Rattus norvegicus</i> liver Δ 5 desaturase
AB072976	<i>Mus musculus</i> D5D mRNA for Δ 5 desaturase
AF489588	<i>Thraustochytrium</i> sp. ATCC21685 Δ 5 fatty acid desaturase
AJ510244	<i>Phytophthora megasperma</i> mRNA for Δ 5 fatty acid desaturase
AF419297	<i>Pythium irregulare</i> Δ 5 fatty acid desaturase
AF07879	<i>Caenorhabditis elegans</i> Δ 5 fatty acid desaturase
AF067654	<i>Mortierella alpina</i> Δ 5 fatty acid desaturase
AB022097	<i>Dictyostelium discoideum</i> mRNA for Δ 5 fatty acid desaturase
AF489589.1	<i>Thraustochytrium</i> sp. ATCC21685 Δ 4 fatty acid desaturase
AY332747	<i>Pavlova lutheri</i> Δ 4 fatty acid desaturase (des1) mRNA
AAG36933	<i>Emericella nidulans</i> oleate Δ 12 desaturase
AF110509, AB020033	<i>Mortierella alpina</i> Δ 12 fatty acid desaturase mRNA
AAL13300	<i>Mortierella alpina</i> Δ 12 fatty acid desaturase
AF417244	<i>Mortierella alpina</i> ATCC 16266 Δ 12 fatty acid desaturase

Some Publicly Available Genes Involved In PUFA Production	
Genbank Accession No.	Description
AF161219	<i>Mucor rouxii</i> $\Delta 12$ desaturase mRNA
X86736	<i>Spirulina platensis</i> $\Delta 12$ desaturase
AF240777	<i>Caenorhabditis elegans</i> $\Delta 12$ desaturase
AB007640	<i>Chlamydomonas reinhardtii</i> $\Delta 12$ desaturase
AB075526	<i>Chlorella vulgaris</i> $\Delta 12$ desaturase
AP002063	<i>Arabidopsis thaliana</i> microsomal $\Delta 12$ desaturase
NP_441622, BAA18302, BAA02924	<i>Synechocystis</i> sp. PCC 6803 $\Delta 15$ desaturase
AAL36934	<i>Perilla frutescens</i> $\Delta 15$ desaturase
AF338466	<i>Acheta domesticus</i> $\Delta 9$ desaturase 3 mRNA
AF438199	<i>Picea glauca</i> desaturase $\Delta 9$ (Des9) mRNA
E11368	<i>Anabaena</i> $\Delta 9$ desaturase
E11367	<i>Synechocystis</i> $\Delta 9$ desaturase
D83185	<i>Pichia angusta</i> DNA for $\Delta 9$ fatty acid desaturase
U90417	<i>Synechococcus vulcanus</i> $\Delta 9$ acyl-lipid fatty acid desaturase (desC) gene
AF085500	<i>Mortierella alpina</i> $\Delta 9$ desaturase mRNA
AY504633	<i>Emericella nidulans</i> $\Delta 9$ stearic acid desaturase (sdeB) gene
NM_069854	<i>Caenorhabditis elegans</i> essential fatty acid desaturase, stearyl-CoA desaturase (39.1 kD) (fat-6) complete mRNA
AF230693	<i>Brassica oleracea</i> cultivar Rapid Cycling stearyl-ACP desaturase ($\Delta 9$ -BO-1) gene, exon sequence
AX464731	<i>Mortierella alpina</i> elongase gene (also WO 02/08401)
NM_119617	<i>Arabidopsis thaliana</i> fatty acid elongase 1 (FAE1) (At4q34520) mRNA
NM_134255	<i>Mus musculus</i> ELOVL family member 5, elongation of long chain fatty acids (yeast) (Elovl5), mRNA
NM_134383	<i>Rattus norvegicus</i> fatty acid elongase 2 (rELO2), mRNA
NM_134382	<i>Rattus norvegicus</i> fatty acid elongase 1 (rELO1), mRNA
NM_068396, NM_068392, NM_070713, NM_068746, NM_064685	<i>Caenorhabditis elegans</i> fatty acid ELongation (elo-6), (elo-5), (elo-2), (elo-3), and (elo-9) mRNA

[0103] Additionally, the patent literature provides many additional DNA sequences of genes (and/or details concerning several of the genes above and their methods of isolation) involved in PUFA production. See, for example: U.S. 5,968,809 ($\Delta 6$ desaturases); U.S. 5,972,664 and U.S. 6,075,183 ($\Delta 5$ desaturases); WO 91/13972 and U.S. 5,057,419 ($\Delta 9$ desaturases); WO 93/11245 ($\Delta 15$ desaturases); WO 94/11516, U.S. 5,443,974 and WO 03/099216 ($\Delta 12$ desaturases); U.S. 2003/0196217 A1 ($\Delta 17$ desaturase); WO 02/090493 ($\Delta 4$ desaturases); and, WO 00/12720 and U.S. 2002/0139974A1 (elongases). As will be obvious to one skilled in the art, the particular functionalities required to be introduced into a host organism for production of a particular PUFA final product will depend on the host cell (and its native PUFA profile and/or desaturase profile), the availability of substrate and the desired end product(s). As shown in Figure 2, LA, GLA, DGLA, ARA, ALA, STA, ETA, EPA, DPA and DHA may all be produced in oleaginous yeasts, by introducing various combinations of the following PUFA enzyme functionalities: a $\Delta 4$ desaturase, a $\Delta 5$ desaturase, a $\Delta 6$ desaturase, a $\Delta 12$ desaturase, a $\Delta 15$ desaturase, a $\Delta 17$ desaturase, a $\Delta 9$ desaturase and/or an elongase. Accordingly, in the claimed invention the oleaginous yeast comprises at least a $\Delta 17$ desaturase, a $\Delta 5$ desaturase and an elongase. One skilled in the art will be able to identify various candidate genes encoding each of the above enzymes, according to publicly available literature (e.g., GenBank), the patent literature, and experimental analysis of microorganisms having the ability to produce PUFAs. The sequences may be derived from any source, e.g., isolated from a natural source (from bacteria, algae, fungi, plants, animals, etc.), produced via a semi-synthetic route or synthesized *de novo*. In some embodiments,

manipulation of genes endogenous to the host is preferred; for other purposes, it is necessary to introduce heterologous genes.

[0104] Although the particular source of the desaturase and elongase genes introduced into the host is not critical to the invention, considerations for choosing a specific polypeptide having desaturase or elongase activity include: 1.) the substrate specificity of the polypeptide; 2.) whether the polypeptide or a component thereof is a rate-limiting enzyme; 3.) whether the desaturase or elongase is essential for synthesis of a desired PUFA; and/or 4.) co-factors required by the polypeptide. The expressed polypeptide preferably has parameters compatible with the biochemical environment of its location in the host cell. For example, the polypeptide may have to compete for substrate with other enzymes in the host cell. Analyses of the K_M and specific activity of the polypeptide are therefore considered in determining the suitability of a given polypeptide for modifying PUFA production in a given host cell. The polypeptide used in a particular host cell is one that can function under the biochemical conditions present in the intended host cell but otherwise can be any polypeptide having desaturase or elongase activity capable of modifying the desired PUFA.

Endogenous PUFA Genes

[0105] In some cases, the host organism in which it is desirable to produce PFAs will possess endogenous genes encoding some PUFA biosynthetic pathway enzymes. For example, oleaginous yeast can typically produce 18:2 fatty acids (and some have the additional capability of synthesizing 18:3 fatty acids); thus, oleaginous yeast typically possess native $\Delta 12$ desaturase activity and may also have $\Delta 15$ desaturases. In some embodiments, therefore, expression of the native desaturase enzyme is preferred over a heterologous (or "foreign") enzyme since: 1.) the native enzyme is optimized for interaction with other enzymes and proteins within the cell; and 2.) heterologous genes are unlikely to share the same codon preference in the host organism. Additionally, advantages are incurred when the sequence of the native gene is known, as it permits facile disruption of the endogenous gene by targeted disruption.

Heterologous PUFA Genes

[0106] In many instances, the appropriate desaturases and elongases are not present in the host organism of choice to enable production of the desired PUFA products. Thus, it is necessary to introduce heterologous genes.

[0107] For the purposes of the present invention herein, it was desirable to demonstrate an example of the introduction of an ω -3 biosynthetic pathway into an oleaginous host organism; and thus, a *Mortierella alpina* $\Delta 5$ desaturase, *M. alpina* $\Delta 6$ desaturase, *Saprolegnia diclina* $\Delta 17$ desaturase and *M. alpina* elongase were introduced into *Yarrowia lipolytica*. However, the specific enzymes (and genes encoding those enzymes) introduced into the host organism and the specific PFAs produced are by no means limiting to the invention herein.

[0108] If one desired to produce EPA, as demonstrated herein, it will be obvious to one skilled in the art that numerous other genes derived from different sources would be suitable to introduce $\Delta 5$ desaturase, $\Delta 6$ desaturase, $\Delta 17$ desaturase and elongase activity into the preferred microbial host. Thus, in one embodiment of the present invention, other DNAs which are substantially identical to the *M. alpina* $\Delta 6$ desaturase, $\Delta 5$ desaturase and high-affinity PUFA elongase and the *S. diclina* $\Delta 17$ desaturase also can be used for production of ω -6 and/or Δ -3 fatty acids (e.g., EPA) in oleaginous yeast. By "substantially identical" is intended an amino acid sequence or nucleic acid sequence exhibiting in order of increasing preference at least 80%, 90% or 95% homology to the selected polypeptides, or nucleic acid sequences encoding the amino acid sequence. For polypeptides, the length of comparison sequences generally is at least 16 amino acids, preferably at least 20 amino acids or most preferably 35 amino acids. For nucleic acids, the length of comparison sequences generally is at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

[0109] Homology typically is measured using sequence analysis software, wherein the term "sequence analysis software" refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences. "Sequence analysis software" may be commercially available or independently developed. Typical sequence analysis software will include, but is not limited to: 1.) the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, WI); 2.) BLASTP, BLASTN, BLASTX (Altschul et al., J. Mol. Biol. 215:403-410 (1990)); 3.) DNASTAR (DNASTAR, Inc., Madison, WI); and 4.) the FASTA program incorporating the Smith-Waterman algorithm (W. R. Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Suhai, Sandor, Ed. Plenum: New York, NY). Within the context of this application it will be understood that where sequence analysis software is used for analysis, the results of the analysis will be based on the "default values" of the program referenced, unless otherwise specified. As used herein "default values" will mean

any set of values or parameters that originally load with the software when first initialized. In general, such computer software matches similar sequences by assigning degrees of homology to various substitutions, deletions, and other modifications.

[0110] Additionally it will be appreciated by one of skill in the art that polypeptides may have amino acids conservatively substituted in a manner such that the function of the polypeptide is not altered or compromised. Polypeptides having the desaturase and elongase activities as described herein and possessing such conservative substitutions are considered within the scope of the present invention. Conservative substitutions typically include substitutions within the following groups: 1.) glycine and alanine; 2.) valine, isoleucine and leucine; 3.) aspartic acid, glutamic acid, asparagine and glutamine; 4.) serine and threonine; 5.) lysine and arginine; and 6.) phenylalanine and tyrosine. Substitutions may also be made on the basis of conserved hydrophobicity or hydrophilicity (Kyte and Doolittle, J. Mol. Biol. 157:105-132 (1982)), or on the basis of the ability to assume similar polypeptide secondary structure (Chou and Fasman, Adv. Enzymol. 47:45-148 (1978)).

[0111] In alternate embodiments of the invention, other DNAs which, although not substantially identical to the *M. alpina* $\Delta 6$ desaturase, $\Delta 5$ desaturase and high-affinity PUFA elongase and the *S. diclina* $\Delta 17$ desaturase, also can be used for the purposes herein (e.g., for production of ω -3 and/or ω -6 PUFAs such as ARA and EPA). For example, DNA sequences encoding $\Delta 6$ desaturase polypeptides that would be useful for introduction into an oleaginous yeast according to the teachings of the present invention may be obtained from microorganisms having an ability to produce GLA or STA. Such microorganisms include, for example, those belonging to the genera *Mortierella*, *Conidiobolus*, *Pythium*, *Phytophthora*, *Penicillium*, *Porphyridium*, *Codosporium*, *Mucor*, *Fusarium*, *Aspergillus*, *Rhodotorula* and *Entomophthora*. Within the genus *Porphyridium*, of particular interest is *P. cruentum*. Within the genus *Mortierella*, of particular interest are *M. elongata*, *M. exigua*, *M. hygrophila*, *M. ramanniana* var. *angulispora* and *M. alpina*. Within the genus *Mucor*, of particular interest are *M. circinelloides* and *M. javanicus*.

[0112] Alternatively, a related desaturase that is not substantially identical to the *M. alpina* $\Delta 6$ desaturase, but which can desaturate a fatty acid molecule at carbon 6 from the carboxyl end of the molecule would also be useful in the present invention as a $\Delta 6$ desaturase, assuming the desaturase can still effectively convert LA to GLA and/or ALA to STA. As such, related desaturases and elongases can be identified by their ability of function substantially the same as the desaturases and elongase disclosed herein.

[0113] In summary, genes encoding PUFA biosynthetic pathway enzymes suitable for the purposes herein may be isolated from a variety of sources. Desaturases for the purposes herein are characterized by the ability to:

1. 1.) desaturate a fatty acid between the 17th and 18th carbon atom numbered from the carboxyl-terminal end of the molecule and catalyze the conversion of ARA to EPA and DGLA to ETA ($\Delta 17$ desaturases);
2. 2.) catalyze the conversion of LA to GLA and/or ALA to STA ($\Delta 6$ desaturases); 3.) catalyze the conversion of DGLA to ARA and/or ETA to EPA ($\Delta 5$ desaturases); 4.) catalyze the conversion of DPA to DHA ($\Delta 4$ desaturases); 5.) catalyze the conversion of oleic acid to LA ($\Delta 12$ desaturases); 6.) catalyze the conversion of LA to ALA ($\Delta 15$ desaturases); and/or 7.) catalyze the conversion of palmitate to palmitoleic acid and/or stearate to oleic acid ($\Delta 9$ desaturases). In like manner, suitable elongases for the purposes herein are not limited to those from a specific source; instead, the enzymes having use for the purposes herein are characterized by their ability to elongate a fatty acid carbon chain by 2 carbons relative to the substrate the elongase acts upon, to thereby produce a mono- or polyunsaturated fatty acid.

Optimization Of Omega Fatty Acid Genes For Expression In Particular Organisms

[0114] Although the particular source of a PUFA desaturase or elongase is not critical in the invention herein, it will be obvious to one of skill in the art that heterologous genes will be expressed with variable efficiencies in an alternate host. Thus, ω -3 and/or ω -6 PUFA production may be optimized by selection of a particular desaturase or elongase whose level of expression in a heterologous host is preferred relative to the expression of an alternate desaturase or elongase in the host organism of interest. Furthermore, it may be desirable to modify the expression of particular PUFA biosynthetic pathway enzymes to achieve optimal conversion efficiency of each, according to the specific PUFA product composition of interest. A variety of genetic engineering techniques are available to optimize expression of a particular enzyme. Two such techniques include codon optimization and gene mutation, as described below. Genes produced by, e.g., either of these two methods, having desaturase and/or elongase activity(s) would be useful in the invention herein for synthesis of ω -3 PUFAs.

Codon Optimization

[0115] As will be appreciated by one skilled in the art, it is frequently useful to modify a portion of the codons encoding a particular polypeptide that is to be expressed in a foreign host, such that the modified polypeptide uses codons that are preferred by the alternate host. Use of host-preferred codons can substantially enhance the expression of the foreign gene encoding the polypeptide.

[0116] In general, host-preferred codons can be determined within a particular host species of interest by examining codon usage in proteins (preferably those expressed in the largest amount) and determining which codons are used with highest frequency. Then, the coding sequence for a polypeptide of interest having desaturase or elongase activity can be synthesized in whole or in part using the codons preferred in the host species. All (or portions) of the DNA also can be synthesized to remove any destabilizing sequences or regions of secondary structure that would be present in the transcribed mRNA. All (or portions) of the DNA also can be synthesized to alter the base composition to one more preferable in the desired host cell.

[0117] In the present invention, it was desirable to modify a portion of the codons encoding the polypeptide having $\Delta 17$ desaturase activity, to enhance the expression of the gene in *Yarrowia lipolytica*. The nucleic acid sequence of the native gene (e.g., the *Saprolegnia diclina* $\Delta 17$ desaturase) was modified to employ host-preferred codons. The skilled artisan will appreciate that this optimization method will be equally applicable to other genes in the ω -3/ ω -6 fatty acids biosynthetic pathway (see for example, co-pending U.S. Provisional Application No. 60/468718,). Furthermore, modulation of the *S. diclina* $\Delta 17$ desaturase is only exemplary.

Gene Mutation

[0118] Methods for synthesizing sequences and bringing sequences together are well established in the literature. For example, *in vitro* mutagenesis and selection, site-directed mutagenesis, error prone PCR (Melnikov et al., Nucleic Acids Research, 27(4):1056-1062 (February 15, 1999)), "gene shuffling" or other means can be employed to obtain mutations of naturally occurring desaturase or elongase genes. This would permit production of a polypeptide having desaturase or elongase activity, respectively, *in vivo* with more desirable physical and kinetic parameters for function in the host cell such as a longer half-life or a higher rate of production of a desired PUFA.

[0119] If desired, the regions of a polypeptide of interest (i.e., a desaturase or an elongase) important for enzymatic activity can be determined through routine mutagenesis, expression of the resulting mutant polypeptides and determination of their activities. Mutants may include deletions, insertions and point mutations, or combinations thereof. A typical functional analysis begins with deletion mutagenesis to determine the N- and C-terminal limits of the protein necessary for function, and then internal deletions, insertions or point mutants are made to further determine regions necessary for function. Other techniques such as cassette mutagenesis or total synthesis also can be used. Deletion mutagenesis is accomplished, for example, by using exonucleases to sequentially remove the 5' or 3' coding regions. Kits are available for such techniques. After deletion, the coding region is completed by ligating oligonucleotides containing start or stop codons to the deleted coding region after the 5' or 3' deletion, respectively. Alternatively, oligonucleotides encoding start or stop codons are inserted into the coding region by a variety of methods including site-directed mutagenesis, mutagenic PCR or by ligation onto DNA digested at existing restriction sites. Internal deletions can similarly be made through a variety of methods including the use of existing restriction sites in the DNA, by use of mutagenic primers via site-directed mutagenesis or mutagenic PCR. Insertions are made through methods such as linker-scanning mutagenesis, site-directed mutagenesis or mutagenic PCR, while point mutations are made through techniques such as site-directed mutagenesis or mutagenic PCR.

[0120] Chemical mutagenesis also can be used for identifying regions of a desaturase or elongase polypeptide important for activity. A mutated construct is expressed, and the ability of the resulting altered protein to function as a desaturase or elongase is assayed. Such structure-function analysis can determine which regions may be deleted, which regions tolerate insertions, and which point mutations allow the mutant protein to function in substantially the same way as the native desaturase or native elongase. All such mutant proteins and nucleotide sequences encoding them that are derived from the codon-optimized gene described herein are within the scope of the present invention.

[0121] In the present invention, it was desirable to modify a portion of the codons encoding the polypeptide having $\Delta 17$ desaturase activity, to enhance the expression of the gene in *Yarrowia lipolytica*. The nucleic acid sequence of the native gene (e.g., the *S. diclina* $\Delta 17$ desaturase) was modified to employ host preferred codons. The skilled artisan will appreciate that these optimization methods will be equally applicable to other genes in the ω -3/ ω -6 fatty acids biosynthetic pathway and that modulation

of the *S. diclina* $\Delta 17$ desaturase and *M. alpina* $\Delta 6$ desaturase, $\Delta 5$ desaturase are only exemplary.

Microbial Production Of ω -3 And/Or ω -6 Fatty Acids

[0122] Microbial production of ω -3 and/or ω -6 fatty acids has several advantages over purification from natural sources such as fish or plants. For example:

1. 1.) Many microbes are known with greatly simplified oil compositions compared with those of higher organisms, making purification of desired components easier;
2. 2.) Microbial production is not subject to fluctuations caused by external variables, such as weather and food supply;
3. 3.) Microbially produced oil is substantially free of contamination by environmental pollutants;
4. 4.) Microbes can provide PUFAs in particular forms which may have specific uses; and
5. 5.) Microbial oil production can be manipulated by controlling culture conditions, notably by providing particular substrates for microbially expressed enzymes, or by addition of compounds/genetic engineering to suppress undesired biochemical pathways.

In addition to these advantages, production of ω -3 and/or ω -6 fatty acids from recombinant microbes provides the ability to alter the naturally occurring microbial fatty acid profile by providing new biosynthetic pathways in the host or by suppressing undesired pathways, thereby increasing levels of desired PUFAs, or conjugated forms thereof, and decreasing levels of undesired PUFAs. For example, it is possible to modify the ratio of ω -3 to ω -6 fatty acids so produced, produce either ω -3 or ω -6 fatty acids exclusively while eliminating production of the alternate omega fatty acid, or engineer production of a specific PUFA without significant accumulation of other PUFA downstream or upstream products.

Expression Systems, Cassettes And Vectors

[0123] The genes and gene products described herein may be produced in heterologous microbial host cells, particularly in the cells of oleaginous yeasts (e.g., *Yarrowia lipolytica*). Expression in recombinant microbial hosts may be useful for the production of various PUFA pathway intermediates, or for the modulation of PUFA pathways already existing in the host for the synthesis of new products heretofore not possible using the host.

[0124] Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct chimeric genes for production of any of the gene products of the preferred desaturase and/or elongase sequences. These chimeric genes could then be introduced into appropriate microorganisms via transformation to provide high-level expression of the encoded enzymes.

[0125] Accordingly, it is expected that introduction of chimeric genes encoding a PUFA biosynthetic pathway (e.g., the $\Delta 5$ desaturase, $\Delta 6$ desaturase, $\Delta 17$ desaturase and elongase described herein), under the control of the appropriate promoters will result in increased production of ω -3 and/or ω -6 fatty acids. It is contemplated that it will be useful to express various combinations of these PUFA desaturase and elongase genes together in a host microorganism. It will be obvious to one skilled in the art that the particular genes included within a particular expression cassette(s) will depend on the host cell, its ability to synthesize PUFAs using native desaturases and elongases, the availability of substrate and the desired end product(s). For example, it may be desirable for an expression cassette to be constructed comprising genes encoding one or more of the following enzymatic activities: a $\Delta 4$ desaturase, a $\Delta 5$ desaturase, a $\Delta 6$ desaturase, a $\Delta 12$ desaturase, a $\Delta 15$ desaturase, a $\Delta 17$ desaturase, a $\Delta 9$ desaturase and/or an elongase. As such, PUFAs may be produced by exposing a fatty acid substrate to the PUFA enzyme(s) described herein, such that the substrate is converted to the desired fatty acid product. Thus, each PUFA gene and corresponding enzyme product described herein (e.g., a wildtype, codon-optimized, synthetic and/or mutant enzyme having appropriate desaturase or elongase activity) can be used directly or indirectly for the production of PUFAs. Direct production of PUFAs occurs wherein the fatty acid substrate is converted directly into the desired fatty acid product without any intermediate steps or pathway intermediates. For example, production of ARA would occur in a host cell which produces or which is provided DLGA, by adding or introducing into said cell an expression cassette that provides $\Delta 5$ desaturase activity.

[0126] In contrast, multiple genes encoding the PUFA biosynthetic pathway may be used in combination, such that a series of reactions occur to produce a desired PUFA. For example, expression cassette(s) encoding elongase, $\Delta 5$ desaturase, $\Delta 17$ desaturase and $\Delta 4$ desaturase activity would enable a host cell that naturally produces GLA, to instead produce DHA (such that GLA is converted to DGLA by an elongase; DGLA may then be converted to ARA by a $\Delta 5$ desaturase; ARA is then converted to EPA by a $\Delta 17$ desaturase, which may in turn be converted to DPA by an elongase; and DPA would be converted to DHA by a $\Delta 4$

desaturase). In a preferred embodiment, wherein the host cell is an oleaginous yeast, expression cassettes encoding each of the enzymes necessary for PUFA biosynthesis will need to be introduced into the organism, since naturally produced PUFAs in these organisms are limited to 18:2 fatty acids (i.e., LA), and less commonly, 18:3 fatty acids (i.e., ALA). Alternatively, substrate feeding may be required.

[0127] Vectors or DNA cassettes useful for the transformation of suitable host cells are well known in the art. The specific choice of sequences present in the construct is dependent upon the desired expression products (*supra*), the nature of the host cell and the proposed means of separating transformed cells versus non-transformed cells. Typically, however, the vector or cassette contains sequences directing transcription and translation of the relevant gene(s), a selectable marker and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene that controls transcriptional initiation and a region 3' of the DNA fragment that controls transcriptional termination. It is most preferred when both control regions are derived from genes from the transformed host cell, although it is to be understood that such control regions need not be derived from the genes native to the specific species chosen as a production host.

[0128] Initiation control regions or promoters which are useful to drive expression of desaturase and/or elongase ORFs in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of directing expression of these genes in the selected host cell is suitable for the present invention. Expression in a host cell can be accomplished in a transient or stable fashion. Transient expression can be accomplished by inducing the activity of a regulatable promoter operably linked to the gene of interest. Stable expression can be achieved by the use of a constitutive promoter operably linked to the gene of interest. As an example, when the host cell is yeast, transcriptional and translational regions functional in yeast cells are provided, particularly from the host species. The transcriptional initiation regulatory regions can be obtained, for example, from: 1.) genes in the glycolytic pathway, such as alcohol dehydrogenase, glyceraldehyde-3-phosphate-dehydrogenase (see U.S. Patent Application Number 60/482263, incorporated herein by reference), phosphoglycerate mutase (see U.S. Patent Application Number 60/482263, incorporated herein by reference), fructose-bisphosphate aldolase (see U.S. Patent Application Number 60/519971, incorporated herein by reference), phosphoglucose-isomerase, phosphoglycerate kinase, etc.; or, 2.) regulatable genes such as acid phosphatase, lactase, metallothionein, glucoamylase, the translation elongation factor EF1- α (TEF) protein (U.S. 6,265,185), ribosomal protein S7 (U.S. 6,265,185), etc. Any one of a number of regulatory sequences can be used, depending upon whether constitutive or induced transcription is desired, the efficiency of the promoter in expressing the ORF of interest, the ease of construction and the like.

[0129] Nucleotide sequences surrounding the translational initiation codon 'ATG' have been found to affect expression in yeast cells. If the desired polypeptide is poorly expressed in yeast, the nucleotide sequences of exogenous genes can be modified to include an efficient yeast translation initiation sequence to obtain optimal gene expression. For expression in yeast, this can be done by site-directed mutagenesis of an inefficiently expressed gene by fusing it in-frame to an endogenous yeast gene, preferably a highly expressed gene. Alternatively, as demonstrated in the invention herein in *Yarrowia lipolytica*, one can determine the consensus translation initiation sequence in the host and engineer this sequence into heterologous genes for their optimal expression in the host of interest.

[0130] The termination region can be derived from the 3' region of the gene from which the initiation region was obtained or from a different gene. A large number of termination regions are known and function satisfactorily in a variety of hosts (when utilized both in the same and different genera and species from where they were derived). The termination region usually is selected more as a matter of convenience rather than because of any particular property. Preferably, the termination region is derived from a yeast gene, particularly *Saccharomyces*, *Schizosaccharomyces*, *Candida*, *Yarrowia* or *Kluyveromyces*. The 3'-regions of mammalian genes encoding γ -interferon and α -2 interferon are also known to function in yeast. Termination control regions may also be derived from various genes native to the preferred hosts. Optionally, a termination site may be unnecessary; however, it is most preferred if included.

[0131] As one of skill in the art is aware, merely inserting a gene into a cloning vector does not ensure that it will be successfully expressed at the level needed. In response to the need for a high expression rate, many specialized expression vectors have been created by manipulating a number of different genetic elements that control aspects of transcription, translation, protein stability, oxygen limitation and secretion from the host cell. More specifically, some of the molecular features that have been manipulated to control gene expression include: 1.) the nature of the relevant transcriptional promoter and terminator sequences; 2.) the number of copies of the cloned gene and whether the gene is plasmid-borne or integrated into the genome of the host cell; 3.) the final cellular location of the synthesized foreign protein; 4.) the efficiency of translation in the host organism; 5.) the intrinsic stability of the cloned gene protein within the host cell; and 6.) the codon usage within the cloned gene, such that its frequency approaches the frequency of preferred codon usage of the host cell. Each of these types of modifications are encompassed in the present invention, as means to further optimize expression of the PUFA biosynthetic pathway enzymes.

Transformation Of Microbial Hosts

[0132] Once the DNA encoding a desaturase or elongase polypeptide suitable for expression in an oleaginous yeast has been obtained, it is placed in a plasmid vector capable of autonomous replication in a host cell or it is directly integrated into the genome of the host cell. Integration of expression cassettes can occur randomly within the host genome or can be targeted through the use of constructs containing regions of homology with the host genome sufficient to target recombination within the host locus. Where constructs are targeted to an endogenous locus, all or some of the transcriptional and translational regulatory regions can be provided by the endogenous locus.

[0133] Where two or more genes are expressed from separate replicating vectors, it is desirable that each vector has a different means of selection and should lack homology to the other constructs to maintain stable expression and prevent reassortment of elements among constructs. Judicious choice of regulatory regions, selection means and method of propagation of the introduced construct can be experimentally determined so that all introduced genes are expressed at the necessary levels to provide for synthesis of the desired products.

[0134] Constructs comprising the gene of interest may be introduced into a host cell by any standard technique. These techniques include transformation (e.g., lithium acetate transformation [Methods in Enzymology, 194:186-187 (1991)]), protoplast fusion, bolistic impact, electroporation, microinjection, or any other method that introduces the gene of interest into the host cell. More specific teachings applicable for oleaginous yeasts (i.e., *Yarrowia lipolytica*) include U.S. Patent Nos. 4,880,741 and 5,071,764 and Chen, D. C. et al. (Appl Microbiol Biotechnol. 48(2):232-235 (1997)).

[0135] For convenience, a host cell that has been manipulated by any method to take up a DNA sequence (e.g., an expression cassette) will be referred to as "transformed" or "recombinant" herein. The transformed host will have at least one copy of the expression construct and may have two or more, depending upon whether the gene is integrated into the genome, amplified or is present on an extrachromosomal element having multiple copy numbers. The transformed host cell can be identified by selection for a marker contained on the introduced construct. Alternatively, a separate marker construct may be co-transformed with the desired construct, as many transformation techniques introduce many DNA molecules into host cells. Typically, transformed hosts are selected for their ability to grow on selective media. Selective media may incorporate an antibiotic or lack a factor necessary for growth of the untransformed host, such as a nutrient or growth factor. An introduced marker gene may confer antibiotic resistance, or encode an essential growth factor or enzyme, thereby permitting growth on selective media when expressed in the transformed host. Selection of a transformed host can also occur when the expressed marker protein can be detected, either directly or indirectly. The marker protein may be expressed alone or as a fusion to another protein. The marker protein can be detected by: 1.) its enzymatic activity (e.g., β -galactosidase can convert the substrate X-gal [5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside] to a colored product; luciferase can convert luciferin to a light-emitting product); or 2.) its light-producing or modifying characteristics (e.g., the green fluorescent protein of *Aequorea victoria* fluoresces when illuminated with blue light). Alternatively, antibodies can be used to detect the marker protein or a molecular tag on, for example, a protein of interest. Cells expressing the marker protein or tag can be selected, for example, visually, or by techniques such as FACS or panning using antibodies. For selection of yeast transformants, any marker that functions in yeast may be used. Preferred for use herein are resistance to kanamycin, hygromycin and the amino glycoside G418, as well as ability to grow on media lacking uracil or leucine.

[0136] Following transformation, substrates suitable for the recombinantly expressed desaturases and/or elongases (and optionally other PUFA enzymes that are expressed within the host cell) may be produced by the host either naturally or transgenically, or they may be provided exogenously.

Metabolic Engineering Of ω -3 And/Or ω -6 Fatty Acid Biosynthesis In Microbes

[0137] Methods for manipulating biochemical pathways are well known to those skilled in the art; and, it is expected that numerous manipulations will be possible to maximize ω -3 and/or ω -6 fatty acid biosynthesis in oleaginous yeasts, and particularly, in *Yarrowia lipolytica*. This may require metabolic engineering directly within the PUFA biosynthetic pathway or additional manipulation of pathways that contribute carbon to the PUFA biosynthetic pathway.

[0138] In the case of manipulations within the PUFA biosynthetic pathway, it may be desirable to increase the production of LA to enable increased production of ω -6 and/or ω -3 fatty acids. This may be accomplished by introducing and/or amplifying genes encoding $\Delta 9$ and/or $\Delta 12$ desaturases.

[0139] To maximize production of ω -6 unsaturated fatty acids, such as ARA, it is well known to one skilled in the art that production is favored in a host microorganism that is substantially free of ALA. Thus, preferably, the host is selected or obtained by removing or inhibiting Δ 15 or ω -3 type desaturase activity that permits conversion of LA to ALA. The endogenous desaturase activity can be reduced or eliminated by, for example: 1.) providing a cassette for transcription of antisense sequences to the Δ 15 desaturase transcription product; 2.) disrupting the Δ 15 desaturase gene through insertion, substitution and/or deletion of all or part of the target gene; or 3.) using a host cell which naturally has [or has been mutated to have] low or no Δ 15 desaturase activity. Inhibition of undesired desaturase pathways can also be accomplished through the use of specific desaturase inhibitors such as those described in U.S. 4,778,630.

[0140] Alternatively, it may be desirable to maximize production of ω -3 fatty acids (and minimize synthesis of ω -6 fatty acids). Thus, one could utilize a host microorganism wherein the Δ 12 desaturase activity that permits conversion of oleic acid to LA is removed or inhibited, using any of the means described above (see also, for example, co-pending U.S. Provisional Application No. 60/484209). Subsequently, appropriate expression cassettes would be introduced into the host, along with appropriate substrates (e.g., ALA) for conversion to ω -3 fatty acid derivatives of ALA (e.g., STA, ETA, EPA, DPA, DHA).

[0141] Beyond the immediate PUFA biosynthetic pathway, it is expected that manipulation of several other enzymatic pathways leading to the biosynthesis of precursor fatty acids may contribute to the overall net biosynthesis of specific PUFAs. Identification and manipulation of these related pathways will be useful in the future.

Techniques To Up-Regulate Desirable Biosynthetic Pathways

[0142] Additional copies of desaturase and elongase genes may be introduced into the host to increase the output of ω -3 and/or ω -6 fatty acid biosynthetic pathways. Expression of the desaturase or elongase genes also can be increased at the transcriptional level through the use of a stronger promoter (either regulated or constitutive) to cause increased expression, by removing/deleting destabilizing sequences from either the mRNA or the encoded protein, or by adding stabilizing sequences to the mRNA (U.S. 4,910,141). Yet another approach to increase expression of the desaturase or elongase genes, as demonstrated in the instant invention, is to increase the translational efficiency of the encoded mRNAs by replacement of codons in the native gene with those for optimal gene expression in the selected host microorganism.

Techniques To Down-Regulate Undesirable Biosynthetic Pathways

[0143] Conversely, biochemical pathways competing with the ω -3 and/or ω -6 fatty acid biosynthetic pathways for energy or carbon, or native PUFA biosynthetic pathway enzymes that interfere with production of a particular PUFA end-product, may be eliminated by gene disruption or downregulated by other means (e.g., antisense mRNA). For gene disruption, a foreign DNA fragment (typically a selectable marker gene) is inserted into the structural gene to be disrupted in order to interrupt its coding sequence and thereby functionally inactivate the gene. Transformation of the disruption cassette into the host cell results in replacement of the functional native gene by homologous recombination with the non-functional disrupted gene (see, for example: Hamilton et al. J. Bacteriol. 171:4617-4622 (1989); Balbas et al. Gene 136:211-213 (1993); Gueldener et al. Nucleic Acids Res. 24:2519-2524 (1996); and Smith et al. Methods Mol. Cell. Biol. 5:270-277(1996)).

[0144] Antisense technology is another method of down-regulating genes when the sequence of the target gene is known. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the antisense strand of RNA will be transcribed. This construct is then introduced into the host cell and the antisense strand of RNA is produced. Antisense RNA inhibits gene expression by preventing the accumulation of mRNA that encodes the protein of interest. The person skilled in the art will know that special considerations are associated with the use of antisense technologies in order to reduce expression of particular genes. For example, the proper level of expression of antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan.

[0145] Although targeted gene disruption and antisense technology offer effective means of down-regulating genes where the sequence is known, other less specific methodologies have been developed that are not sequence-based. For example, cells may be exposed to UV radiation and then screened for the desired phenotype. Mutagenesis with chemical agents is also effective for generating mutants and commonly used substances include chemicals that affect nonreplicating DNA (e.g., HNO_2 and NH_2OH), as well as agents that affect replicating DNA (e.g., acridine dyes, notable for causing frameshift mutations). Specific methods for creating mutants using radiation or chemical agents are well documented in the art. See, for example: Thomas D.

Brock in Biotechnology: A Textbook of Industrial Microbiology, 2nd ed. (1989) Sinauer Associates: Sunderland, MA ; or Deshpande, Mukund V., Appl. Biochem. Biotechnol., 36:227 (1992).

[0146] Another non-specific method of gene disruption is the use of transposable elements or transposons. Transposons are genetic elements that insert randomly into DNA but can be later retrieved on the basis of sequence to determine where the insertion has occurred. Both *in vivo* and *in vitro* transposition methods are known. Both methods involve the use of a transposable element in combination with a transposase enzyme. When the transposable element or transposon is contacted with a nucleic acid fragment in the presence of the transposase, the transposable element will randomly insert into the nucleic acid fragment. The technique is useful for random mutagenesis and for gene isolation, since the disrupted gene may be identified on the basis of the sequence of the transposable element. Kits for *in vitro* transposition are commercially available [see, for example: 1.) The Primer Island Transposition Kit, available from Perkin Elmer Applied Biosystems, Branchburg, NJ, based upon the yeast Ty1 element; 2.) The Genome Priming System, available from New England Biolabs, Beverly, MA, based upon the bacterial transposon Tn7; and 3.) the EZ::TN Transposon Insertion Systems, available from Epicentre Technologies, Madison, WI, based upon the Tn5 bacterial transposable element].

[0147] Within the context of the present invention, it may be useful to modulate the expression of the fatty acid biosynthetic pathway by any one of the methods described above. For example, in the present invention genes encoding key enzymes in the biosynthetic pathways are introduced into oleaginous yeasts for the production of ω -3 fatty acids. It will be particularly useful to express these genes in oleaginous yeasts that do not naturally possess ω -3 fatty acid biosynthetic pathways and coordinate the expression of these genes, to maximize production of preferred PUFA products using various means for metabolic engineering of the host organism.

Preferred Microbial Hosts For Recombinant Production Of ω -3 And/Or ω -6 Fatty Acids

[0148] Host cells for production of omega fatty acids may include microbial hosts that grow on a variety of feedstocks, including simple or complex carbohydrates, organic acids and alcohols, and/or hydrocarbons over a wide range of temperature and pH values.

[0149] Preferred microbial hosts, however, are oleaginous yeasts. These organisms are naturally capable of oil synthesis and accumulation, wherein the oil can comprise greater than about 25% of the cellular dry weight, more preferably greater than about 30% of the cellular dry weight, and most preferably greater than about 40% of the cellular dry weight. Genera typically identified as oleaginous yeast include, but are not limited to: *Yarrowia*, *Candida*, *Rhodotorula*, *Rhodospiridium*, *Cryptococcus*, *Trichosporon* and *Lipomyces*. More specifically, illustrative oil-synthesizing yeasts include: *Rhodospiridium toruloides*, *Lipomyces starkeyii*, *L. lipoferus*, *Candida reikauhi*, *C. pulcherrima*, *C. tropicalis*, *C. utilis*, *Trichosporon pullans*, *T. cutaneum*, *Rhodotorula glutinus*, *R. graminis*, and *Yarrowia lipolytica* (formerly classified as *Candida lipolytica*).

[0150] Most preferred is the oleaginous yeast *Yarrowia lipolytica*; and, in a further embodiment, most preferred are the *Y. lipolytica* strains designated as ATCC #20362, ATCC #8862, ATCC #18944, ATCC #76982 and/or LGAM S(7)1 (Papanikolaou S., and Aggelis G., Bioresour. Technol. 82(1):43-9 (2002)).

[0151] Historically, various strains of *Y. lipolytica* have been used for the manufacture and production of: isocitrate lyase (DD259637); lipases (SU1454852, WO2001083773, DD279267); polyhydroxyalkanoates (WO2001088144); citric acid (RU2096461, RU2090611, DD285372, DD285370, DD275480, DD227448, PL160027); erythritol (EP770683); 2-oxoglutaric acid (DD267999); γ -decalactone (U.S. 6,451,565, FR2734843); γ -dodecalactone (EP578388); and pyruvic acid (JP09252790).

Fermentation Processes For PUFA Production

[0152] The transformed microbial host cell is grown under conditions that optimize desaturase and elongase activities and produce the greatest and the most economical yield of the preferred PUFAs. In general, media conditions that may be optimized include the type and amount of carbon source, the type and amount of nitrogen source, the carbon-to-nitrogen ratio, the oxygen level, growth temperature, pH, length of the biomass production phase, length of the oil accumulation phase and the time of cell harvest. Microorganisms of interest, such as oleaginous yeast, are grown in complex media (e.g., yeast extract-peptone-dextrose broth (YPD)) or a defined minimal media that lacks a component necessary for growth and thereby forces selection of the desired expression cassettes (e.g., Yeast Nitrogen Base (DIFCO Laboratories, Detroit, MI)).

[0153] Fermentation media in the present invention must contain a suitable carbon source. Suitable carbon sources may include, but are not limited to: monosaccharides (e.g., glucose, fructose), disaccharides (e.g., lactose, sucrose), oligosaccharides, polysaccharides (e.g., starch, cellulose or mixtures thereof), sugar alcohols (e.g., glycerol) or mixtures from renewable feedstocks (e.g., cheese whey permeate, cornsteep liquor, sugar beet molasses, barley malt). Additionally, carbon sources may include alkanes, fatty acids, esters of fatty acids, monoglycerides, diglycerides, triglycerides, phospholipids and various commercial sources of fatty acids including vegetable oils (e.g., soybean oil) and animal fats. Additionally, the carbon source may include one-carbon sources (e.g., carbon dioxide, methanol, formaldehyde, formate and carbon-containing amines) for which metabolic conversion into key biochemical intermediates has been demonstrated. Hence it is contemplated that the source of carbon utilized in the present invention may encompass a wide variety of carbon-containing sources and will only be limited by the choice of the host organism. Although all of the above mentioned carbon sources and mixtures thereof are expected to be suitable in the present invention, preferred carbon sources are sugars and/or fatty acids. Most preferred is glucose and/or fatty acids containing between 10-22 carbons.

[0154] Nitrogen may be supplied from an inorganic (e.g., $(\text{NH}_4)_2\text{SO}_4$) or organic source (e.g., urea or glutamate). In addition to appropriate carbon and nitrogen sources, the fermentation media must also contain suitable minerals, salts, cofactors, buffers, vitamins and other components known to those skilled in the art suitable for the growth of the microorganism and promotion of the enzymatic pathways necessary for PUFA production. Particular attention is given to several metal ions (e.g., Mn^{+2} , Co^{+2} , Zn^{+2} , Mg^{+2}) that promote synthesis of lipids and PUFAs (Nakahara, T. et al., *Ind. Appl. Single Cell Oils*, D. J. Kyle and R. Colin, eds. pp 61-97 (1992)).

[0155] Preferred growth media in the present invention are common commercially prepared media, such as Yeast Nitrogen Base (DIFCO Laboratories, Detroit, MI). Other defined or synthetic growth media may also be used and the appropriate medium for growth of the particular microorganism will be known by one skilled in the art of microbiology or fermentation science. A suitable pH range for the fermentation is typically between about pH 4.0 to pH 8.0, wherein pH 5.5 to pH 7.0 is preferred as the range for the initial growth conditions. The fermentation may be conducted under aerobic or anaerobic conditions, wherein microaerobic conditions are preferred.

[0156] Typically, accumulation of high levels of PUFAs in oleaginous yeast cells requires a two-stage process, since the metabolic state must be "balanced" between growth and synthesis/storage of fats. Thus, most preferably, a two-stage fermentation process is necessary for the production of PUFAs in oleaginous yeast. In this approach, the first stage of the fermentation is dedicated to the generation and accumulation of cell mass and is characterized by rapid cell growth and cell division. In the second stage of the fermentation, it is preferable to establish conditions of nitrogen deprivation in the culture to promote high levels of lipid accumulation. The effect of this nitrogen deprivation is to reduce the effective concentration of AMP in the cells, thereby reducing the activity of the NAD-dependent isocitrate dehydrogenase of mitochondria. When this occurs, citric acid will accumulate, thus forming abundant pools of acetyl-CoA in the cytoplasm and priming fatty acid synthesis. Thus, this phase is characterized by the cessation of cell division followed by the synthesis of fatty acids and accumulation of oil.

[0157] Although cells are typically grown at about 30°C, some studies have shown increased synthesis of unsaturated fatty acids at lower temperatures (Yongmanitchai and Ward, *Appl. Environ. Microbiol.* 57:419-25 (1991)). Based on process economics, this temperature shift should likely occur after the first phase of the two-stage fermentation, when the bulk of the organisms' growth has occurred.

[0158] It is contemplated that a variety of fermentation process designs may be applied, where commercial production of omega fatty acids using recombinant expression of desaturase and/or elongase genes is desired. For example, commercial production of PUFAs from a recombinant microbial host may be produced by a batch, fed-batch or continuous fermentation process.

[0159] A batch fermentation process is a closed system wherein the media composition is fixed at the beginning of the process and not subject to further additions beyond those required for maintenance of pH and oxygen level during the process. Thus, at the beginning of the culturing process the media is inoculated with the desired organism and growth or metabolic activity is permitted to occur without adding additional sources (i.e., carbon and nitrogen sources) to the medium. In batch processes the metabolite and biomass compositions of the system change constantly up to the time the culture is terminated. In a typical batch process, cells proceed through a static lag phase to a high-growth log phase and finally to a stationary phase, wherein the growth rate is diminished or halted. Left untreated, cells in the stationary phase will eventually die. A variation of the standard batch process is the fed-batch process, wherein the carbon source is continually added to the fermentor over the course of the fermentation process. A fed-batch process is also suitable in the present invention. Fed-batch processes are useful when catabolite repression is apt to inhibit the metabolism of the cells or where it is desirable to have limited amounts of carbon source in the media at any one time. Measurement of the carbon source concentration in fed-batch systems is difficult and therefore may

be estimated on the basis of the changes of measurable factors such as pH, dissolved oxygen and the partial pressure of waste gases (e.g., CO₂). Batch and fed-batch culturing methods are common and well known in the art and examples may be found in Thomas D. Brock in *Biotechnology: A Textbook of Industrial Microbiology*, 2nd ed., (1989) Sinauer Associates: Sunderland, MA ; or Deshpande, Mukund V., *Appl. Biochem. Biotechnol.*, 36:227 (1992).

[0160] Commercial production of omega fatty acids using recombinant expression of desaturase and/or elongase genes may also be accomplished by a continuous fermentation process wherein a defined media is continuously added to a bioreactor while an equal amount of culture volume is removed simultaneously for product recovery. Continuous cultures generally maintain the cells in the log phase of growth at a constant cell density. Continuous or semi-continuous culture methods permit the modulation of one factor or any number of factors that affect cell growth or end product concentration. For example, one approach may limit the carbon source and allow all other parameters to moderate metabolism. In other systems, a number of factors affecting growth may be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth and thus the cell growth rate must be balanced against cell loss due to media being drawn off the culture. Methods of modulating nutrients and growth factors for continuous culture processes, as well as techniques for maximizing the rate of product formation, are well known in the art of industrial microbiology and a variety of methods are detailed by Brock, *supra*.

Purification Of PUFAs

[0161] The PUFAs may be found in the host microorganism as free fatty acids or in esterified forms such as acylglycerols, phospholipids, sulfolipids or glycolipids, and may be extracted from the host cell through a variety of means well-known in the art. One review of extraction techniques, quality analysis and acceptability standards for yeast lipids is that of Z. Jacobs (*Critical Reviews in Biotechnology* 12(5/6):463-491 (1992)). A brief review of downstream processing is also available by A. Singh and O. Ward (*Adv. Appl. Microbiol.* 45:271-312 (1997)).

[0162] In general, means for the purification of PUFAs may include extraction with organic solvents, sonication, supercritical fluid extraction (e.g., using carbon dioxide), saponification and physical means such as presses, or combinations thereof. Of particular interest is extraction with methanol and chloroform in the presence of water (E. G. Bligh & W.J. Dyer, *Can. J. Biochem. Physiol.* 37:911-917 (1959)). Where desirable, the aqueous layer can be acidified to protonate negatively-charged moieties and thereby increase partitioning of desired products into the organic layer. After extraction, the organic solvents can be removed by evaporation under a stream of nitrogen. When isolated in conjugated forms, the products may be enzymatically or chemically cleaved to release the free fatty acid or a less complex conjugate of interest, and can then be subject to further manipulations to produce a desired end product. Desirably, conjugated forms of fatty acids are cleaved with potassium hydroxide.

[0163] If further purification is necessary, standard methods can be employed. Such methods may include extraction, treatment with urea, fractional crystallization, HPLC, fractional distillation, silica gel chromatography, high-speed centrifugation or distillation, or combinations of these techniques. Protection of reactive groups, such as the acid or alkenyl groups, may be done at any step through known techniques (e.g., alkylation, iodination). Methods used include methylation of the fatty acids to produce methyl esters. Similarly, protecting groups may be removed at any step. Desirably, purification of fractions containing GLA, STA, ARA, DHA and EPA may be accomplished by treatment with urea and/or fractional distillation.

DESCRIPTION OF PREFERRED EMBODIMENTS

[0164] The present description demonstrates the feasibility of introducing an ω -3 and/or ω -6 biosynthetic pathway into oleaginous yeast for the production of PUFAs. Toward this end, ARA (representative of ω -6 fatty acids) and EPA (representative of ω -3 fatty acids) were selected as desirable products to produce in the oleaginous yeast, *Yarrowia lipolytica*. Thus, the synthesis of ARA required the introduction of genes encoding Δ 6 desaturase, elongase and Δ 5 desaturase activities into *Yarrowia*, whereas the synthesis of EPA required the introduction of genes encoding Δ 6 desaturase, elongase, Δ 5 desaturase and Δ 17 desaturase activities into *Yarrowia*.

[0165] A variety of publicly available Δ 5 desaturases from different organisms having the ability to convert DGLA to ARA and ETA to EPA were expressed in *Yarrowia lipolytica* and screened for activity, in order to identify the gene demonstrating the highest level of activity in the alternate host. On this basis, a *Mortierella alpina* Δ 5 desaturase (SEQ ID NO:4) was selected as the preferred gene for expression in oleaginous yeast, based on its ability to convert ~30% of intracellular DGLA to ARA in a substrate feeding trial.

[0166] Additional substrate feeding trials were conducted to verify the enzymatic activities encoded by the following genes:

- A *M. alpina* $\Delta 6$ desaturase (SEQ ID NO:2) converts LA to GLA and ALA to STA (wherein the percent substrate conversion of LA to GLA in *Y. lipolytica* was ~30%);
- A *Saprolegnia diclina* $\Delta 17$ desaturase (SEQ ID NO:6) converts DGLA to ETA and ARA to EPA (wherein the percent substrate conversion of ARA to EPA in *Y. lipolytica* was ~23%); and
- A *M. alpina* high affinity PUFA elongase (SEQ ID NO:8) converts GLA to DGLA, STA to ETA and EPA to DPA (wherein the percent substrate conversion of GLA to DGLA in *Y. lipolytica* was ~30%).

Based on the lower percent substrate conversion of the *S. diclina* $\Delta 17$ desaturase (relative to the $\Delta 6$ and $\Delta 5$ desaturase and the elongase), this particular gene was codon-optimized to enhance its expression in *Yarrowia*. This was accomplished by determining the codon usage and signature of structural genes in *Yarrowia lipolytica*, designing a codon-optimized $\Delta 17$ desaturase gene, and then synthesizing the gene *in vitro* to enable its increased efficiency in the alternate host (with respect to the wildtype gene).

[0167] To enable synthesis of ARA or EPA (and thereby demonstrate proof-of-concept for the ability of oleaginous hosts to be engineered for production of ω -6 and ω -3 fatty acids (i.e., ARA and EPA)), two different DNA expression constructs were subsequently prepared: 1.) the first contained the $\Delta 6$ desaturase, $\Delta 5$ desaturase and high-affinity PUFA elongase; and 2.) the second contained the $\Delta 6$ desaturase, $\Delta 5$ desaturase, high-affinity PUFA elongase and codon-optimized $\Delta 17$ desaturase. Both constructs were separately transformed into *Yarrowia lipolytica* and integrated into the chromosomal URA3 gene encoding the enzyme orotidine-5'-phosphate decarboxylase (EC 4.1.1.23). GC analysis of the host cells fed with appropriate substrates detected production of ARA (Example 5) and EPA (Example 6), respectively. Thus, this is the first demonstration of PUFA biosynthesis in an oleaginous yeast whereby the ω -3 and/or ω -6 biosynthetic pathways have been introduced into an oleaginous yeast.

[0168] On the basis of the teachings and results described herein, it is expected that one skilled in the art will recognize the feasibility and commercial utility created by using oleaginous yeast as a production platform for the synthesis of a variety of ω -3 and/or ω -6 PUFAs.

EXAMPLES

[0169] The present invention is further defined in the following Examples. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and can make various changes and modifications of the invention to adapt it to various usages and conditions.

GENERAL METHODS

[0170] Standard recombinant DNA and molecular cloning techniques used in the Examples are well known in the art and are described by: 1.) Sambrook, J., Fritsch, E. F. and Maniatis, T. Molecular Cloning: A Laboratory Manual; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY (1989) (Maniatis); 2.) T. J. Silhavy, M. L. Bennis, and L. W. Enquist, Experiments with Gene Fusions; Cold Spring Harbor Laboratory: Cold Spring Harbor, NY (1984); and 3.) Ausubel, F. M. et al., Current Protocols in Molecular Biology, published by Greene Publishing Assoc. and Wiley-Interscience (1987).

[0171] Materials and methods suitable for the maintenance and growth of microbial cultures are well known in the art. Techniques suitable for use in the following examples may be found as set out in Manual of Methods for General Bacteriology (Phillipp Gerhardt, R. G. E. Murray, Ralph N. Costilow, Eugene W. Nester, Willis A. Wood, Noel R. Krieg and G. Briggs Phillips, Eds), American Society for Microbiology: Washington, D.C. (1994)); or by Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, 2nd ed., Sinauer Associates: Sunderland, MA (1989). All reagents, restriction enzymes and materials used for the growth and maintenance of microbial cells were obtained from Aldrich Chemicals (Milwaukee, WI), DIFCO Laboratories (Detroit, MI), GIBCO/BRL (Gaithersburg, MD), or Sigma Chemical Company (St. Louis, MO), unless otherwise specified.

[0172] *E. coli* (XL1-Blue) competent cells were purchased from the Stratagene Company (San Diego, CA). *E. coli* strains were typically grown at 37 °C on Luria Bertani (LB) plates.

[0173] General molecular cloning was performed according to standard methods (Sambrook et al., *supra*). Oligonucleotides were

synthesized by Sigma-Genosys (Spring, TX). Site-directed mutagenesis was performed using Stratagene's QuickChange™ Site-Directed Mutagenesis kit, per the manufacturers' instructions. When polymerase chain reaction (PCR) or site-directed mutagenesis was involved in subcloning, the constructs were sequenced to confirm that no errors had been introduced to the sequence. PCR products were cloned into Promega's pGEM-T-easy vector (Madison, WI).

[0174] DNA sequence was generated on an ABI Automatic sequencer using dye terminator technology (U.S. 5,366,860; EP 272,007) using a combination of vector and insert-specific primers. Sequence editing was performed in Sequencher (Gene Codes Corporation, Ann Arbor, MI). All sequences represent coverage at least two times in both directions. Comparisons of genetic sequences were accomplished using DNASTAR software (DNA Star, Inc.). Alternatively, manipulations of genetic sequences were accomplished using the suite of programs available from the Genetics Computer Group Inc. (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, WI). The GCG program "Pileup" was used with the gap creation default value of 12, and the gap extension default value of 4. The GCG "Gap" or "Bestfit" programs were used with the default gap creation penalty of 50 and the default gap extension penalty of 3. Unless otherwise stated, in all other cases GCG program default parameters were used.

[0175] The meaning of abbreviations is as follows: "sec" means second(s), "min" means minute(s), "h" means hour(s), "d" means day(s), "μL" means microliter(s), "mL" means milliliter(s), "L" means liter(s), "μM" means micromolar, "mM" means millimolar, "M" means molar, "mmol" means millimole(s), "μmole" means micromole(s), "g" means gram(s), "μg" means microgram(s), "ng" means nanogram(s), "U" means unit(s), "bp" means base pair(s), and "kB" means kilobase(s).

Cultivation Of *Yarrowia lipolytica*

[0176] *Yarrowia lipolytica* strains ATCC #76982 and ATCC #90812 were purchased from the American Type Culture Collection (Rockville, MD). *Y. lipolytica* strains were usually grown at 28 °C on YPD agar (1 % yeast extract, 2% bactopectone, 2% glucose, 2% agar). For selection of transformants, minimal medium (0.17% yeast nitrogen base (DIFCO Laboratories, Detroit, MI) without ammonium sulfate or amino acids, 2% glucose, 0.1% proline, pH 6.1) was used. Supplements of adenine, leucine, lysine and/or uracil were added as appropriate to a final concentration of 0.01 %.

Fatty Acid Analysis Of *Yarrowia lipolytica*

[0177] For fatty acid analysis, cells were collected by centrifugation and lipids were extracted as described in Bligh, E. G. & Dyer, W. J. (Can. J. Biochem. Physiol. 37:911-917 (1959)). Fatty acid methyl esters were prepared by transesterification of the lipid extract with sodium methoxide (Roughan, G., and Nishida I. Arch Biochem Biophys. 276(1):38-46 (1990)) and subsequently analyzed with a Hewlett-Packard 6890 GC fitted with a 30-m X 0.25 mm (i.d.) HP-INNOWAX (Hewlett-Packard) column. The oven temperature was from 170 °C (25 min hold) to 185 °C at 3.5 °C/min.

[0178] For direct base transesterification, *Yarrowia* culture (3 mL) was harvested, washed once in distilled water, and dried under vacuum in a Speed-Vac for 5-10 min. Sodium methoxide (100 μl of 1 %) was added to the sample, and then the sample was vortexed and rocked for 20 min. After adding 3 drops of 1 M NaCl and 400 μl hexane, the sample was vortexed and spun. The upper layer was removed and analyzed by GC as described above.

EXAMPLE 1

Construction Of Plasmids Suitable For Heterologous Gene Expression In *Yarrowia lipolytica*

[0179] The plasmid pY5, a derivative of pINA532 (a gift from Dr. Claude Gaillardin, Institut National Agronomique, Centre de biotechnologie Agro-Industrielle, laboratoire de Genetique Moleculaire et Cellulaire INRA-CNRS, F-78850 Thiverval-Grignon, France), was constructed for expression of heterologous genes in *Yarrowia lipolytica*, as diagrammed in Figure 3.

[0180] First, the partially-digested 3598 bp *EcoRI* fragment containing the ARS18 sequence and LEU2 gene of pINA532 was subcloned into the *EcoRI* site of pBluescript (Stratagene, San Diego, CA) to generate pY2. The TEF promoter (Muller S., et al. Yeast, 14: 1267-1283 (1998)) was amplified from *Yarrowia lipolytica* genomic DNA by PCR using TEF5' (SEQ ID NO:38) and

TEF3' (SEQ ID NO:39) as primers. PCR amplification was carried out in a 50 µl total volume containing: 100 ng *Yarrowia* genomic DNA, PCR buffer containing 10 mM KCl, 10 mM (NH₄)₂SO₄, 20 mM Tris-HCl (pH 8.75), 2 mM MgSO₄, 0.1% Triton X-100, 100 µg/mL BSA (final concentration), 200 µM each deoxyribonucleotide triphosphate, 10 pmole of each primer and 1 µl of PfuTurbo DNA polymerase (Stratagene, San Diego, CA). Amplification was carried out as follows: initial denaturation at 95 °C for 3 min, followed by 35 cycles of the following: 95 °C for 1 min, 56 °C for 30 sec, 72 °C for 1 min. A final extension cycle of 72 °C for 10 min was carried out, followed by reaction termination at 4 °C. The 418 bp PCR product was ligated into pCR-Blunt to generate pIP-tef. The *Bam*HI/*Eco*RV fragment of pIP-tef was subcloned into the *Bam*HI/*Sma*I sites of pY2 to generate pY4.

[0181] The XPR2 transcriptional terminator was amplified by PCR using pINA532 as template and XPRS' (SEQ ID NO:40) and XPR3' (SEQ ID NO:41) as primers. The PCR amplification was carried out in a 50 µl total volume, using the components and conditions described above. The 179 bp PCR product was digested with *Sac*II and then ligated into the *Sac*II site of pY4 to generate pY5. Thus, pY5 (shown in Figures 3 and 4) is useful as a *Yarrowia-E. coli* shuttle plasmid containing:

1. 1.) a *Yarrowia* autonomous replication sequence (ARS18);
2. 2.) a ColE1 plasmid origin of replication;
3. 3.) an ampicillin-resistance gene (Amp^R), for selection in *E. coli*;
4. 4.) a *Yarrowia* LEU2 gene (E.C. 4.2.1.33, encoding isopropylmalate isomerase), for selection in *Yarrowia*;
5. 5.) the translation elongation promoter (TEF P), for expression of heterologous genes in *Yarrowia*; and
6. 6.) the extracellular protease gene terminator (XPR2) for transcriptional termination of heterologous gene expression in *Yarrowia*.

[0182] pY5-13 (Figure 4) was constructed as a derivative of pY5 to facilitate subcloning and heterologous gene expression in *Yarrowia lipolytica*. Specifically, pY5-13 was constructed by 6 rounds of site-directed mutagenesis using pY5 as template. Both *Sall* and *Clal* sites were eliminated from pY5 by site-directed mutagenesis using oligonucleotides YL5 and YL6 (SEQ ID NOs:106 and 107) to generate pY5-5. A *Sall* site was introduced into pY5-5 between the Leu2 gene and the TEF promoter by site-directed mutagenesis using oligonucleotides YL9 and YL10 (SEQ ID NOs:110 and 111) to generate pY5-6. A *PacI* site was introduced into pY5-6 between the LEU2 gene and ARS18 using oligonucleotides YL7 and YL8 (SEQ ID NOs:108 and 109) to generate pY5-8. A *NcoI* site was introduced into pY5-8 around the translation start codon of the TEF promoter using oligonucleotides YL3 and YL4 (SEQ ID NOs:104 and 105) to generate pY5-9. The *NcoI* site inside the Leu2 gene of pY5-9 was eliminated using YL1 and YL2 oligonucleotides (SEQ ID NOs:102 and 103) to generate pY5-12. Finally, a *Bsi*WI site was introduced into pY5-12 between the ColEI and XPR2 region using oligonucleotides YL61 and YL62 (SEQ ID NOs:88 and 89) to generate pY5-13.

[0183] A second derivative of plasmid pY5 was constructed to facilitate subcloning. Specifically, pY5-4 (Figure 4) was constructed by three rounds of site-directed mutagenesis using pY5 as template. A *NcoI* site located inside the *Leu2* reporter gene was eliminated from pY5 using oligonucleotides YL1 and YL2 (SEQ ID NOs:102 and 103) to generate pY5-1. A *NcoI* site was introduced into pY5-1 between the TEF promoter and XPR2 transcriptional terminator by site-directed mutagenesis using oligonucleotides YL3 and YL4 (SEQ ID NOs:104 and 105) to generate pY5-2. A *PacI* site was then introduced into pY5-2 between the TEF promoter and XPR2 transcriptional terminator using oligonucleotides YL23 and YL24 (SEQ ID NOs:112 and 113) to generate pY5-4.

EXAMPLE 2

Selection Of $\Delta 6$ Desaturase, $\Delta 5$ Desaturase, $\Delta 17$ Desaturase And High Affinity PUFA Elongate Genes For Expression In *Yarrowia lipolytica*

[0184] Prior to the introduction of specific genes encoding an ω -3 and/or ω -6 biosynthetic pathway into oleaginous yeast, it was necessary to confirm the functionality of heterologous $\Delta 6$ desaturase, elongase, $\Delta 5$ desaturase and $\Delta 17$ desaturase genes expressed in *Yarrowia*. This was accomplished by measuring the conversion efficiency encoded by each wildtype gene in the alternate host. Specifically, four $\Delta 5$ desaturases, a *Mortierella alpina* $\Delta 6$ desaturase, a *Saprolegnia diclina* $\Delta 17$ desaturase and a *M. alpina* high affinity PUFA elongase were separately expressed and screened for activity in substrate-feeding trials. Based on these results, a *M. alpina* $\Delta 5$ desaturase gene was selected for use in conjunction with the $\Delta 6$ and $\Delta 17$ desaturase and high affinity PUFA elongase genes.

Construction Of Expression Plasmids

[0185] In general, wildtype desaturase or elongase genes were either isolated by restriction digestion or amplified by PCR and inserted into appropriate vectors for expression. Each PCR amplification was carried out in a 50 µl total volume, comprising PCR buffer containing: 10 ng template, 10 mM KCl, 10 mM (NH₄)₂SO₄, 20 mM Tris-HCl (pH 8.75), 2 mM MgSO₄, 0.1% Triton X-100, 100 µg/mL BSA (final concentration), 200 µM each deoxyribonucleotide triphosphate, 10 pmole of each primer and 1 µl of PfuTurbo DNA polymerase (Stratagene, San Diego, CA). Amplification was carried out as follows (unless otherwise specified): initial denaturation at 95 °C for 3 min, followed by 35 cycles of the following: 95 °C for 1 min, 56 °C for 30 sec, 72 °C for 1 min. A final extension cycle of 72 °C for 10 min was carried out, followed by reaction termination at 4 °C.

Wild Type *Mortierella alpina* (Accession #AF465281) Δ6 Desaturase

[0186] The 1384 bp *NcoII/NotI* fragment of pCGR5 (U.S. 5,968,809), which contains the *M. alpina* Δ6 desaturase gene (SEQ ID NO:1), was inserted into the *NcoII/NotI* sites of pY5-2 (Example 1) to generate pY54.

Wild Type *Mortierella alpina* (Accession #AF067654) Δ5 Desaturase

[0187] The *M. alpina* Δ5 desaturase gene (SEQ ID NO:3) was amplified by PCR using oligonucleotides YL11 and YL12 (SEQ ID NOs:72 and 73) as primers and plasmid pCGR-4 (U.S. 6,075,183) as template. PCR amplification was carried out as described above, with the exception that the elongation step was extended to 1.5 min (for cycles 1-35). The 1357 bp PCR product was digested with *NcoII/NotI* and ligated to *NcoII/NotI*-digested pY5-13 (described in Example 1) to generate pYMA5pb (Figure 5).

Wild Type *Saprolegnia diclina* (ATCC #56851) Δ5 Desaturase

[0188] The *S. diclina* Δ5 desaturase gene (SEQ ID NO:114) was amplified by PCR using oligonucleotides YL13A and YL14 (SEQ ID NOs:116 and 117) as primers and plasmid pRSP3 (WO 02/081668) as template. PCR amplification was carried out as described above, with the exception that the elongation step was extended to 1.5 min (for cycles 1-35). The 1.4 kbp PCR product was digested with *NcoII/PacI* and ligated to *NcoII/PacI*-digested pY5-4 (Figure 4; described in Example 1) to generate pYSD5.

Wild Type *Isochrysis galbana* CCMP1323 Δ5 Desaturase

[0189] The *I. galbana* Δ5-desaturase gene (SEQ ID NO:118) was amplified by PCR using oligonucleotides YL19A and YL20 (SEQ ID NOs:120 and 121) as primers and plasmid pRIG-1 (WO 02/081668 A2) as template. PCR amplification was carried out as described above, with the exception that the elongation step was extended to 1.5 min (for cycles 1-35). The 1.4 kbp PCR product was digested with *BamHI/PacII* and ligated to *BamHI/PacII* - digested pY5-4 (described in Example 1) to generate pYIG5.

Wild Type *Thraustochytrium aureum* (ATCC #34304) Δ5 Desaturase

[0190] The *T. aureum* Δ5-desaturase gene (SEQ ID NO:122) was amplified by PCR using oligonucleotides YL15 and YL16B (SEQ ID NOs:124 and 125) as primers and plasmid pRTA4 (WO 02/081668 A2) as template. PCR amplification was carried out as described above, with the exception that the elongation step was extended to 1.5 min (for cycles 1-35). The 1.4 kbp PCR product was digested with *NcoII/NotI* and ligated to *NcoII/NotI*-digested pY5-2 (described in Example 1) to generate pYTA5.

Wild Type *Saprolegnia diclina* (ATCC #56851) Δ17 Desaturase

[0191] The wild type Δ17 desaturase gene of *S. diclina* was amplified from plasmid pRSP19 (US 2003/0196217 A1) by PCR using oligonucleotides YL21A (SEQ ID NO:42) and YL22 (SEQ ID NO:43) as primers. The PCR products were digested with *NcoII/PacI* and then ligated to *NcoII/PacI* - digested pY5-4 (Figure 4; described in Example 1) to generate pYSD17.

Wild Type *Mortierella alpina* (Accession #AX464731) High Affinity Elongase

[0192] The 973 bp *NotI* fragment of pRPB2 (WO 00/12720), containing the coding region of a *M. alpina* high affinity PUFA elongase gene (SEQ ID NO:7), was inserted into the *NotI* site of pY5 (described in Example 1; Figures 3 and 4) to generate pY58.

Transformation Of *Yarrowia lipolytica*

[0193] The plasmids pY54, pYMA5pb, pYSD5, pYIG5, pYTA5, pYSD17 and pY58 were transformed separately into *Y. lipolytica* ATCC #76982 according to the method of Chen, D. C. et al. (Appl Microbiol Biotechnol. 48(2):232-235-(1997)).

[0194] Briefly, a leucine auxotroph of *Yarrowia* was streaked onto a YPD plate and grown at 30 °C for approximately 18 hr. Several large loopfuls of cells were scraped from the plate and resuspended in 1 mL of transformation buffer containing:

- 2.25 mL of 50% PEG, average MW 3350;
- 0.125 mL of 2 M Li acetate, pH 6.0;
- 0.125 mL of 2M DTT; and
- 50 µg sheared salmon sperm DNA.

[0195] About 500 ng of plasmid DNA were incubated in 100 µl of resuspended cells, and maintained at 39 °C for 1 hr with vortex mixing at 15 min intervals. The cells were plated onto minimal media plates lacking leucine and maintained at 30 °C for 2 to 3 days.

Determination Of Percent Substrate Conversion

[0196] Single colonies of transformant *Y. lipolytica* containing pY54, pYMA5pb, pYSD5, pYIG5, pYTA5, pYSD17 or pY58 were each grown in 3 mL minimal media (20 g/L glucose, 1.7 g/L yeast nitrogen base without amino acids, 1 g/L L-proline, 0.1 g/L L-adenine, 0.1 g/L L-lysine, pH 6.1) at 30 °C to an OD₆₀₀ ~ 1.0. For substrate feeding, 100 µl of cells were then subcultured in 3 mL minimal media containing 10 µg of substrate for about 24 hr at 30 °C. Cells were subsequently collected by centrifugation, the lipids were extracted, and fatty acid methyl esters were prepared by transesterification and subsequently analyzed by GC (as described in the General Methods). Percent substrate conversion was determined as: [product/(substrate + product)]*100.

Percent Substrate Conversion By *M. alpina* Δ6 Desaturase

[0197] The *M. alpina* Δ6 desaturase converts LA to GLA and ALA to STA. *Y. lipolytica* strains containing pY54 were grown as described above (no substrate feeding required) and lipids were analyzed. The results showed that *Yarrowia* strains with pY54 converted about 30% LA to GLA.

Percent Substrate Conversion By *M. alpina*, *S. diclina*, *I. galbana* and *T. aureum* Δ5 Desaturases

[0198] The Δ5 desaturases from *M. alpina*, *S. diclina*, *I. galbana* and *T. aureum* each convert DGLA to ARA and ETA to EPA. *Y. lipolytica* strains containing pYMA5pb, pYSD5, pYIG5 or pYTA5 were grown separately from single colonies, subcultured in minimal media containing 10 µg of DGLA, and then subjected to lipid analysis as described above. *Yarrowia* strains with pYMA5pb (*M. alpina*) converted about 30% of intracellular DGLA to ARA; the *Yarrowia* strains with pYSD5 (*S. diclina*) converted about 12%; the *Yarrowia* strains with pYIG5 (*I. galbana*) converted about 7%; and the *Yarrowia* strains with pYTA5 (*T. aureum*) converted about 23% of intracellular DGLA to ARA.

Percent Substrate Conversion By *S. diclina* Δ17 Desaturase

[0199] The *S. diclina* $\Delta 17$ desaturase converts ARA to EPA and DGLA to ETA. *Y. lipolytica* strains containing pYSD17 were grown from single colonies, subcultured in minimal media containing 10 μ g of ARA, and subjected to lipid analysis as described above. The results of the ARA feeding experiments showed that *Yarrowia* strains with pYSD17 converted about 23% of intracellular ARA to EPA.

Percent Substrate Conversion Of Wild Type *M. alpina* High Affinity Elongase

[0200] The *M. alpina* high affinity PUFA elongase converts GLA to DGLA, STA to ETA and EPA to DPA. *Y. lipolytica* strains containing pY58 were grown from single colonies, subcultured in minimal media containing 10 μ g of GLA, and subjected to lipid analysis as described above. The results of the GLA feeding experiments showed that *Yarrowia* strains with pY58 converted about 30% of intracellular GLA to DGLA.

EXAMPLE 3

Synthesis And Expression Of A Codon-Optimized $\Delta 17$ Desaturase Gene In *Yarrowia lipolytica*

[0201] Based on the results of Example 2, genes encoding $\Delta 6$ desaturase, elongase and $\Delta 5$ desaturase activities were available that each enabled ~30% substrate conversion in *Yarrowia lipolytica*. The $\Delta 17$ desaturase from *S. diclina*, however, had a maximum percent substrate conversion of only 23%. Thus, a codon-optimized $\Delta 17$ desaturase gene was designed, based on the *Saprolegnia diclina* DNA sequence (SEQ ID NO:5), according to the *Yarrowia* codon usage pattern, the consensus sequence around the ATG translation initiation codon and the general rules of RNA stability (Guhaniyogi, G. and J. Brewer, Gene 265(1-2):11-23 (2001)).

[0202] In addition to modification to the translation initiation site, 127 bp of the 1077 bp coding region (comprising 117 codons) were codon-optimized. A comparison between this codon-optimized DNA sequence (SEQ ID NO:9) and the *S. diclina* $\Delta 17$ desaturase gene DNA sequence (SEQ ID NO:5) is shown in Figure 6, wherein nucleotides in bold text correspond to nucleotides that were modified in the codon-optimized gene. None of the modifications in the codon-optimized gene changed the amino acid sequence of the encoded protein (SEQ ID NO:6).

Determining The Preferred Codon Usage In *Yarrowia lipolytica*

[0203] Approximately 100 genes of *Y. lipolytica* were found in the National Center for Biotechnology Information public database. The coding regions of these genes, comprising 121,167 bp, were translated by the Editseq program of DNASTar to the corresponding 40,389 amino acids and were tabulated to determine the *Y. lipolytica* codon usage profile shown in Table 3. The column titled "No." refers to the number of times a given codon encodes a particular amino acid in the sample of 40,389 amino acids. The column titled "%" refers to the frequency that a given codon encodes a particular amino acid. Entries shown in bold text represent the codons favored in *Yarrowia lipolytica*.

TABLE 3

Codon Usage In <i>Yarrowia lipolytica</i>			
Codon	Amino Acid	No.	%
GCA	Ala (A)	359	11.4
GCC	Ala (A)	1523	48.1
GCG	Ala (A)	256	8.1
GCU	Ala (A)	1023	32.3
AGA	Arg (R)	263	13.2
AGG	Arg (R)	91	4.6
CGA	Arg (R)	1133	56.8
CGC	Arg (R)	108	5.4
CGG	Arg (R)	209	1.0

Codon Usage In <i>Yarrowia lipolytica</i>			
Codon	Amino Acid	No.	%
CGU	Arg (R)	189	9.5
AAC	Ans (N)	1336	84.0
AAU	Ans (N)	255	16.0
GAC	Asp (D)	1602	66.8
GAU	Asp (D)	795	33.2
UGC	Cys (C)	268	53.2
UGU	Cys (C)	236	46.8
CAA	Gln (Q)	307	17.0
CAG	Gln (Q)	1490	83.0
GAA	Glu (E)	566	23.0
GAG	Glu (E)	1893	77.0
GGA	Gly (G)	856	29.7
GGC	Gly (G)	986	34.2
GGG	Gly (G)	148	5.1
GGU	Gly (G)	893	31.0
CAC	His (H)	618	65.5
CAU	His (H)	326	34.5
AUA	Ile (I)	42	2.1
AUC	Ile (I)	1106	53.7
AUU	Ile (I)	910	44.2
CUA	Leu (L)	166	4.7
CUC	Leu (L)	1029	29.1
CUG	Leu (L)	1379	38.9
AAA	Lys (K)	344	14.8
AAG	Lys (K)	1987	85.2
AUG	Met (M)	1002	100
UUC	Phe (F)	996	61.1
UUU	Phe (F)	621	38.9
CCA	Pro (P)	207	9.6
CCC	Pro (P)	1125	52.0
CCG	Pro (P)	176	8.2
CCU	Pro (P)	655	30.2
AGC	Ser (S)	335	11.3
AGU	Ser (S)	201	6.8
UCA	Ser (S)	221	7.5
UCC	Ser (S)	930	31.5
UCG	Ser (S)	488	16.5
UCU	Ser (S)	779	26.4
UAA	Term	38	46.9
UAG	Term	30	37.0
UGA	Term	13	16.1
ACA	Thr (T)	306	12.7

Codon Usage In <i>Yarrowia lipolytica</i>			
Codon	Amino Acid	No.	%
ACC	Thr (T)	1245	51.6
ACG	Thr (T)	269	11.1
ACU	Thr (T)	595	24.6
UGG	Trp (W)	488	100
UAC	Tyr (Y)	988	83.2
UAU	Tyr (Y)	200	16.8
GUA	Val (V)	118	4.2
GUC	Val (V)	1052	37.3
GUG	Val (V)	948	33.6
GUU	Val (V)	703	24.9
CUU	Leu (L)	591	16.7
UUA	Leu (L)	54	1.5
UUG	Leu (L)	323	9.1

[0204] For further optimization of gene expression in *Y. lipolytica*, the consensus sequence around the 'ATG' initiation codon of 79 genes was examined. In Figure 7, the first 'A' of the underlined ATG translation codon is considered to be +1. Seventy seven percent of the genes analyzed had an 'A' in the -3 position, indicating a strong preference for 'A' at this position. There was also preference for 'A' or 'C' at the -4, -2 and -1 positions, an 'A', 'C' or 'T' at position +5, and a 'G' or 'C' at position +6. Thus, the preferred consensus sequence of the codon-optimized translation initiation site for optimal expression of genes in *Y. lipolytica* is 'MAMMATGNHS' (SEQ ID NO:126), wherein the nucleic acid degeneracy code used is as follows: M=A/C; S=C/G; H=A/C/T; and N=A/C/G/T.

In Vitro Synthesis Of A Codon-Optimized Gene

[0205] The method used to synthesize the codon-optimized $\Delta 17$ desaturase gene is illustrated in Figure 8. First, eleven pairs of oligonucleotides were designed to extend the entire length of the codon-optimized coding region of the *S. diclina* $\Delta 17$ desaturase gene (e.g., D17-1A, D17-1B, D17-2A, D17-2B, D17-3A, D17-3B, D17-4A, D17-4B, D17-5A, D17-5B, D17-6A, D17-6B, D17-7A, D17-7B, D17-8A, D17-8B, D17-9A, D17-9B, D17-10A, D17-10B, D17-11A and D17-11B, corresponding to SEQ ID NOs:10-31). Each pair of sense (A) and anti-sense (B) oligonucleotides were complementary, with the exception of a 4 bp overhang at each 5'-end. Additionally, primers D17-1A, D17-4B, D17-5A, D17-8A and D17-8B also introduced *NcoI*, *BglII* and *Sall* restriction sites for subsequent subcloning, respectively.

[0206] 100 ng of each oligonucleotide was phosphorylated at 37 °C for 1 hr in a volume of 20 μ l containing 50 mM Tris-HCl (pH 7.5), 10 mM $MgCl_2$, 10 mM DTT, 0.5 mM spermidine, 0.5 mM ATP and 10 U of T4 polynucleotide kinase. Each pair of sense and antisense oligonucleotides was mixed and annealed in a thermocycler using the following parameters: 95 °C (2 min), 85 °C (2 min), 65 °C (15 min), 37 °C (15 min), 24 °C (15 min) and 4 °C (15 min). Thus, D17-1A (SEQ ID NO:10) was annealed to D17-1B (SEQ ID NO:11) to produce the double-stranded product "D17-1AB". Similarly, D17-2A (SEQ ID NO:12) was annealed to D17-2B (SEQ ID NO:13) to produce the double-stranded product "D17-2AB", etc.

[0207] Three separate pools of annealed, double-stranded oligonucleotides were then ligated together, as shown below.

- Pool 1: comprised D17-1AB, D17-2AB, D17-3AB and D17-4AB;
- Pool 2: comprised D17-5AB, D17-6AB, D17-7AB and D17-8AB; and
- Pool 3: comprised D17-9AB, D17-10AB and D17-11AB.

Each pool of annealed oligonucleotides was mixed in a volume of 20 μ l with 10 U of T4 DNA ligase and the ligation reaction was incubated overnight at 16 °C.

[0208] The product of each ligation reaction was then amplified by PCR. Specifically, using the ligated "Pool 1" mixture (i.e., D17-

1AB, D17-2AB, D17-3AB and D17-4AB) as template, and oligonucleotides D17-1 (SEQ ID NO:32) and D17-4R (SEQ ID NO:33) as primers, the first portion of the codon-optimized $\Delta 17$ desaturase gene was amplified by PCR. The PCR amplification was carried out in a 50 μ l total volume, comprising PCR buffer containing 10 mM KCl, 10 mM $(\text{NH}_4)_2\text{SO}_4$, 20 mM Tris-HCl (pH 8.75), 2 mM MgSO_4 , 0.1% Triton X-100, 100 $\mu\text{g}/\text{mL}$ BSA (final concentration), 200 μM each deoxyribonucleotide triphosphate, 10 pmole of each primer and 1 μ l of PfuTurbo DNA polymerase (Stratagene, San Diego, CA). Amplification was carried out as follows: initial denaturation at 95 °C for 3 min, followed by 35 cycles of the following: 95 °C for 1 min, 56 °C for 30 sec, 72 °C for 40 sec. A final extension cycle of 72 °C for 10 min was carried out, followed by reaction termination at 4 °C. The 430 bp PCR fragment was subcloned into the pGEM-T easy vector (Promega) to generate pT17(1-4).

[0209] Using the ligated "Pool 2" mixture (i.e., D17-5AB, D17-6AB, D17-7AB and D17-8AB) as template, and oligonucleotides D17-5 (SEQ ID NO:34) and D17-8D (SEQ ID NO:35) as primers, the second portion of the codon-optimized $\Delta 17$ desaturase gene was amplified similarly by PCR and cloned into pGEM-T-easy vector to generate pT17(5-8). Finally, using the "Pool 3" ligation mixture (i.e., D17-9AB, D17-10AB and D17-11AB) as template, and oligonucleotides D17-8U (SEQ ID NO:36) and D17-11 (SEQ ID NO:37) as primers, the third portion of the codon-optimized $\Delta 17$ desaturase gene was amplified similarly by PCR and cloned into pGEM-T-easy vector to generate pT17(9-11).

[0210] *E. coli* was transformed separately with pT17(1-4), pT17(5-8) and pT17(9-11) and the plasmid DNA was isolated from ampicillin-resistant transformants. Plasmid DNA was purified and digested with the appropriate restriction endonucleases to liberate the 420 bp *NcoII/BglII* fragment of pT17(1-4), the 400 bp *BglII/SalI* fragment of pT17(5-8) and the 300 bp *SalI/NotI* fragment of pT17(9-11). These fragments were then combined, ligated together and used as template for amplification of the entire synthetic codon-optimized $\Delta 17$ desaturase gene using D17-1 (SEQ ID NO: 32) and D17-11 (SEQ ID NO:37) as primers. The PCR amplification was carried out in a 50 μ l total volume, using the conditions described above for each portion of the $\Delta 17$ desaturase gene and the thermocycling program as follows: initial denaturation at 95 °C for 3 min, followed by 35 cycles of the following: 95 °C for 1 min, 56 °C for 30 sec, 72 °C for 1.1 min. A final extension cycle of 72 °C for 10 min was carried out, followed by reaction termination at 4 °C. This generated a 1.1 kbp PCR product.

Construction Of Plasmid pYSD17s Containing The Codon-Optimized $\Delta 17$ Desaturase

[0211] The 1.1 kbp PCR product comprising the entire synthetic $\Delta 17$ desaturase was digested with *NcoII/NotI* and subcloned into *NcoII/NotI* - digested pY5-13 (Example 1) to generate pYSD17S (Figure 9A).

[0212] As an additional "control", to compare the efficiency of the wild type and synthetic genes in *Yarrowia*, the AT-rich *PacI* site in pYSD17 (comprising the wild-type gene; described in Example 2) was eliminated by site-directed mutagenesis using YL53 (SEQ ID NO:44) and YL54 (SEQ ID NO:45) as primers to generate pYSD17M (Figure 9B).

Transformation Of *Yarrowia lipolytica* With The Codon-Optimized $\Delta 17$ Desaturase Gene

[0213] Plasmids containing the wildtype and codon-optimized $\Delta 17$ desaturase were transformed separately into *Y. lipolytica* ATCC #76982 according to the methods described above in Example 2. Using this technique, transformants were obtained that contained the following plasmids:

Table 4

Summary Of Plasmids In Transformant <i>Yarrowia</i>	
Plasmid	Description
pYSD17	wildtype $\Delta 17$ desaturase
pYSD17M	wildtype $\Delta 17$ desaturase, minus AT-rich <i>PacI</i> site
pYSD17S	codon-optimized $\Delta 17$ desaturase

Percent Substrate Conversion With The Codon-Optimized $\Delta 17$ Desaturase Gene

[0214] $\Delta 17$ desaturase converts ARA to EPA (see Figure 2). The percent substrate conversion ($[\text{product}]/[\text{substrate} + \text{product}] \times 100$) of the wildtype and codon-optimized $\Delta 17$ desaturase genes was determined in *Yarrowia lipolytica* containing each

alternate plasmid construct, using the methodology described in the General Methods.

[0215] The results of the ARA feeding experiments showed that *Yarrowia* strains with control plasmids pYSD17 or pYSD17M converted about 23% of intracellular ARA to EPA (Figure 10A) while those containing the codon-optimized $\Delta 17$ desaturase gene within pYSD17S converted about 45% of intracellular ARA to EPA (Figure 10B). Thus, *Yarrowia* containing the codon-optimized $\Delta 17$ desaturase converted about 2-fold more ARA than the strains containing the wild type *S. diclina* gene.

EXAMPLE 4

Construction Of Plasmids Suitable For The Coordinate Expression Of Multiple Omega Fatty Acid Biosynthesis Genes In *Yarrowia lipolytica*

[0216] The present Example describes the synthesis of a variety of expression plasmids that were required in order to construct: 1.) a DNA fragment suitable for integration into the *Yarrowia* genome for expression of the $\Delta 6$ desaturase, PUFA elongase and $\Delta 5$ desaturase (for ARA production); and 2.) a DNA fragment suitable for integration into the *Yarrowia* genome for expression of the $\Delta 6$ desaturase, PUFA elongase, $\Delta 5$ desaturase and $\Delta 17$ desaturase (for EPA production).

Construction Of Plasmid pY24

[0217] Plasmid pY24 (Figure 11) was a parent vector for construction of expression cassettes suitable for integration into the genome of *Yarrowia lipolytica*. pY24 was constructed as follows:

[0218] Using oligonucleotides KU5 and KU3 (SEQ ID NOs:46 and 47) as primers and *Yarrowia* genomic DNA as template, a 1.7 kB DNA fragment (SEQ ID NO:48) containing the *Yarrowia* URA3 gene was PCR amplified. The PCR amplification was carried out in a 50 μ l total volume containing: 100 ng *Yarrowia* genomic DNA, PCR buffer containing 10 mM KCl, 10 mM $(\text{NH}_4)_2\text{SO}_4$, 20 mM Tris-HCl (pH 8.75), 2 mM MgSO_4 , 0.1% Triton X-100, 100 μ g/mL BSA (final concentration), 200 μ M each deoxyribonucleotide triphosphate, 10 pmole of each primer and 1 μ l of PfuTurbo DNA polymerase (Stratagene, San Diego, CA). Amplification was carried out as follows: initial denaturation at 95 °C for 3 min, followed by 35 cycles of the following: 95 °C for 1 min, 56 °C for 30 sec, 72 °C for 2 min. A final extension cycle of 72 °C for 10 min was carried out, followed by reaction termination at 4 °C. The PCR product was inserted into pGEM-T easy vector (Promega, Madison, WI) to generate pGYUM.

[0219] Using oligonucleotides KI5 and KI3 (SEQ ID NOs:50 and 51), a 1.1 kB DNA fragment (SEQ ID NO:52) containing the conjugase gene (or "imp H8") of *Impatiens balsama* (clone ids.pk0001.h8; E. I. du Pont de Nemours and Company, Inc., Wilmington, DE) was PCR amplified. The PCR amplification was carried out in a 50 μ l total volume using the components described above, with the exception that 10 ng plasmid DNA of ids.pk0001.h8 was used as template. Amplification was carried out as follows: initial denaturation at 95 °C for 3 min, followed by 35 cycles of the following: 95 °C for 1.5 min, 56 °C for 30 sec, 72 °C for 1.2 min. A final extension cycle of 72 °C for 10 min was carried out, followed by reaction termination at 4 °C. The PCR products were digested with *NotI*, and then inserted into the *NotI* site of pY5 (Figure 3) to generate pY9.

[0220] Using oligonucleotides KT15 and KT13 (SEQ ID NOs:54 and 55), a 1.7 kB DNA fragment (SEQ ID NO:56) containing the TEF::IMP H8::XPR chimeric gene of pY9 was PCR amplified. The PCR amplification was carried out in a 50 μ l total volume as described above, with the exception that 10 ng plasmid DNA of pGYUM was used as template. Amplification was carried out as follows: initial denaturation at 95 °C for 3 min, followed by 35 cycles of the following: 95 °C for 1 min, 56 °C for 30 sec, 72 °C for 2 min. A final extension cycle of 72 °C for 10 min was carried out, followed by reaction termination at 4 °C. The PCR products were inserted into PCR-Script (Stratagene) to generate pY9R. The 1.7 kB *XhoI*/*EcoRV* fragment of pY9R was exchanged with the *XhoI*/*EcoRV* fragment of pGYUM to generate pY21.

[0221] Using oligonucleotides KH5 and KH3 (SEQ ID NOs:58 and 59) as primers and genomic DNA of KS65 as template, a 1 kB DNA fragment (SEQ ID NO:60) containing the *E. coli* hygromycin resistance gene ("HPT"; Kaster, K.R., et al., Nucleic Acids Res. 11:6895-6911 (1983)) was PCR amplified. The PCR amplification was carried out in a 50 μ l total volume using the components described above, with the exception that 10 ng plasmid DNA of ids.pk0001.h8 was used as template. Amplification was carried out as follows: initial denaturation at 95 °C for 3 min, followed by 35 cycles of the following: 95 °C for 1 min, 56 °C for 30 sec, 72 °C for 1.2 min. A final extension cycle of 72 °C for 10 min was carried out, followed by reaction termination at 4 °C. The PCR

products were digested with *NotI*, and then inserted into the *NotI* site of pY5 (Figure 3) to generate pTHPT-1.

[0222] Using oligonucleotides KTH5 and KTH3 (SEQ ID NOs:62 and 63) as primers and pTHPT-1 plasmid DNA as template, a 1.6 kb DNA fragment (SEQ ID NO:64) containing the TEF::HPT::XPR fusion gene was amplified as described above. The PCR products were digested with *BglII* and then inserted into pY21 to generate pY24.

Construction Of pY24-4

[0223] Plasmid pY24 (Figure 11) was used for construction of expression cassettes suitable for integration into the *Yarrowia lipolytica* genome. The 401 bp of 5'-sequence (SEQ ID NO:66) and the 568 bp of 3'-sequence (SEQ ID NO:67) from the *Y. lipolytica* URA3 gene in pY24 plasmid were used to direct integration of expression cassettes into the Ura loci of the *Yarrowia* genome. Two chimeric genes (TEF::HPT::XPR and TEF::IMP H8::XPR) were first removed from pY24 by digestion with *BamHI* and self-ligation to generate pY24-1. *PacI* and *BsiWI* sites were introduced into pY24-1 by site-directed mutagenesis using YL63/YL64 (SEQ ID NOs:68 and 69) and YL65/YL66 (SEQ ID NOs:70 and 71) primer pairs, respectively, to generate pY24-4.

Construction Of An Integration Vector For Expression Of $\Delta 5$ Desaturase

[0224] The 4261 bp *PacI/BsiWI* fragment of pYMA5pb (comprising the *M. alpina* $\Delta 5$ desaturase gene; described in Example 2) was ligated into the *PacI/BsiWI* sites of pY24-4 (Figure 11) to generate pYZM5 (Figure 5). *HindIII* and *Clal* sites were introduced into pYZM5 by site-directed mutagenesis using primer pairs YL81 and YL82 (SEQ ID NOs:74 and 75) and YL83 and YL84 (SEQ ID NOs:76 and 77), respectively, to generate pYZM5CH. A *PmeI* site was introduced into pYZM5CH by site-directed mutagenesis using YL105 and YL106 (SEQ ID NOs:78 and 79) as primers to generate pYZM5CHPP. An *AscI* site was introduced into pYZM5CHPP by site-directed mutagenesis using YL119 and YL120 (SEQ ID NOs:80 and 81) as primers to generate pYZM5CHPPA (Figure 5).

[0225] To optimize the integration vector, 440 bp of 5'-non-coding DNA sequence upstream from the *Yarrowia lipolytica* URA3 gene (SEQ ID NO:84) was amplified by PCR using YL121 and YL122 (SEQ ID NOs:82 and 83) as primers. The PCR product was digested with *AscI* and *BsiWI* and then exchanged with the *AscI/BsiWI* fragment of pYZM5CHPPA (Figure 5 and 12) to generate pYZM5UPA (Figure 12). An *AscI* site was introduced into pYZM5UPA by site-directed mutagenesis using oligonucleotides YL114 and YL115 (SEQ ID NOs:85 and 86) to generate pYZV5. In order to reduce the size of the 3'-non-coding region of the URA3 gene in pYZV5, a second *PacI* site was introduced into the middle of this region by site-directed mutagenesis using oligonucleotides YL114 and YL115 (described above) to generate pYZV5P. The *PacI* fragment of pYZV5P was excised by digestion with *PacI* and religation to generate pYZV16 (Figure 12). Digestion of pYZV16 with *AscI* liberates a 5.2 kb DNA fragment (SEQ ID NO:87) suitable for integration and expression of the $\Delta 5$ desaturase gene ("MAD5") in the *Y. lipolytica* genome.

Construction Of An Integration Vector For Expression Of The High Affinity Elongase And $\Delta 5$ Desaturase

[0226] *BsiWI* and *HindIII* sites were introduced into pY58 (containing the coding region of the *M. alpina* high affinity PUFA elongase; described in Example 2) by site-directed mutagenesis using YL61/YL62 (SEQ ID NOs:88 and 89) and YL69/YL70 (SEQ ID NOs:90 and 91) primer pairs, respectively, to generate pY58BH (Figure 13; elongase gene labeled as "EL"). The 1.7 kb *BsiWI/HindIII* fragment of pY58BH, which contains the TEF::EL::XPR chimeric gene, was ligated into the *BsiWI/HindIII* site of pYZM5CHPP (construction described in Figure 5) to generate pYZM5EL (Figure 13). This plasmid is suitable for integration and coordinate expression of the *M. alpina* $\Delta 5$ desaturase and high affinity PUFA elongase genes in *Y. lipolytica*.

Construction Of An Integration Vector For Expression Of The $\Delta 6$ Desaturase, High Affinity Elongase And $\Delta 5$ Desaturase

[0227] *PacI* and *Clal* sites were introduced into pY54 (containing the *M. alpina* $\Delta 6$ desaturase; described in Example 2) by site-directed mutagenesis using YL77/YL78 (SEQ ID NOs:92 and 93) and YL79A/YL80A (SEQ ID NOs:94 and 95) primer pairs, respectively, to generate pY54PC (Figure 13; $\Delta 6$ desaturase gene labeled as "MAD6"). The 2 kb *Clal/PacI* DNA fragment of pY54PC, which contains the TEF::MAD6::XPR chimeric gene, was ligated into the *Clal/PacI* sites of pYZM5EL to generate pYZM5EL6 (Figure 13). This plasmid is suitable for integration and coordinate expression of the *M. alpina* $\Delta 6$ desaturase, $\Delta 5$

desaturase and high affinity PUFA elongase genes in the *Y. lipolytica* genome.

Construction Of A DNA Fragment Suitable For Integration Into The *Yarrowia* Genome, For Expression Of The $\Delta 6$ Desaturase, PUFA Elongase And $\Delta 5$ Desaturase

[0228] The plasmid pYZV16 (construction described in Figure 12) was used for construction of plasmids containing multiple expression cassettes.

[0229] First, the 3.5 kB *BsiWII/PacI* fragment of pYZV16 was ligated to the 7.9 kB *BsiWII/PacI* fragment of pYZM5EL6 (construction described in Figure 13) to generate pYZV5EL6 (Figure 14). Digestion of pYZV5EL6 with *AscI* liberates a 8.9 kB DNA fragment (SEQ ID NO:96) suitable for integration and coordinate expression of the $\Delta 6$ desaturase, PUFA elongase and $\Delta 5$ desaturase genes in the *Y. lipolytica* genome.

Construction Of A DNA Fragment Suitable For Integration Into The *Yarrowia* Genome, For Expression Of The $\Delta 6$ Desaturase, PUFA Elongase, $\Delta 5$ Desaturase And $\Delta 17$ Desaturase

[0230] As described in Example 3, the synthetic *S. diclina* $\Delta 17$ desaturase gene was inserted into the *NcoI/NotI* sites of pY5-13 to generate pYSD17S (Figure 9A). *Clal* and *PmeI* sites were introduced into pYSD17S by site-directed mutagenesis using YL101/YL102 (SEQ ID NOs:97 and 98) and YL103/YL104 (SEQ ID NOs:99 and 100) primer pairs, respectively, to generate pYSD17SPC (Figure 14).

[0231] The 347 bp *Clal/PmeI* fragment of pYZV5EL6 (Figure 14) was exchanged with the 1760 bp *Clal/PmeI* fragment from pYSD17SPC containing the $\Delta 17$ desaturase expression cassette to generate pYZV5E6/17. Digestion of pYZV5E6/17 with *AscI* liberates a 10.3 kB DNA fragment (SEQ ID NO:101) suitable for integration and coordinate expression of the $\Delta 6$ desaturase, PUFA elongase, $\Delta 5$ desaturase and $\Delta 17$ desaturase genes in the *Y. lipolytica* genome.

EXAMPLE 5

Biosynthesis Of ω -6 Fatty Acids In *Yarrowia lipolytica* Transformants

[0232] pYZV5EL6 (from Example 4, containing the $\Delta 6$ desaturase, PUFA elongase and $\Delta 5$ desaturase genes) was digested with the *AscI* restriction endonuclease and transformed into *Yarrowia lipolytica* according to the methodology described in Example 2.

[0233] Of 52 transformants selected on minimal media lacking leucine, 34 could not grow on media also lacking uracil, suggesting that 65% of the transformants contained the 8.9 kB multi-gene expression cassette integrated into the targeted *Yarrowia lipolytica* URA3 locus. Transformants from single colonies were inoculated in minimal media lacking leucine and were incubated at 30 °C for up to 48 hr.

[0234] The cells were collected by centrifugation, lipids were extracted, and fatty acid methyl esters were prepared by transesterification and subsequently analyzed with a Hewlett-Packard 6890 GC (according to the methodology described in the General Methods).

[0235] GC analyses showed the presence of arachidonic acid (ARA) in the transformants containing the 3 chimeric genes (Figure 15), but not in the wild type *Yarrowia* control strain. These data confirmed that *Yarrowia lipolytica* was engineered to produce ARA, an ω -6 fatty acid.

EXAMPLE 6

Biosynthesis Of ω -3 Fatty Acids In *Yarrowia lipolytica* Transformants

[0236] In a manner similar to that in Example 5, pYZV5E6/17 (from Example 4, containing the $\Delta 6$ desaturase, PUFA elongase, $\Delta 5$ desaturase and $\Delta 17$ desaturase) was digested with the *AscI* restriction endonuclease and transformed into *Yarrowia lipolytica* (ATCC #76982). Of 133 transformants selected on minimal media lacking leucine, 89 could not grow on media also lacking uracil, suggesting that 67% of the transformants contained the 10.3 kB multi-gene expression cassette integrated into the targeted *Yarrowia lipolytica* URA3 locus.

[0237] GC analyses (according to the methodology described in the General Methods) showed the presence of eicosapentaenoic acid (EPA) in the transformants containing the 4 chimeric genes (Figure 16), but not in the wild-type *Yarrowia* control strain. These data confirmed that *Yarrowia lipolytica* was engineered to produce EPA, an ω -3 fatty acid.

PARTICULARLY PREFERRED EMBODIMENTS

[0238] Particularly preferred embodiments of the invention are given below:

1. 1. A method for producing omega-3 or omega-6 fatty acids comprising:
 1. a) providing an oleaginous yeast comprising the genes encoding a functional ω -3/ ω -6 fatty acid biosynthetic pathway;
 2. b) growing the yeast of step (a) in the presence of a fermentable carbon source whereby one or more ω -3 or ω -6 fatty acids are produced; and
 3. c) optionally recovering the ω -3 or ω -6 fatty acid.
2. 2. A method according to Claim 1 wherein the genes encoding a functional ω -3/ ω -6 fatty acid biosynthetic pathway are selected from the group consisting of: $\Delta 12$ desaturase, $\Delta 6$ desaturase, elongase, $\Delta 5$ desaturase, $\Delta 17$ desaturase, $\Delta 15$ desaturase, $\Delta 9$ desaturase and $\Delta 4$ desaturase.
3. 3. A method according to Claim 1 wherein the fermentable carbon source is selected from the group consisting of monosaccharides, oligosaccharides, polysaccharides, monoglycerides, diglycerides, triglycerides, methanol and carbon-containing amines.
4. 4. A method according to Claim 1 wherein the oleaginous yeast is selected from the group consisting of *Yarrowia*, *Candida*, *Rhodotorula*, *Rhodospiridium*, *Cryptococcus*, *Trichosporon* and *Lipomyces*.
5. 5. A method according to Claim 4 wherein the oleaginous yeast is *Yarrowia lipolytica*.
6. 6. A method for producing linoleic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 12$ desaturase polypeptide; and
 2. (ii) a source of desaturase substrate consisting of oleic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable carbon source wherein the gene encoding a $\Delta 12$ desaturase polypeptide is expressed and the oleic acid is converted to linoleic acid; and
 3. c) optionally recovering the linoleic acid of step (b).
7. 7. A method for producing γ -linolenic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 6$ desaturase polypeptide; and
 2. (ii) a source of desaturase substrate consisting of linoleic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable carbon source wherein the gene encoding a $\Delta 6$ desaturase polypeptide is expressed and the linoleic acid is converted to γ -linolenic acid; and
 3. c) optionally recovering the γ -linolenic acid of step (b).
8. 8. A method for producing stearidonic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 6$ desaturase polypeptide; and
 2. (ii) a source of desaturase substrate consisting of α -linoleic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon substrate wherein the gene encoding a $\Delta 6$ desaturase polypeptide is expressed and the α -linoleic acid is converted to stearidonic acid; and
 3. c) optionally recovering the stearidonic acid of step (b).
9. 9. A method for producing α -linoleic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 15$ desaturase polypeptide; and
 2. (ii) a source of desaturase substrate consisting of linoleic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding a $\Delta 15$ desaturase polypeptide is expressed and the linoleic acid is converted to α -linoleic acid; and

3. c) optionally recovering the α -linoleic acid of step (b).
10. 10. A method for producing dihomo- γ -linoleic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a C_{18/20} elongase polypeptide; and
 2. (ii) a source of elongase substrate consisting of γ -linolenic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding an elongase polypeptide is expressed and the γ -linolenic acid is converted to dihomo- γ -linoleic acid; and
 3. c) optionally recovering the dihomo- γ -linoleic acid of step (b).
11. 11. A method for producing eicosatetraenoic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a C_{18/20} elongase polypeptide; and
 2. (ii) a source of elongase substrate consisting of stearidonic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding an elongase polypeptide is expressed and the stearidonic acid is converted to eicosatetraenoic acid; and
 3. c) optionally recovering the eicosatetraenoic acid of step (b).
12. 12. A method for producing docosapentaenoic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding an a C_{20/22} elongase polypeptide; and
 2. (ii) a source of elongase substrate consisting of eicosapentaenoic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding an elongase polypeptide is expressed and the eicosapentaenoic acid is converted to docosapentaenoic acid; and
 3. c) optionally recovering the docosapentaenoic acid of step (b).
13. 13. A method for producing arachidonic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 5$ desaturase polypeptide; and
 2. (ii) a source of desaturase substrate consisting of dihomo- γ -linoleic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding a $\Delta 5$ desaturase polypeptide is expressed and the dihomo- γ -linoleic acid is converted to arachidonic acid; and
 3. c) optionally recovering the arachidonic acid of step (b).
14. 14. A method for producing eicosapentaenoic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 5$ desaturase polypeptide; and
 2. (ii) a source of desaturase substrate consisting of eicosatetraenoic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding a $\Delta 5$ desaturase polypeptide is expressed and the eicosatetraenoic acid is converted to eicosapentaenoic acid; and
 3. c) optionally recovering the eicosapentaenoic acid of step (b)
15. 15. A method for producing docosahexaenoic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 4$ desaturase polypeptide; and
 2. (ii) a source of desaturase substrate consisting of docosapentaenoic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding a $\Delta 4$ desaturase polypeptide is expressed and the docosapentaenoic acid is converted to docosahexaenoic acid; and
 3. c) optionally recovering the docosahexaenoic acid of step (b).
16. 16. A method for producing eicosatetraenoic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 17$ desaturase polypeptide; and
 2. (ii) a source of desaturase substrate consisting of dihomo- γ -linoleic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding a $\Delta 17$ desaturase polypeptide is expressed and dihomo- γ -linoleic acid is converted to eicosatetraenoic acid; and
 3. c) optionally recovering the eicosatetraenoic acid of step (b).
17. 17. A method for producing eicosapentaenoic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) a gene encoding a $\Delta 17$ desaturase polypeptide; and
 2. (ii) a source desaturase substrate consisting of arachidonic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the gene encoding a $\Delta 17$ desaturase polypeptide is expressed and arachidonic acid is converted to eicosapentaenoic acid; and

3. c) optionally recovering the eicosapentaenoic acid of step (b).
18. 18. A method according to any one of Claims 6-17 wherein the source of desaturase or elongase substrate is endogenous to the oleaginous yeast.
19. 19. A method according to any one of Claims 6-17 wherein the source of desaturase or elongase substrate is exogenous to the oleaginous yeast.
20. 20. A method according to any one of Claims 6-17 wherein the oleaginous yeast is selected from the group consisting of *Yarrowia*, *Candida*, *Rhodotorula*, *Rhodospiridium*, *Cryptococcus*, *Trichosporon* and *Lipomyces*.
21. 21. A method according to Claim 20 wherein the oleaginous yeast is *Yarrowia lipolytica*.
22. 22. A method according to either of Claims 7 or 8, wherein the gene encoding a $\Delta 6$ desaturase polypeptide is selected from the group consisting of:
 1. (a) an isolated nucleic acid molecule encoding the amino acid sequence as set forth in SEQ ID NO:2; and
 2. (b) an isolated nucleic acid molecule that hybridizes with (a) under the following hybridization conditions: 0.1X SSC, 0.1 % SDS, 65 °C and washed with 2X SSC, 0.1 % SDS followed by 0.1 X SSC, 0.1 % SDS.
23. 23. A method according to any of Claims 10, 11 and 12, wherein the gene encoding an elongase polypeptide is selected from the group consisting of:
 1. (a) an isolated nucleic acid molecule encoding the amino acid sequence as set forth in SEQ ID NO:8; and
 2. (b) an isolated nucleic acid molecule that hybridizes with (a) under the following hybridization conditions: 0.1X SSC, 0.1 % SDS, 65 °C and washed with 2X SSC, 0.1 % SDS followed by 0.1X SSC, 0.1% SDS.
24. 24. A method according to any of Claims 13 or 14, wherein the gene encoding a $\Delta 5$ desaturase polypeptide is selected from the group consisting of:
 1. (a) an isolated nucleic acid molecule encoding the amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:115, SEQ ID NO:119 and SEQ ID NO: 123; and
 2. (b) an isolated nucleic acid molecule that hybridizes with (a) under the following hybridization conditions: 0.1X SSC, 0.1% SDS, 65 °C and washed with 2X SSC, 0.1% SDS followed by 0.1X SSC, 0.1% SDS.
25. 25. A method according to any of Claims 16 or 17, wherein the gene encoding a $\Delta 17$ desaturase polypeptide is selected from the group consisting of:
 1. (a) an isolated nucleic acid molecule encoding the amino acid sequence as set forth in SEQ ID NO:6; and
 2. (b) an isolated nucleic acid molecule that hybridizes with (a) under the following hybridization conditions: 0.1X SSC, 0.1 % SDS, 65 °C and washed with 2X SSC, 0.1 % SDS followed by 0.1 X SSC, 0.1 % SDS.
26. 26. A method according to any of Claims 5 or 21, wherein the host cell is selected from the group consisting of *Yarrowia lipolytica* ATCC #20362, *Yarrowia lipolytica* ATCC #8862, *Yarrowia lipolytica* ATCC #18944, *Yarrowia lipolytica* ATCC #76982 and *Yarrowia lipolytica* LGAM S(7)1.
27. 27. A method for producing eicosapentaenoic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) genes encoding enzymes in the ω -3/ ω -6 fatty acid biosynthetic pathway; and
 2. (ii) an endogenous source of oleic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the genes encoding the enzymes in the ω -3/ ω -6 fatty acid biosynthetic pathway are expressed and the oleic acid is converted to eicosapentaenoic acid; and
 3. c) optionally recovering the eicosapentaenoic acid of step (b).
28. 28. A method for producing docosahexaenoic acid comprising:
 1. a) providing an oleaginous yeast comprising:
 1. (i) genes encoding enzymes in the ω -3/ ω -6 fatty acid biosynthetic pathway; and
 2. (ii) an endogenous source of oleic acid;
 2. b) growing the yeast of step (a) in the presence of a suitable fermentable carbon source wherein the genes encoding the enzymes in the ω -3/ ω -6 fatty acid biosynthetic pathway are expressed and the oleic acid is converted to docosahexaenoic acid; and
 3. c) optionally recovering the docosahexaenoic acid of step (b).
29. 29. A transformed oleaginous yeast comprising genes encoding enzymes of the ω -3/ ω -6 fatty acid biosynthetic pathway.
30. 30. An oleaginous yeast according to Claim 29 selected from the group consisting of *Yarrowia*, *Candida*, *Rhodotorula*, *Rhodospiridium*, *Cryptococcus*, *Trichosporon* and *Lipomyces*.
31. 31. An oleaginous yeast according to Claim 30 wherein the yeast is *Yarrowia lipolytica*.
32. 32. A microbial oil produced by the method of any one of Claims 1-28.

SEQUENCE LISTING

[0239]

<110> E.I. du Pont de Nemours and Company, Inc.

<120> PRODUCTION OF POLYUNSATURATED FATTY ACIDS IN OLEAGINOUS YEASTS

<130> CL2233 PCT

<140> EP 04751769.3

<141> 2004-05-07

<150> US 60/468677

<151> 2003-05-07

<160> 126

<170> PatentIn version 3.2

<210> 1

<211> 1374

<212> DNA

<213> Mortierella alpina

<400> 1

```

atggctgctg ctcccagtg gaggacgttt actcgggccg aggttttgaa tgccgaggct    60
ctgaatgagg gcaagaagga tgccgaggca ccttcttgga tgatcatcga caacaagggt    120
tacgatgtcc gcgagttcgt cctgacatc cccggtggaa gtgtgattct caccgacgtt    180
ggcaaggacg gcaactgacgt ctttgacact ttccaccccg aggcctgctt ggagactctt    240
gccaaacttt acgttgggtga tattgacgag agcgaccgcg atatcaagaa tgatgacttt    300
gcggccgagg tccgcaagct gogtaccttg ttccagtcct ttggttacta cgattcttcc    360
aaggcactact acgccttcaa ggtctcgttc aacctctgca tctggggttt gtgcacggtc    420
atttgtggcca agtggggcca gacctcgacc ctgcaccaac tgctctcggc tgcgcttttg    480
ggtctgttct ggacgacgtg cggatgggtt gctcagcact ttttgcatca ccaggctctc    540
caggaccgtt tctggggtga tcttttcggc gccttcttgg gaggtgtctg ccagggtctc    600
tcgtcctcgt ggtggaagga caagcacaac actcaccacg cggcccccac cgtccacggc    660
gaggatcccg acattgacac ccaccctctg ttgacctgga gtgagcatgc gttggagatg    720
ttctcggatg tccagatga ggagctgacc cgcattgtgt cgctttcat ggctctgaac    780
cagacctggt ttactctccc cattctctcg ttgcccgtc tctcctggtg cctccagtcc    840
attctctttg tgctgcctaa cggtcaggcc cacaagccct cgggcgcgcg tgtgcccac    900
tcgttggtcg agcagctgtc gcttgcgatg cactggacct ggtacctcgc caccatgttc    960

ctgttcatca aggatcccg tcaacatgctg gtgtactttt tgggtgtcga ggcgggtgtc   1020
ggaaacttgt tggcgatcgt gttctcgtc aaccacaacg gtatgcctgt gatctcgaag   1080
gaggaggcgg tcgatatgga tttcttcacg aagcagatca tcacgggtcg tgatgtocac   1140
ccgggtctat ttgccaaactg gttcacgggt ggattgaact atcagatcga gcaccacttg   1200
ttcccttcga tgcctcgcca caacttttca aagatccagc ctgctgtcga gaccctgtgc   1260
aaaaagtaca atgtccgata ccacaccacc ggtatgatcg agggaaactgc agaggctctt   1320
agcgcgtctga acgaggtctc caaggctacc tccaagatgg gtaaggcgca gtaa       1374

```

<210> 2

<211> 457

<212> PRT

<213> Mortierella alpina

<400> 2

Met Ala Ala Ala Pro Ser Val Arg Thr Phe Thr Arg Ala Glu Val Leu
 1 5 10 15
 Asn Ala Glu Ala Leu Asn Glu Gly Lys Lys Asp Ala Glu Ala Pro Phe
 20 25 30
 Leu Met Ile Ile Asp Asn Lys Val Tyr Asp Val Arg Glu Phe Val Pro
 35 40 45
 Asp His Pro Gly Gly Ser Val Ile Leu Thr His Val Gly Lys Asp Gly
 50 55 60
 Thr Asp Val Phe Asp Thr Phe His Pro Glu Ala Ala Trp Glu Thr Leu
 65 70 75 80
 Ala Asn Phe Tyr Val Gly Asp Ile Asp Glu Ser Asp Arg Asp Ile Lys
 85 90 95
 Asn Asp Asp Phe Ala Ala Glu Val Arg Lys Leu Arg Thr Leu Phe Gln
 100 105 110
 Ser Leu Gly Tyr Tyr Asp Ser Ser Lys Ala Tyr Tyr Ala Phe Lys Val
 115 120 125
 Ser Phe Asn Leu Cys Ile Trp Gly Leu Ser Thr Val Ile Val Ala Lys
 130 135 140
 Trp Gly Gln Thr Ser Thr Leu Ala Asn Val Leu Ser Ala Ala Leu Leu
 145 150 155 160
 Gly Leu Phe Trp Gln Gln Cys Gly Trp Leu Ala His Asp Phe Leu His
 165 170 175
 His Gln Val Phe Gln Asp Arg Phe Trp Gly Asp Leu Phe Gly Ala Phe
 180 185 190
 Leu Gly Gly Val Cys Gln Gly Phe Ser Ser Ser Trp Trp Lys Asp Lys
 195 200 205
 His Asn Thr His His Ala Ala Pro Asn Val His Gly Glu Asp Pro Asp
 210 215 220
 Ile Asp Thr His Pro Leu Leu Thr Trp Ser Glu His Ala Leu Glu Met
 225 230 235 240
 Phe Ser Asp Val Pro Asp Glu Glu Leu Thr Arg Met Trp Ser Arg Phe
 245 250 255
 Met Val Leu Asn Gln Thr Trp Phe Tyr Phe Pro Ile Leu Ser Phe Ala
 260 265 270
 Arg Leu Ser Trp Cys Leu Gln Ser Ile Leu Phe Val Leu Pro Asn Gly
 275 280 285
 Gln Ala His Lys Pro Ser Gly Ala Arg Val Pro Ile Ser Leu Val Glu
 290 295 300
 Gln Leu Ser Leu Ala Met His Trp Thr Trp Tyr Leu Ala Thr Met Phe
 305 310 315 320
 Leu Phe Ile Lys Asp Pro Val Asn Met Leu Val Tyr Phe Leu Val Ser
 325 330 335
 Gln Ala Val Cys Gly Asn Leu Leu Ala Ile Val Phe Ser Leu Asn His
 340 345 350
 Asn Gly Met Pro Val Ile Ser Lys Glu Glu Ala Val Asp Met Asp Phe
 355 360 365

Phe Thr Lys Gln Ile Ile Thr Gly Arg Asp Val His Pro Gly Leu Phe
370 375 380

Ala Asn Trp Phe Thr Gly Gly Leu Asn Tyr Gln Ile Glu His His Leu
385 390 395 400

Phe Pro Ser Met Pro Arg His Asn Phe Ser Lys Ile Gln Pro Ala Val
405 410 415

Glu Thr Leu Cys Lys Lys Tyr Asn Val Arg Tyr His Thr Thr Gly Met
420 425 430

Ile Glu Gly Thr Ala Glu Val Phe Ser Arg Leu Asn Glu Val Ser Lys
435 440 445

Ala Thr Ser Lys Met Gly Lys Ala Gln
450 455

<210> 3

<211> 1341

<212> DNA

<213> Mortierella alpina

<400> 3

atgggaacgg accaaggaaa aaccttcacc tgggaagagc tggcggccca taacaccaag	60
gacgacctac tcttgcccat ccgcggcagg gtgtacgatg tcacaaagtt cttgagccgc	120
catcctggtg gagtggacac tctcctgctc ggagctggcc gagatgttac tccggtcttt	180
gagatgtatc acgcgttttg ggctgcagat gccattatga agaagtacta tgtcgttaca	240
ctggtctcga atgagctgcc catcttccc gagccaacgg tgttcacaa aaccatcaag	300
acgagagtcg agggctactt tacggatcgg aacattgatc ccaagaatag accagagatc	360
tggggacgat acgctcttat ctttggatcc ttgatcgctt cctactacgc gcagctcttt	420
gtgcctttcg ttgtcgaacg cacatggctt caggtggtgt ttgcaatcat catgggattt	480
gcgtgcgcac aagtcggact caaccctctt catgatgcgt ctcacttttc agtgacccac	540
aaccccactg totggaagat totgggagcc acgcacgact ttttcaacgg agcatcgtac	600
ctggtgtgga tgtaccaaca tatgctcggc catcaccctt acaccaacat tgctggagca	660
gatcccgacg tgtcgacgto tgagcccgat gttcgtcgta tcaagcccaa ccaaaagtgg	720
tttgtcaacc acatcaacca gcacatgttt gttcctttcc tgtacggact gctggcgctc	780
aaggtgcgca ttcaggacat caacattttg tactttgtca agaccaatga cgctattcgt	840
gtcaatccca tctcgacatg gcacactgtg atgttctggg gcggcaaggc tttctttgtc	900
tggtatcgcc tgattgttcc cctgcagtat ctgccctgg gcaaggtgct gctcttgctc	960
acggtcgcgg acatggtgtc gtcttactgg ctggcgctga ccttcaggc gaaccacgtt	1020
gttaggaag ttcagtggcc gttgcctgac gagaacggga tcatccaaaa ggactgggca	1080
gctatgcagg tcgagactac gcaggattac gcacacgatt cgcacctctg gaccagcatc	1140
actggcagct tgaactacca ggctgtgcac catctgttcc ccaacgtgtc gcagcaccat	1200
tatcccgata ttctggccat catcaagaac acctgcagcg agtacaaggt tccatacctt	1260
gtcaaggata cgttttggca agcatttgct tcacatttgg agcacttgcg tgttcttgga	1320
ctccgtccca aggaagagta g	1341

<210> 4

<211> 446

<212> PRT

<213> Mortierella alpina

<400> 4

Met Gly Thr Asp Gln Gly Lys Thr Phe Thr Trp Glu Glu Leu Ala Ala
 1 5 10 15
 His Asn Thr Lys Asp Asp Leu Leu Leu Ala Ile Arg Gly Arg Val Tyr
 20 25 30
 Asp Val Thr Lys Phe Leu Ser Arg His Pro Gly Gly Val Asp Thr Leu
 35 40 45
 Leu Leu Gly Ala Gly Arg Asp Val Thr Pro Val Phe Glu Met Tyr His
 50 55 60
 Ala Phe Gly Ala Ala Asp Ala Ile Met Lys Lys Tyr Tyr Val Gly Thr
 65 70 75 80
 Leu Val Ser Asn Glu Leu Pro Ile Phe Pro Glu Pro Thr Val Phe His
 85 90 95
 Lys Thr Ile Lys Thr Arg Val Glu Gly Tyr Phe Thr Asp Arg Asn Ile
 100 105 110
 Asp Pro Lys Asn Arg Pro Glu Ile Trp Gly Arg Tyr Ala Leu Ile Phe
 115 120 125
 Gly Ser Leu Ile Ala Ser Tyr Tyr Ala Gln Leu Phe Val Pro Phe Val
 130 135 140
 Val Glu Arg Thr Trp Leu Gln Val Val Phe Ala Ile Ile Met Gly Phe
 145 150 155 160
 Ala Cys Ala Gln Val Gly Leu Asn Pro Leu His Asp Ala Ser His Phe
 165 170 175
 Ser Val Thr His Asn Pro Thr Val Trp Lys Ile Leu Gly Ala Thr His
 180 185 190
 Asp Phe Phe Asn Gly Ala Ser Tyr Leu Val Trp Met Tyr Gln His Met
 195 200 205
 Leu Gly His His Pro Tyr Thr Asn Ile Ala Gly Ala Asp Pro Asp Val
 210 215 220
 Ser Thr Ser Glu Pro Asp Val Arg Arg Ile Lys Pro Asn Gln Lys Trp
 225 230 235 240
 Phe Val Asn His Ile Asn Gln His Met Phe Val Pro Phe Leu Tyr Gly
 245 250 255
 Leu Leu Ala Phe Lys Val Arg Ile Gln Asp Ile Asn Ile Leu Tyr Phe
 260 265 270
 Val Lys Thr Asn Asp Ala Ile Arg Val Asn Pro Ile Ser Thr Trp His
 275 280 285
 Thr Val Met Phe Trp Gly Gly Lys Ala Phe Phe Val Trp Tyr Arg Leu
 290 295 300
 Ile Val Pro Leu Gln Tyr Leu Pro Leu Gly Lys Val Leu Leu Leu Phe
 305 310 315 320
 Thr Val Ala Asp Met Val Ser Ser Tyr Trp Leu Ala Leu Thr Phe Gln
 325 330 335

Ala Asn His Val Val Glu Glu Val Gln Trp Pro Leu Pro Asp Glu Asn
340 345 350

Gly Ile Ile Gln Lys Asp Trp Ala Ala Met Gln Val Glu Thr Thr Gln
355 360 365

Asp Tyr Ala His Asp Ser His Leu Trp Thr Ser Ile Thr Gly Ser Leu
370 375 380

Asn Tyr Gln Ala Val His His Leu Phe Pro Asn Val Ser Gln His His
385 390 395 400

Tyr Pro Asp Ile Leu Ala Ile Ile Lys Asn Thr Cys Ser Glu Tyr Lys
405 410 415

Val Pro Tyr Leu Val Lys Asp Thr Phe Trp Gln Ala Phe Ala Ser His
420 425 430

Leu Glu His Leu Arg Val Leu Gly Leu Arg Pro Lys Glu Glu
435 440 445

<210> 5

<211> 1077

<212> DNA

<213> Saprolegnia diclina

<400> 5

```

atgactgagg ataagacgaa ggtcgagttc cgcacgctca cggagctcaa gcactcgatc   60
ccgaacgcgt gctttgagtc gaacctcggc ctctcgctct actacacggc ccgcgcgac   120
ttcaacgcgt cggcctcggc ggcgctgctc tacgcggcgc gctcgacgcc gttcattgcc   180
gataacgttc tgctccacgc gctcgtttgc gccacctaca tctacgtgca gggcgctatc   240
ttctgggggt tcttcaaggc cggccaacgc tgcggccact cggccttctc ggcctaccac   300
agcgtaact ttatcatcgg ctgcatcatg cactctgcga ttttgacgcc gttcgagagc   360
tgggcgcgtga cgcaccgcca ccaccacaag aacacgggca acattgataa ggacgagatc   420
ttttacccgc accggtcggt caaggacctc caggacgtgc gccaatgggt ctacacgctc   480
ggcggtgctg ggtttgtcta cttgaaggtc gggtatgccc cgcgcacgat gagccacttt   540
gaccctgggg acccgctcct ccttcgccgc gcgtcggccg tcatcgtgtc gctcggcgctc   600

tgggccgcct tcttcgccgc gtacgcgtac ctacatact cgctcggctt tgccgtcatg   660
ggcctctact actatgcgcc gctctttgtc tttgcttcgt tctcgtcat tacgacctc   720
ttgcaccaca acgacgaagc gaccccgtag tacggcgact cggagtggac gtacgtcaag   780
ggcaacctct cgagcgtcga ccgctcgtac ggcgcgttcg tggacaacct gagccaccac   840
attggcacgc accaggtcca ccacttgctc ccgatcatc cgcactacaa gctcaacgaa   900
gccaccaagc acttttcggc cgcgtacccg cacctcgtgc gcaggaacga cgagcccata   960
atcacggcct tcttcaagac cgcgcacctc tttgtcaact accgctcgtg gcccgagacg  1020
gcgcagatct tcacgctcaa agagtcggcc gcggccgccca aggccaaagtc ggactaa   1077

```

<210> 6

<211> 358

<212> PRT

<213> Saprolegnia diclina

<400> 6

Met Ala Glu Asp Lys Thr Lys Val Glu Phe Pro Thr Leu Thr Glu Leu
 1 5 10 15
 Lys His Ser Ile Pro Asn Ala Cys Phe Glu Ser Asn Leu Gly Leu Ser
 20 25 30
 Leu Tyr Tyr Thr Ala Arg Ala Ile Phe Asn Ala Ser Ala Ser Ala Ala
 35 40 45
 Leu Leu Tyr Ala Ala Arg Ser Thr Pro Phe Ile Ala Asp Asn Val Leu
 50 55 60
 Leu His Ala Leu Val Cys Ala Thr Tyr Ile Tyr Val Gln Gly Val Ile
 65 70 75 80
 Phe Trp Gly Phe Phe Thr Val Gly His Asp Cys Gly His Ser Ala Phe
 85 90 95
 Ser Arg Tyr His Ser Val Asn Phe Ile Ile Gly Cys Ile Met His Ser
 100 105 110
 Ala Ile Leu Thr Pro Phe Glu Ser Trp Arg Val Thr His Arg His His
 115 120 125
 His Lys Asn Thr Gly Asn Ile Asp Lys Asp Glu Ile Phe Tyr Pro His
 130 135 140
 Arg Ser Val Lys Asp Leu Gln Asp Val Arg Gln Trp Val Tyr Thr Leu
 145 150 155 160
 Gly Gly Ala Trp Phe Val Tyr Leu Lys Val Gly Tyr Ala Pro Arg Thr
 165 170 175
 Met Ser His Phe Asp Pro Trp Asp Pro Leu Leu Leu Arg Arg Ala Ser
 180 185 190
 Ala Val Ile Val Ser Leu Gly Val Trp Ala Ala Phe Phe Ala Ala Tyr
 195 200 205
 Ala Tyr Leu Thr Tyr Ser Leu Gly Phe Ala Val Met Gly Leu Tyr Tyr
 210 215 220
 Tyr Ala Pro Leu Phe Val Phe Ala Ser Phe Leu Val Ile Thr Thr Phe
 225 230 235 240
 Leu His His Asn Asp Glu Ala Thr Pro Trp Tyr Gly Asp Ser Glu Trp
 245 250 255
 Thr Tyr Val Lys Gly Asn Leu Ser Ser Val Asp Arg Ser Tyr Gly Ala
 260 265 270
 Phe Val Asp Asn Leu Ser His His Ile Gly Thr His Gln Val His His
 275 280 285
 Leu Phe Pro Ile Ile Pro His Tyr Lys Leu Asn Glu Ala Thr Lys His
 290 295 300
 Phe Ala Ala Ala Tyr Pro His Leu Val Arg Arg Asn Asp Glu Pro Ile
 305 310 315 320
 Ile Thr Ala Phe Phe Lys Thr Ala His Leu Phe Val Asn Tyr Gly Ala
 325 330 335
 Val Pro Glu Thr Ala Gln Ile Phe Thr Leu Lys Glu Ser Ala Ala Ala
 340 345 350
 Ala Lys Ala Lys Ser Asp
 355

<210> 7

<211> 957

<212> DNA

<213> Mortierella alpina

<400> 7

```

atggagtcga ttgcgccatt cctcccatca aagatgccgc aagatctgtt tatggacctt    60
gccaccgcta tcggtgtccg ggccgcgccc tatgtcgatc ctctcgaggc cgcgctgggtg    120
gcccaggccg agaagtacat cccacgatt gtccatcaca cgcgtggggt cctggtcgcg    180
gtggagtcgc ctttgcccg tgagctgccg ttgatgaacc cgttccacgt gctgttgatc    240
gtgctcgctt atttggtcac ggtctttgtg ggcattgcaga tcatgaagaa ctttgagcgg    300
ttcgagggtc agacgttttc gctcctgcac aacttttgtc tggctcgcgt cagcgcctac    360
atgtgcgggt ggatcctgta cgaggcttat caggccaact atggactgtt tgagaacgct    420
gctgatcata ccttcaaggg tcttcctatg gccaatga tctggctctt ctacttctcc    480
aagatcatgg agtttgtcga caccatgatc atggtcctca agaagaacaa ccgcagatc    540
tccttcttgc acgtttacca ccacagctcc atcttcacca tctggtggtt ggtcaccttt    600
gttgcaccca acggtgaagc ctacttctct gctgcgttga actcggtcat ccatgtgatc    660
atgtacggct actacttctt gtcggccttg ggcttcaagc aggtgtcgtt catcaagtcc    720
tacatcacgc gctcgcagat gacacagtto tgcattgatg cggtcagtc ttctctgggac    780
atgtacgcc aagaaggctct tggccgcccc ggataccctt tcttcacac ggctctgctt    840
tggttctaca tgtggaccat gctcgggtct tcttacaact ttacagaaa gaacgccaag    900
ttggccaagc aggccaaggc cgacgctgcc aaggagaagg caagggaagt gcagtaa    957

```

<210> 8

<211> 318

<212> PRT

<213> Mortierella alpina

<400> 8

```

Met Glu Ser Ile Ala Pro Phe Leu Pro Ser Lys Met Pro Gln Asp Leu
1           5           10          15

Phe Met Asp Leu Ala Thr Ala Ile Gly Val Arg Ala Ala Pro Tyr Val
                20          25          30

```

Asp Pro Leu Glu Ala Ala Leu Val Ala Gln Ala Glu Lys Tyr Ile Pro
 35 40 45
 Thr Ile Val His His Thr Arg Gly Phe Leu Val Ala Val Glu Ser Pro
 50 55 60
 Leu Ala Arg Glu Leu Pro Leu Met Asn Pro Phe His Val Leu Leu Ile
 65 70 75 80
 Val Leu Ala Tyr Leu Val Thr Val Phe Val Gly Met Gln Ile Met Lys
 85 90 95
 Asn Phe Glu Arg Phe Glu Val Lys Thr Phe Ser Leu Leu His Asn Phe
 100 105 110
 Cys Leu Val Ser Ile Ser Ala Tyr Met Cys Gly Gly Ile Leu Tyr Glu
 115 120 125
 Ala Tyr Gln Ala Asn Tyr Gly Leu Phe Glu Asn Ala Ala Asp His Thr
 130 135 140
 Phe Lys Gly Leu Pro Met Ala Lys Met Ile Trp Leu Phe Tyr Phe Ser
 145 150 155 160
 Lys Ile Met Glu Phe Val Asp Thr Met Ile Met Val Leu Lys Lys Asn
 165 170 175
 Asn Arg Gln Ile Ser Phe Leu His Val Tyr His His Ser Ser Ile Phe
 180 185 190
 Thr Ile Trp Trp Leu Val Thr Phe Val Ala Pro Asn Gly Glu Ala Tyr
 195 200 205
 Phe Ser Ala Ala Leu Asn Ser Phe Ile His Val Ile Met Tyr Gly Tyr
 210 215 220
 Tyr Phe Leu Ser Ala Leu Gly Phe Lys Gln Val Ser Phe Ile Lys Phe
 225 230 235 240
 Tyr Ile Thr Arg Ser Gln Met Thr Gln Phe Cys Met Met Ser Val Gln
 245 250 255
 Ser Ser Trp Asp Met Tyr Ala Met Lys Val Leu Gly Arg Pro Gly Tyr
 260 265 270
 Pro Phe Phe Ile Thr Ala Leu Leu Trp Phe Tyr Met Trp Thr Met Leu
 275 280 285
 Gly Leu Phe Tyr Asn Phe Tyr Arg Lys Asn Ala Lys Leu Ala Lys Gln
 290 295 300
 Ala Lys Ala Asp Ala Ala Lys Glu Lys Ala Arg Lys Leu Gln
 305 310 315

<210> 9

<211> 1077

<212> DNA

<213> Saprolegnia diclina

<400> 9

```

atggctgagg ataagaccaa ggtcgagttc cctaccctga ctgagctgaa gcaactctatc    60
cctaacgctt gctttgagtc caacctcgga ctctcgctct actacactgc ccgagcgatc    120
ttcaacgcat ctgcctctgc tgctctgctc tacgtgccc gatctactcc cttcattgcc    180
gataacgttc tgctccacgc tctggtttgc gccacctaca tctacgtgca ggggtgtcatc    240
ttctgggggtt tctttaccgt cggtcacgac tgtgggtaact ctgccttctc ccgataccac    300
tccgtcaact tcatcattgg ctgcacatgc cactctgcca ttctgactcc cttcgagtec    360
tggcgagtga cccaccgaca coatcacaag aacactggca acattgataa ggacgagatc    420
ttctaccctc atcggtccgt caaggacctc caggacgtgc gacaatgggt ctacaccctc    480
ggaggtgctt ggtttgtcta cctgaaggtc ggatatgttc ctgaacctat gtcccacttt    540
gacccctggg accctctcct gcttcgacga gccctcgtg tcatcgtgtc cctcggagtc    600
tgggtgcctt tcttcgctgc ctacgcctac ctacatact cgctcggctt tgccgtcatg    660
ggcctctact actatgtctc tctctttgtc tttgcttcgt tctcgtcat tactaccttc    720
ttgcatcaca acgacgaagc tactccctgg tacggtgact cggagtgga ctacgtcaag    780
ggcaacctga gctccgtoga ccgatcgta ggagctttcg tggacaacct gtctaccac    840
attggcacc accaggtoca tcaattgttc cctatcatc cccactacaa gctcaacgaa    900
gccaccaagc actttgtgct cgttaccct cactcgtga gacgtaacga cgagcccatc    960

attactgctt tcttcaagac cgctcacctc tttgtcaact acggagctgt gcccgagact   1020
gctcagattt tcacctcaa agagtctgcc gctgcagcca aggccaagag cgactaa       1077

```

<210> 10

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-1A

<400> 10

```

catggctgag gataagacca aggtcgagtt ccctaccctg actgagctga agcactctat    60
ccctaacgct tgctttgagt ccaacctcgg actctcgctc tacta                    105

```

<210> 11

<211> 106

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-1B

<400> 11

```

cagtgtagta gacgagagat ccgaggttgg actcaaagca agcgttaggg atagagtgtc    60
tcagctcagt cagggtaggg aactcgacct tggctcttate ctacgc                    106

```

<210> 12

<211> 106

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-2A

<400> 12

```

cactgccgga gcgacttca acgcatctgc ctctgctgct ctgctctacg ctgcccgatc    60
tactcccttc attgcgata acgttctgct ccacgctctg gtttgc                    106

```

<210> 13

<211> 106

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-2B

<400> 13

gtggcgcaaa ccagagcgtg gagcagaacg ttatcggcaa tgaagggagt agatcgggca 60

gcgtagagca gagcagcaga ggcagatgcg ttgaagatcg ctcggg 105

<210> 14

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-3A

<400> 14

gccacctaca tctacgtgca ggggtgcatc ttctgggggt tctttaccgt cggtcacgac 60

tgtggteact ctgccttctc ccgataccac tccgtcaact tcac 105

<210> 15

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-3B

<400> 15

ccaatgatga agttgacgga gtggtatcgg gagaaggcag agtgaccaca gtcgtgaccg 60

acggtaaaga aacccacaga gatgacaccc tgcacgtaga tgtag 105

<210> 16

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-4A

<400> 16

attggtgca tcatgcactc tgccattctg actcccttcg agtcctggcg agtgaccac 60

cgacaccatc acaagaacac tggcaacatt gataaggacg agatc 105

<210> 17

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-4B

<400> 17

tagaagatct cgtccttctc aatgttgcca gtgttcttgt gatgggtgctg gtgggtcact 60

cgccaggact cgaagggagt cagaatggca gattgcatga tgcag 105

<210> 18

<211> 105

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-5A

<400> 18
acgagatctt ctaccctcat cggtcctga aggacctcca ggacgtgca caatgggtct 60
acaccctcgg aggtgcttgg ttgtctacc tgaaggctgg atatg 105

<210> 19
<211> 107
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer D17-5B

<400> 19
aggagcatat ccgaccttca ggtagacaaa ccaagcacct ccgagggtgt agaccattg 60
tcgcacgtcc tggaggctct tgacggaccg atgagggtag aagatct 107

<210> 20
<211> 105
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer D17-6A

<400> 20
ctctctgaac catgtccac tttagacctt gggacctctt cctgcttoga cgagcctcgg 60
ctgtcatcgt gtccctcggg gtctgggctg cctctcttgc tgcct 105

<210> 21
<211> 106
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer D17-6B

<400> 21
aggcgtaggc agcgaagaag gcagcccaga ctccgaggga cacgatgaca gcggaggctc 60
gtcgaagcag gagagggtcc caggggtcaa agtgggacat ggttcg 106

<210> 22
<211> 104
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer D17-7A

<400> 22
acgcctacct cacatactcg ctgggctttg ccgtcatggg cctctactac tatgctctc 60
tctttgtctt tgettcttgc ctgctatta ctaccttctt gcat 104

<210> 23
<211> 103
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer D17-7B

<400> 23
ttgtgatgca agaaggtagt aatgacgagg aacgaagcaa agacaaagag aggagcatag 60
tagtagaggg ccatgaaggc aaagccgagc gagtatgtga ggt 103

<210> 24
 <211> 106
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer D17-8A

<400> 24
 cacaacgacg aagctactcc ctggtacggg gactcggagt ggacctacgt caagggaac 60
 ctgagctccg tcgaccgatc gtacggagct ttcgtggaca acctgt 106

<210> 25
 <211> 106
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer D17-8B

<400> 25
 gtgagacagg ttgtccacga aagctccgta cgatcgggctg acggagctca ggttgccctt 60
 gacgtaggtc cactccgagt caccgtacca gggagtagct tcgtcg 106

<210> 26
 <211> 102
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer D17-9A

<400> 26
 ctaccacat tggcaccac caggtccatc acttggtccc tatcattccc cactacaagc 60
 tcaacgaagc caccaagcac ttgtctgccc cttaccctca cc 102

<210> 27
 <211> 102
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer D17-9B

<400> 27
 cagcaggtga gggtaagcgg cagcaaagtg cttggtggct tcgttgagct tgtagtgggg 60
 aatgataggg aacaagtgat ggacctgggtg ggtgccaatg tg 102

<210> 28
 <211> 76
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer D17-10A

<400> 28
 tcgtgagacg taacgacgag cccatcatta ctgccttctt caagaccgt caccctcttg 60
 tcaactacgg agctgt 76

<210> 29
 <211> 76
 <212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-10B

<400> 29

cgggcacagc tccgtagttg acaaagaggt gagcggtctt gaagaaggca gtaatgatgg 60

gctcgtcgtt acgtct 76

<210> 30

<211> 67

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-11A

<400> 30

gcccgagact gctcagattt tcacctcaa agagtctgcc gctgcagcca aggcccaagag 60

cgactaa 67

<210> 31

<211> 62

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-11B

<400> 31

ttagtcgctc ttggccttgg ctgcagcggc agactctttg aggggtgaaaa tctgagcagt 60

ct 62

<210> 32

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-1

<400> 32

ttccatggc tgaggataag accaaggctg ag 32

<210> 33

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-4R

<400> 33

ccctagaaga tctcgtcctt atcaatgttg ccag 34

<210> 34

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-5

<400> 34

cccacgagat cttctaccct catcggt 27

<210> 35

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-8D

<400> 35

gaaagctcgc tacgatcggt cgac 24

<210> 36

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-8U

<400> 36

gtcgaccgat cgtacggagc ttc 24

<210> 37

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer D17-11

<400> 37

aaagcggccg ctagtcgct cttggccttg gctg 34

<210> 38

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer TEF5'

<400> 38

agagaccggg ttggcggcg 19

<210> 39

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer TEF3'

<400> 39

ttggatcctt tgaatgattc ttatactcag 30

<210> 40

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer XPR5'

<400> 40

ttccgcggc ccgagattcc ggcctctc 29

<210> 41

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer XPR3'

<400> 41

ttccgcgga cacaatatct ggtcaaatt c 31

<210> 42

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL21A

<400> 42

ttccatggc tgaggataag acgaaggtcg agt 33

<210> 43

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL22

<400> 43

ccctaatta attagtccga cttggccttg gggcc 36

<210> 44

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL53

<400> 44

gccaagtcgg actaagctgc taactagagc ggccgc 36

<210> 45

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL54

<400> 45

gcgccgctc tagttagcag cttagtccga cttggc 36

<210> 46

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer KU5

<400> 46

ttgcccggg cgagtatctg tctgactcgt cattg 35

<210> 47

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer KU3

<400> 47

aaagcccggg caaaggcctg ttctcgggtg tac 33

<210> 48

<211> 1710

<212> DNA

<213> Yarrowia lipolytica

<400> 48

gtcgacgagt atctgtctga ctcgtcattg cgccttttgg agtacgactc caactatgag	60
tgtgcttggg tcaactttgac gatacattct tcgttggagg ctgtgggtct gacagctgag	120
ttttcggcgc ggttggccga caacaatctc agctgcaacg tcattgctgg ctttcatcat	180
gatcacattt ttgtcgcaa aggcgacgcc cagagagcca ttgacgttct ttctaatttg	240
gaccgatagc cgtatagtcc agtctatcta taagttcaac taactcgtaa ctattaccat	300
aacatatact tcaactgccc agataagggt cggataaaaa gttctgcaga ctaaatttat	360
ttcagttctc tcttcaccac caaaatgccc tctacgaag ctcgagctaa cgtccacaag	420
tccgcctttg ccgtctgagt gctcaagctc gtggcagcca agaaaaccaa cctgtgtgct	480
tctctggatg ttaccaccac caaggagctc attgagcttg ccgataaggt cggaccttat	540
gtgtgcatga tcaagaccca tatcgacatc attgacgact tcacctacgc cggcaactgtg	600
ctcccccctc aggaacttgc tcttaagcac ggtttcttcc tgttcgagga cagaaagttc	660
gcagatattg gcaacactgt caagcaccag tacaagaacg gtgtctaccg aatcgccgag	720
tggtcagata tcaccaacgc ccacgggtga cccggaacgg gaatcattgc tggcctgcga	780
gctggtgccg aggaactgt ctctgaacag aagaaggagg acgtctctga ctacgagaac	840
tcccagtaac aggagttctc ggtccctct cccaacgaga agctggccag aggtctgctc	900
atgctggccc agctgtcttg caagggtctc ctggccactg cgcagtactc caagcagacc	960
attgagcttg ccgatccga ccccgagttt gtggttggtc tcattgcca gaaccgacct	1020
aagggcgact ctgaggactg gcttattctg acccccgggg tgggtcttga cgacaaggga	1080
gacgtctctg gacagcagta ccgaactgtt gaggatgtca tgtctaccgg aacggatatc	1140
ataattgtcg gccgaggtct gtacggccag aaccgagatc ctattgagga ggccaagcga	1200
taccagaagg ctggctggga ggcttaccag aagattaact gttagaggtt agactatgga	1260
tatgtcattt aactgtgtat atagagagcg tgcaagtatg gagcgttgtt tcagcttgta	1320
tgatggtcag acgacctgtc tgatcgagta tgtatgatac tgcacaacct gtgtatccgc	1380
atgatctgtc caatggggga tgtgtgtgtg tttctcgata cggagatgct gggtaacaag	1440
agctaatacg attgaactac ttatacttat atgaggcttg aagaaagctg acttgtgtat	1500
gacttattct caactacatc ccagtcaca ataccaccac tgcactacca ctacacaaaa	1560
accatgatca aaccacocat ggacttctcg gaggcagaag aacttgttat ggaaaagctc	1620
aagagagaga agccaagata ctatcaagac atgtgtcgca acttcaagga ggaccaagct	1680
ctgtacaccg agaaaacagg ctttgtcgac	1710

<210> 49

<211> 286

<212> PRT

<213> *Yarrowia lipolytica*

<400> 49

```

Met Pro Ser Tyr Glu Ala Arg Ala Asn Val His Lys Ser Ala Phe Ala
1      5      10      15

Ala Arg Val Leu Lys Leu Val Ala Ala Lys Lys Thr Asn Leu Cys Ala
      20      25      30

Ser Leu Asp Val Thr Thr Thr Lys Glu Leu Ile Glu Leu Ala Asp Lys
      35      40      45

Val Gly Pro Tyr Val Cys Met Ile Lys Thr His Ile Asp Ile Ile Asp
      50      55      60

Asp Phe Thr Tyr Ala Gly Thr Val Leu Pro Leu Lys Glu Leu Ala Leu
      65      70      75      80

Lys His Gly Phe Phe Leu Phe Glu Asp Arg Lys Phe Ala Asp Ile Gly
      85      90      95

Asn Thr Val Lys His Gln Tyr Lys Asn Gly Val Tyr Arg Ile Ala Glu
      100     105     110

Trp Ser Asp Ile Thr Asn Ala His Gly Val Pro Gly Thr Gly Ile Ile
      115     120     125

Ala Gly Leu Arg Ala Gly Ala Glu Glu Thr Val Ser Glu Gln Lys Lys
      130     135     140

Glu Asp Val Ser Asp Tyr Glu Asn Ser Gln Tyr Lys Glu Phe Leu Val
      145     150     155     160

Pro Ser Pro Asn Glu Lys Leu Ala Arg Gly Leu Leu Met Leu Ala Glu
      165     170     175

Leu Ser Cys Lys Gly Ser Leu Ala Thr Gly Glu Tyr Ser Lys Gln Thr
      180     185     190

Ile Glu Leu Ala Arg Ser Asp Pro Glu Phe Val Val Gly Phe Ile Ala
      195     200     205

Gln Asn Arg Pro Lys Gly Asp Ser Glu Asp Trp Leu Ile Leu Thr Pro
      210     215     220

Gly Val Gly Leu Asp Asp Lys Gly Asp Ala Leu Gly Gln Gln Tyr Arg
      225     230     235     240

Thr Val Glu Asp Val Met Ser Thr Gly Thr Asp Ile Ile Ile Val Gly
      245     250     255

Arg Gly Leu Tyr Gly Gln Asn Arg Asp Pro Ile Glu Glu Ala Lys Arg
      260     265     270

Tyr Gln Lys Ala Gly Trp Glu Ala Tyr Gln Lys Ile Asn Cys
      275     280     285

```

<210> 50

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer KI5

<400> 50

```

agagcggccg catgggagaa gtgggaccca caaac      35

```

<210> 51
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer KI3

<400> 51
 gtggcgccg ctcaaatgct gttattgtac caataaac 38

<210> 52
 <211> 1152
 <212> DNA
 <213> Impatiens balsamina

<400> 52
 atggggagaag tgggacccac aaaccgaacc aaaaccaagt tggacaagca acaagaatcc 60
 gaaaacaggg ttctctacga gccacctcca ttccactaa gtgaccttaa gaaagccatc 120
 ccacccatt gcttcgagcg ctccctcgtg aaatcattct accacgtgat tcacgacatt 180
 atcatcctgt cctttttcta ctatgtcgcc gcccaattaca tccccatgct accccaaaac 240
 ctccgttacg ttgcatggcc aatttattgg gccatccaag gctgtgtcca acttggtata 300
 ttggtcttag gccatgaatg cggccaccac gccctcagcg actaccaatg ggtagacgac 360
 atggtcgggt tcgtctccca ctgcgccaa ttgattccct acttctcatg gaaacatagc 420
 caccgtcgcc accactccaa caccgctcc atcgagcgcg acgaggtcta cccgccgcg 480
 tacaaaaacg acctgcctg gtctgccaaa tacctaagca acccgcctgg tcgtttcttc 540
 atgattttcg gggcgctact gttcggctgg ccgtcgtacc ttctgttcaa cggaacggc 600
 cgtctctacg accgcttcgc ttccactac gaccgcaat ccccgatctt caacaaccgc 660
 gagaggctgc aagtgatcgc gtccgacgc gggctcgtct tcgcgtactt tgcctgtac 720
 aagatcgcc tggccaaggg atttgtgtgg ttaatttgtg tgtatggcgt cccgtacgtg 780
 atcctcaacg ggcttatcgt cttgatcacg ttctacagc acacgcaccc gaatctgccc 840
 cgttacgacc ttcccgagt ggactggctt aggggagccc tgcgactgt ggaccgcgat 900
 tacgggatgt tgaataaggt gttccataac gtgacggaca cgcacttggg gcacatttg 960
 ttcacgacca tgccacatta tcgcgccaa gaggcgaccg aggtgattaa accgatattg 1020
 ggagactact ataagtttga cgacactccg tttctcaaag cgttgtggaa ggacatggga 1080
 aagtgtatct atgtggagtc ggacgtgcct ggcaagaaca agggagttaa ttggtacaat 1140
 aacgacattt ga 1152

<210> 53
 <211> 383
 <212> PRT
 <213> Impatiens balsamina

<400> 53
 Met Gly Glu Val Gly Pro Thr Asn Arg Thr Lys Thr Lys Leu Asp Lys

```

1           5           10           15

Gln Gln Glu Ser Glu Asn Arg Val Pro His Glu Pro Pro Pro Phe Thr
      20           25           30

Leu Ser Asp Leu Lys Lys Ala Ile Pro Pro His Cys Phe Glu Arg Ser
      35           40           45

Leu Val Lys Ser Phe Tyr His Val Ile His Asp Ile Ile Ile Leu Ser
      50           55           60

Phe Phe Tyr Tyr Val Ala Ala Asn Tyr Ile Pro Met Leu Pro Gln Asn
      65           70           75           80

Leu Arg Tyr Val Ala Trp Pro Ile Tyr Trp Ala Ile Gln Gly Cys Val
      85           90           95

Gln Leu Gly Ile Leu Val Leu Gly His Glu Cys Gly His His Ala Phe
      100           105           110

Ser Asp Tyr Gln Trp Val Asp Asp Met Val Gly Phe Val Leu His Ser
      115           120           125

Ser Gln Leu Ile Pro Tyr Phe Ser Trp Lys His Ser His Arg Arg His
      130           135           140

His Ser Asn Thr Ala Ser Ile Glu Arg Asp Glu Val Tyr Pro Pro Ala
      145           150           155           160

Tyr Lys Asn Asp Leu Pro Trp Phe Ala Lys Tyr Leu Arg Asn Pro Val
      165           170           175

Gly Arg Phe Leu Met Ile Phe Gly Ala Leu Leu Phe Gly Trp Pro Ser
      180           185           190

Tyr Leu Leu Phe Asn Ala Asn Gly Arg Leu Tyr Asp Arg Phe Ala Ser
      195           200           205

His Tyr Asp Pro Gln Ser Pro Ile Phe Asn Asn Arg Glu Arg Leu Gln
      210           215           220

Val Ile Ala Ser Asp Val Gly Leu Val Phe Ala Tyr Phe Val Leu Tyr
      225           230           235           240

Lys Ile Ala Leu Ala Lys Gly Phe Val Trp Leu Ile Cys Val Tyr Gly
      245           250           255

Val Pro Tyr Val Ile Leu Asn Gly Leu Ile Val Leu Ile Thr Phe Leu
      260           265           270

Gln His Thr His Pro Asn Leu Pro Arg Tyr Asp Leu Ser Glu Trp Asp
      275           280           285

Trp Leu Arg Gly Ala Leu Ser Thr Val Asp Arg Asp Tyr Gly Met Leu
      290           295           300

Asn Lys Val Phe His Asn Val Thr Asp Thr His Leu Val His His Leu
      305           310           315           320

Phe Thr Thr Met Pro His Tyr Arg Ala Lys Glu Ala Thr Glu Val Ile
      325           330           335

Lys Pro Ile Leu Gly Asp Tyr Tyr Lys Phe Asp Asp Thr Pro Phe Leu
      340           345           350

Lys Ala Leu Trp Lys Asp Met Gly Lys Cys Ile Tyr Val Glu Ser Asp
      355           360           365

Val Pro Gly Lys Asn Lys Gly Val Tyr Trp Tyr Asn Asn Asp Ile
      370           375           380

```

<210> 54
 <211> 34
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer KT15

<400> 54
 aagctcgaga ccgggttggc ggcgtatttg tgtc 34

<210> 55
 <211> 38
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer KT13

<400> 55
 ggtctcgaga tctccaccgc ggacacaata tctggta 38

<210> 56
 <211> 1756
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> TEF/conjugase/XPR chimeric gene

<400> 56
 gaccgggttg gcggcgattt tgtgtcccaa aaaacagccc caattgcccc aattgacccc 60
 aaattgaccc agtagcgggc ccaaccccg cgagagcccc ctacaccca catatcaaac 120
 ctccccgggt toccacactt gccgttaagg gcgtagggta ctgcagtctg gaatctacgc 180
 ttgttcagac tttgtactag tttctttgtc tggccatccg ggtaacccat gccggacgca 240
 aaatagacta ctgaaaattt ttttgctttg tgggtgggac tttagccaag ggtataaaaag 300
 accaccgtcc ccgaattacc tttctcttct tttctctctt ctctctgtca actcacacc 360
 gaaatcgta agcatttctt tctgagtata agaatactt aaaggatcca ctagtcttag 420
 agcggccgca tgggagaagt gggaccaca aaccgaacca aaaccaagt ggacaagcaa 480
 caagaatccg aaaacagggt tcttcacgag ccacctccat tcacactaag tgaccttaag 540
 aaagccatcc caccacattg cttcgagcgc tccctcgtga aatcattcta ccacgtgatt 600
 caccacatta tcatctctgc ctttttctac tatgtcgccg ccaattacat ccccatgcta 660
 ccccaaaacc tccgttacgt tgcattggca atttatggg ccatccaagg ctgtgtccaa 720
 cttggtatat tgggtctagg ccatgaatgc ggccaccacg ccttcagcga ctaccaatgg 780
 gtagacgaca tggtcggggt cgtctccac tcttcccaat tgattcccta cttctcatgg 840
 aaacatagcc accgtcgcca cactccaac acggcctcca tcgagcgcca cgaggctctac 900
 ccgcccgggt acaaaaacga cctgccgtgg ttcgccaat acctacgcaa ccccgctcgt 960
 cgtttcctca tgattttcgg ggcgtactg ttcggctggc cgctgtacct tctgttcaac 1020
 gcgaacggcc gtctctacga ccgcttccgt tccactacg acccgcaat cccgatcttc 1080
 aacaaccgag agagggtgca agtgatcgcg tccgacgtcg ggctcgtctt cgggtacttt 1140
 gtctctgata agatcgcgct ggccaaggga tttgtgtggt taatttgtgt gtatggcgct 1200

```

ccgtacgtga tcttcaacgg gcttatcgtc ttgatcacgt tctacagca cacgcaccgg 1260
aatctgcccc gttacgacct ttccgagtg gactggctta ggggagccct gtcgactgtg 1320
gaccgcgatt acgggatggt gaataagggt ttccataacg tgacggacac gcacttggtg 1380
catcatttgt tcacgacct gccacattat cgcgccaagg aggcgaccga ggtgattaaa 1440
ccgatatggg gagactacta taagtttgac gacactccgt ttctcaaagc gttgtggaag 1500
gacatgggaa agtgtattta tgtggagtcg gacgtgcctg gcaagaacaa gggagtttat 1560
tggtaacaata acgacatttg agcggccgcc accgcggccc gagattccgg cctcttcggc 1620
cgccaagcga cccgggtgga cgtctagagg tacctagcaa ttaacagata gtttgcoggt 1680
gataattctc ttaacctccc acactccttt gacataacga tttatgtaac gaaactgaaa 1740
tttgaccaga tattgt 1756

```

<210> 57

<211> 383

<212> PRT

<213> Artificial Sequence

<220>

<223> TEF/conjugase/XPR chimeric protein

<400> 57

```

Met Gly Glu Val Gly Pro Thr Asn Arg Thr Lys Thr Lys Leu Asp Lys
1           5           10           15

Gln Gln Glu Ser Glu Asn Arg Val Pro His Glu Pro Pro Pro Phe Thr
20           25           30

Leu Ser Asp Leu Lys Lys Ala Ile Pro Pro His Cys Phe Glu Arg Ser
35           40           45

Leu Val Lys Ser Phe Tyr His Val Ile His Asp Ile Ile Ile Leu Ser
50           55           60

Phe Phe Tyr Tyr Val Ala Ala Asn Tyr Ile Pro Met Leu Pro Gln Asn
65           70           75           80

Leu Arg Tyr Val Ala Trp Pro Ile Tyr Trp Ala Ile Gln Gly Cys Val
85           90           95

Gln Leu Gly Ile Leu Val Leu Gly His Glu Cys Gly His His Ala Phe

```

100 105 110
 Ser Asp Tyr Gln Trp Val Asp Asp Met Val Gly Phe Val Leu His Ser
 115 120 125
 Ser Gln Leu Ile Pro Tyr Phe Ser Trp Lys His Ser His Arg Arg His
 130 135 140
 His Ser Asn Thr Ala Ser Ile Glu Arg Asp Glu Val Tyr Pro Pro Ala
 145 150 155 160
 Tyr Lys Asn Asp Leu Pro Trp Phe Ala Lys Tyr Leu Arg Asn Pro Val
 165 170 175
 Gly Arg Phe Leu Met Ile Phe Gly Ala Leu Leu Phe Gly Trp Pro Ser
 180 185 190
 Tyr Leu Leu Phe Asn Ala Asn Gly Arg Leu Tyr Asp Arg Phe Ala Ser
 195 200 205
 His Tyr Asp Pro Gln Ser Pro Ile Phe Asn Asn Arg Glu Arg Leu Gln
 210 215 220
 Val Ile Ala Ser Asp Val Gly Leu Val Phe Ala Tyr Phe Val Leu Tyr
 225 230 235 240
 Lys Ile Ala Leu Ala Lys Gly Phe Val Trp Leu Ile Cys Val Tyr Gly
 245 250 255
 Val Pro Tyr Val Ile Leu Asn Gly Leu Ile Val Leu Ile Thr Phe Leu
 260 265 270
 Gln His Thr His Pro Asn Leu Pro Arg Tyr Asp Leu Ser Glu Trp Asp
 275 280 285
 Trp Leu Arg Gly Ala Leu Ser Thr Val Asp Arg Asp Tyr Gly Met Leu
 290 295 300
 Asn Lys Val Phe His Asn Val Thr Asp Thr His Leu Val His His Leu
 305 310 315 320
 Phe Thr Thr Met Pro His Tyr Arg Ala Lys Glu Ala Thr Glu Val Ile
 325 330 335
 Lys Pro Ile Leu Gly Asp Tyr Tyr Lys Phe Asp Asp Thr Pro Phe Leu
 340 345 350
 Lys Ala Leu Trp Lys Asp Met Gly Lys Cys Ile Tyr Val Glu Ser Asp
 355 360 365
 Val Pro Gly Lys Asn Lys Gly Val Tyr Trp Tyr Asn Asn Asp Ile
 370 375 380

<210> 58

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer KH5

<400> 58

tagagcggcc gcttaaacca tgaaaaagcc tg 32

<210> 59

<211> 33

<212> DNA

<213> Artificial Sequence

<220>
<223> Primer KH3

<400> 59
gtggcgccg ctttaggtac ctactattc ctt 33

<210> 60
<211> 1026
<212> DNA
<213> Escherichia coli

<400> 60
atgaaaaagc ctgaactcac cgcgacgtct gtcgagaagt ttctgatcga aaagttcgac 60
agcgtctccg acctgatgca gctctcggag ggcgaagaat ctctgtgcttt cagcttcgat 120
gtaggagggc gtggatatgt cctgcgggta aatagctgcg ccgatgggtt ctacaaagat 180
cgttatgttt atcggcaactt tgcacgggcc gcgctcccga ttccggaagt gcttgacatt 240
ggggaattca gcgagagcct gacctattgc atctcccgcc gtgcacaggg tgtcacgttg 300
caagacotgc ctgaaaccga actgcccgct gttctgcagc cggtcgcgga ggccatggat 360

gcgatcgtg cggccgatct tagccagacg agcgggttcg gccatttcg accgcaagga 420
atcgggcaat acactacatg gcgtgatttc atatgcgcga ttgctgatcc ccattgtgat 480
cactggcaaa ctgtgatgga cgacaccgtc agtgcgtccg tcgcgcaggg tctcgatgag 540
ctgatgcttt gggccgagga ctgcccga gtcgggcacc tcgtgcacgc ggatttcggc 600
tccaacaatg tcttgacgga caatggccgc ataacagcgg tcattgactg gagcgaggcg 660
atgttcgggg attccaata cgaggtcgcc aacatcttct tctggaggcc gtggttggt 720
tgtatggagc agcagacgcg ctacttcgag cggaggcacc cggagcttgc aggatcgccg 780
cggctccggg cgtatatgct ccgcatttgt cttgaccaac tctatcagag cttggttgac 840
ggcaatttcg atgatgcagc ttgggcgcag ggtcgatgcg acgcaatcgt ccgatccgga 900
gccgggactg tcgggcgtac acaaatcgcc cgcagaagcg cggccgtctg gaccgatggc 960
tgtgtagaag tactcgccga tagtggaac cgacgccccg gactcgtcc gagggcaaa 1020
gaatag 1026

<210> 61
<211> 341
<212> PRT
<213> Escherichia coli

<400> 61
Met Lys Lys Pro Glu Leu Thr Ala Thr Ser Val Glu Lys Phe Leu Ile
1 5 10 15

Glu Lys Phe Asp Ser Val Ser Asp Leu Met Gln Leu Ser Glu Gly Glu
20 25 30

Glu Ser Arg Ala Phe Ser Phe Asp Val Gly Gly Arg Gly Tyr Val Leu
35 40 45

Arg Val Asn Ser Cys Ala Asp Gly Phe Tyr Lys Asp Arg Tyr Val Tyr
50 55 60

Arg His Phe Ala Ser Ala Ala Leu Pro Ile Pro Glu Val Leu Asp Ile
65 70 75 80

Gly Glu Phe Ser Glu Ser Leu Thr Tyr Cys Ile Ser Arg Arg Ala Gln
85 90 95

Gly Val Thr Leu Gln Asp Leu Pro Glu Thr Glu Leu Pro Ala Val Leu
100 105 110

Gln Pro Val Ala Glu Ala Met Asp Ala Ile Ala Ala Ala Asp Leu Ser
115 120 125

Gln Thr Ser Gly Phe Gly Pro Phe Gly Pro Gln Gly Ile Gly Gln Tyr
130 135 140

Thr Thr Trp Arg Asp Phe Ile Cys Ala Ile Ala Asp Pro His Val Tyr
145 150 155 160

His Trp Gln Thr Val Met Asp Asp Thr Val Ser Ala Ser Val Ala Gln
165 170 175

Ala Leu Asp Glu Leu Met Leu Trp Ala Glu Asp Cys Pro Glu Val Arg
180 185 190

His Leu Val His Ala Asp Phe Gly Ser Asn Asn Val Leu Thr Asp Asn
195 200 205

Gly Arg Ile Thr Ala Val Ile Asp Trp Ser Glu Ala Met Phe Gly Asp
210 215 220

Ser Gln Tyr Glu Val Ala Asn Ile Phe Phe Trp Arg Pro Trp Leu Ala
225 230 235 240

Cys Met Glu Gln Gln Thr Arg Tyr Phe Glu Arg Arg His Pro Glu Leu
245 250 255

Ala Gly Ser Pro Arg Leu Arg Ala Tyr Met Leu Arg Ile Gly Leu Asp
260 265 270

Gln Leu Tyr Gln Ser Leu Val Asp Gly Asn Phe Asp Asp Ala Ala Trp
275 280 285

Ala Gln Gly Arg Cys Asp Ala Ile Val Arg Ser Gly Ala Gly Thr Val
290 295 300

Gly Arg Thr Gln Ile Ala Arg Arg Ser Ala Ala Val Trp Thr Asp Gly
305 310 315 320

Cys Val Glu Val Leu Ala Asp Ser Gly Asn Arg Arg Pro Ser Thr Arg
325 330 335

Pro Arg Ala Lys Glu
340

<210> 62

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer KTH5

<400> 62

tttagatctc gagaccgggt tggcggcgta ttg 34

<210> 63

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer KTH3

<400> 63

tttagatctc caccgggac acaatatctg g 31

<210> 64

<211> 1650

<212> DNA

<213> Artificial Sequence

<220>

<223> TEF::HPT::XPR fusion

<400> 64

```

gaccgggttg gcggcgattt tgtgtcccaa aaaacagccc caattgcccc aattgacccc      60
aaattgaccc agtagcgggc ccaaccccg cagagagcccc cttcacccca catatcaaac      120
ctcccccggt tcccacactt gccgttaagg gcgtagggta ctgcagtcgt gaatctacgc      180
ttgttcagac tttgtactag tttctttgtc tggccatccg ggtaacccat gccggacgca      240
aaatagacta ctgaaaattt ttttgccttg tggttgggac tttagccaag ggtataaaaag      300
accaccgtcc ccgaattacc tttcctcttc tttctctctc ctctctgtca actcacaccc      360
gaaatcggtta agcatttctt tctgagtata agaattcatc aaaggatcca ctagtctotag      420
agcggccgct taaaccatga aaaagcctga actcacccgc acgtctgtcg agaagtttct      480
gatcgaaaag ttcgacagcg tctccgacct gatgcagctc tcggaggggc aagaatctcg      540
tgctttcagc ttcgatgtag gagggcggtg atatgtcctg cgggtaaaata gctgcgccga      600
tggtttctac aaagatcggt atgtttatcg gcactttgca tcggccgcgc tcccgatctc      660
ggaagtgcct gacattgggg aattcagcga gagcctgacc tattgcatct cccgcctgct      720
acaggggtgc acgttgcaag acctgcctga aaccgaactg cccgctgttc tgcagccggt      780
cgcgaggggc atggatgcga tcgctgcggc cgatcttagc cagacgagcg ggttcgggcc      840
attcggaccg caaggaatcg gtcaatacac tacatggcgt gatttcatat gcgcgattgc      900
tgatcccat gtgtatcact ggcaaaactgt gatggacgac accgtcagtg cgtccgtcgc      960
gcaggctctc gatgagctga tgccttgggc cgaggactgc cccgaagtcc ggcacctcgt      1020
gcacgcggat ttcggctcca acaatgtcct gacggacaat ggccgcataa cagcggtcac      1080
tgactggagc gaggcgatgt tcggggatto ccaatacgag gtcgccaaca tcttctctcg      1140
gaggccgtgg ttggcttgta tggagcagca gacgcgtac ttcgagcgga ggcatccgga      1200
gcttgcagga tcgcgcgggc tccgggcgta tatgtccgc attggtcttg accaactcta      1260
tcagagcttg gttgacggca atttcgatga tgcagcttgg gcgcagggtc gatgcgacgc      1320
aatcgtccga tccggagcgc ggactgtcgg gcgtacacaa atcgcgccga gaagcgcggc      1380
cgtctggacc gatggctgtg tagaagta ctgcgatagt ggaaaccgac gccccagcac      1440
tcgtccgagg gcaaagggaat agtgaggta ctaaagcggc cgccaccgcg gcccgagatt      1500
ccggcctctt cggccgcca ggcacccggg tggacgtcta gaggtaccta gcaattaaca      1560
gatagtttgc cgggtataat tctcttaacc tcccacactc ctttgacata acgatttatg      1620
taacgaaact gaaatttgac cagatatgtg

```

<210> 65

<211> 341

<212> PRT

<213> Artificial Sequence

<220>

<223> TEF::HPT::XPR fusion

<400> 65

```

Met Lys Lys Pro Glu Leu Thr Ala Thr Ser Val Glu Lys Phe Leu Ile
1           5           10           15

```

Glu Lys Phe Asp Ser Val Ser Asp Leu Met Gln Leu Ser Glu Gly Glu
 20 25 30
 Glu Ser Arg Ala Phe Ser Phe Asp Val Gly Gly Arg Gly Tyr Val Leu
 35 40 45
 Arg Val Asn Ser Cys Ala Asp Gly Phe Tyr Lys Asp Arg Tyr Val Tyr
 50 55 60
 Arg His Phe Ala Ser Ala Ala Leu Pro Ile Pro Glu Val Leu Asp Ile
 65 70 75 80
 Gly Glu Phe Ser Glu Ser Leu Thr Tyr Cys Ile Ser Arg Arg Ala Gln
 85 90 95
 Gly Val Thr Leu Gln Asp Leu Pro Glu Thr Glu Leu Pro Ala Val Leu
 100 105 110
 Gln Pro Val Ala Glu Ala Met Asp Ala Ile Ala Ala Ala Asp Leu Ser
 115 120 125
 Gln Thr Ser Gly Phe Gly Pro Phe Gly Pro Gln Gly Ile Gly Gln Tyr
 130 135 140
 Thr Thr Trp Arg Asp Phe Ile Cys Ala Ile Ala Asp Pro His Val Tyr
 145 150 155 160
 His Trp Gln Thr Val Met Asp Asp Thr Val Ser Ala Ser Val Ala Gln
 165 170 175
 Ala Leu Asp Glu Leu Met Leu Trp Ala Glu Asp Cys Pro Glu Val Arg
 180 185 190
 His Leu Val His Ala Asp Phe Gly Ser Asn Asn Val Leu Thr Asp Asn
 195 200 205
 Gly Arg Ile Thr Ala Val Ile Asp Trp Ser Glu Ala Met Phe Gly Asp
 210 215 220
 Ser Gln Tyr Glu Val Ala Asn Ile Phe Phe Trp Arg Pro Trp Leu Ala
 225 230 235 240
 Cys Met Glu Gln Gln Thr Arg Tyr Phe Glu Arg Arg His Pro Glu Leu
 245 250 255
 Ala Gly Ser Pro Arg Leu Arg Ala Tyr Met Leu Arg Ile Gly Leu Asp
 260 265 270
 Gln Leu Tyr Gln Ser Leu Val Asp Gly Asn Phe Asp Asp Ala Ala Trp
 275 280 285
 Ala Gln Gly Arg Cys Asp Ala Ile Val Arg Ser Gly Ala Gly Thr Val
 290 295 300
 Gly Arg Thr Gln Ile Ala Arg Arg Ser Ala Ala Val Trp Thr Asp Gly
 305 310 315 320
 Cys Val Glu Val Leu Ala Asp Ser Gly Asn Arg Arg Pro Ser Thr Arg
 325 330 335
 Pro Arg Ala Lys Glu
 340

<210> 66

<211> 401

<212> DNA

<213> Yarrowia lipolytica

<400> 66

```

cgagtatctg tctgactcgt cattgccgcc tttggagtac gactccaact atgagtgtgc      60
ttggatcact ttgacgatac attcttcgtt ggaggctgtg ggtctgacag ctgcgttttc      120
ggcgcggttg gccgacaaca atatcagctg caacgtcatt gctggctttc atcatgatca      180
catttttgtc ggcaaaggcg acgccagag agccattgac gttctttcta atttggaaccg      240
atagccgatg agtcacgtct atctataagt tcaactaact cgtaactatt accataacat      300
atacttcact gccccagata aggttcgat aaaaagttct gcagactaaa tttatttcag      360
tctctcttcc accaccaaaa tgccctccta cgaagctcga g                        401

```

<210> 67

<211> 568

<212> DNA

<213> Yarrowia lipolytica

<400> 67

```

atcataattg tcggccgagg tctgtacggc cagaaccgag atcctattga ggaggccaag      60
cgataccaga aggctggctg ggaggcttac cagaagatta actgttagag gttagactat      120
ggatatgtca ttttaactgt tatatagaga gcgtgcaagt atggagcgct tgttcagctt      180
gtatgatggt cagacgacct gtctgatcga gtatgtatga tactgcacaa cctgtgtatc      240
cgcatgatct gtccaatggg gcattgttgt gtgtttctcg atacggagat gctgggtaca      300
agtagctaatac gatttgaac tacttatact tatatgaggc ttgaagaaag ctgacttgtg      360
tatgacttat tctcaactac atccccagtc acaataccac cactgcacta ccactacacc      420
aaaaccatga tcaaacccac catggacttc ctggaggcag aagaacttgt tatggaaaag      480
ctcaagagag agaagccaag atactatcaa gacatgtgtc gcaacttcaa ggaggaccaa      540
gctctgtaca ccgagaaaca ggcctttg                        568

```

<210> 68

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL63

<400> 68

ttatgatatc gaattaatta acctgcagcc cggggg 36

<210> 69

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL64

<400> 69

ccccgggct gcaggtaat taattcgata tcataa 36

<210> 70

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL65

<400> 70

tacgccgcca accgtacgt ctgagcttc gta 33

<210> 71

<211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL66

 <400> 71
 tacgaagctc gagacgtacg ggtggcggc gta 33

 <210> 72
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL11

 <400> 72
 tttccatgg gaacggacca aggaaaaacc 30

 <210> 73
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL12

 <400> 73
 ttgcgggcg cctactcttc ctgggacgg 30

 <210> 74
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL81

 <400> 74
 gttatccgct cacaagcttc cacacaacgt acg 33

 <210> 75
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL82

 <400> 75
 cgtacgttgt gtggaagctt gtgagcgat aac 33

 <210> 76
 <211> 33
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL83

 <400> 76

atttgaatcg aatcgatgag cctaaaatga acc 33

<210> 77

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL84

<400> 77

ggttcatttt aggctcatcg attcgattca aat 33

<210> 78

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL105

<400> 78

ccaagcacta acctaccgtt taaacaccac taaaaccc 38

<210> 79

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL106

<400> 79

gggttttagt ggtgtttaa cggtaggta gtgcttg 38

<210> 80

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL119

<400> 80

cgggaaacct gtcgtggcgc gccagctgca ttaatg 36

<210> 81

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL120

<400> 81

cattaatgca gctggcgcgc cacgacaggt ttcccg 36

<210> 82

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL121

<400> 82

ttggcgcg cttacacac acgctctcat caag 34

<210> 83

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL122

<400> 83

tttcgtacga accaccaccg tcagcccttc tgac 34

<210> 84

<211> 440

<212> DNA

<213> Yarrowia lipolytica

<400> 84

aaccaccacc gtcagccctt ctgactcacg tattgtagcc accgacacag gcaacagtcc	60
gtggatagca gaatatgtct tgtcgggtcca tttctcacca actttaggcg tcaagtgaat	120
gttcgagaag aagtatgtgc cttcattgag aatcggtggt gctgatttca ataaagtctt	180
gagatcagtt tggccagtc tgttgtgggg ggtaattgga ttgagttatc gcctacagtc	240
tgtacaggta tactcgctgc ccactttata ctttttgatt ccgctgcaat tgaagcaatg	300
tcgtttacca aaagtgagaa tgctccacag aacacacccc agggtaaggt tgagcaaaaa	360
ataaacactc cgatacgggg aatcgaaccc cggctctccac ggttctcaag aagtattctt	420
gatgagagcg tgatgtgata	440

<210> 85

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL114

<400> 85

tgatagatc ttggcgcgcc ttctctct tgac 35

<210> 86

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL115

<400> 86

gctcaagaga gagaaggcg gccaaagatac tatca 35

<210> 87

<211> 5218

<212> DNA

<213> Artificial Sequence

<220>

<223> 5218 bp fragment for integration and expression of the delta-5 desaturase gene

<400> 87

tatcacatca cgctctcatc aagaatactt cttgagaacc gtggagaccg gggttcgatt	60
ccccgtatcg gagtgtttat tttttgctca accataccct ggggtgtgtt ctgtggagca	120
ttctcacttt tggtaaacga cattgcttca agtgcagcgg aatcaaaaag tataaagtgg	180
gcagcgagta tacctgtaca gactgtaggc gataactcaa tccaattacc cccacaaca	240
tgactggcca aactgatcto aagactttat tgaatcagc aacaccgatt ctcaatgaag	300
gcacatactt cttctgcaac attcacttga cgcctaaagt tggtagagaa tggaccgaca	360
agacatatcc tgcctatccac ggactgttgc ctgtgtcggg ggtacaata cgtgagtcag	420
aagggctgac ggtggtgggt cgtacgttgt gtggaagcct gtgagcggat aacaatttca	480
cacaggaaac agctatgacc atgattacgc caagctcgaa attaaccttc actaaaggga	540
acaaaagctg gagctccacc ggggacacaa tatctggtca aatttcagtt tcgttacata	600
aatcgttatg tcaaaggagt gtgggagggt aagagaatta tcaccggcaa actatctgtt	660
aattgctagg tacctctaga cgtccaccgg ggtcgtttgg cggccgaaga ggcgggaatc	720
tcgggcccgg gtggcggccg cctactcttc cttgggacgg agtccaagaa cagcaagtg	780
ctccaaatgt gaagcaaatg cttgccaaaa cgtatccttg acaaggtatg gaaccttgta	840
ctcgtgcag gtgtttctta tgatggccag aatatcggga taatgggtgt gcgacacgtt	900
ggggaacaga tgggtgcacg cggtagttc aagctgccag tgatgctggt ccagagggtc	960
gaatcgtgtg cgtaatctcg cgtagtctcg acctgcatag ctgccagtc cttttgatg	1020
atccccgttc cgtcaggcaa cggccactga acttctctca caacgtgggt cgcctggaag	1080
gtcagcgcca gccagtaaga cgacaccatg tccgcgaccg tgaacaagag cagcaccttg	1140
cccaggggga gatactgcag gggaaacaatc aggcgatacc agacaaagaa agccttgccg	1200
ccccagaaca tcacagtgtg ccatgtcgag atgggattga cacgaatagc gtcattggtc	1260
ttgacaaagt acaaaatgtt gatgtcctga atgcgcacct tgaacgccag cagtcctgac	1320
aggaaaggaa caaacatgtg ctggttgatg tggttgacaa accacttttg gttgggcttg	1380
atcgcacgaa catcgggctc agacgtcgac acgtcgggat ctgctccagc aatgttggtg	1440
taggggtgat ggccgagcat atgttggtac atccacacca ggtacgatgc tccgttgaaa	1500
aagtcgtcgt tggctcccag aatcttcag acagtggggg tgtgggtcac tgaaaagtga	1560
gacgcatcat gaagagggtt gagtccgact tgtgcgcacg caaatcccat gatgattgca	1620
aacaccacct gaagccatgt gcgttcgaca acgaaaggca caaagagctg cgcgtagtag	1680
gaagcgatca aggatccaaa gataagagcg tatcgtcccc agatctcttg tctattcttg	1740
ggatcaatgt tccgatccgt aaagtagccc tcgactctcg tcttgatggt tttgtggaac	1800
accgttggtc ccgggaagat gggcagctca ttcgagacca gtgtaccgac atagtacttc	1860
ttcataatgg catctgcagc cccaaacgcg tgatacatct caaagaccgg agtaacatct	1920
cggccagctc cgagcaggag agtgtccact ccaccaggat ggcgggtcaa gaactttgtg	1980

```

acatcgtaga cctcgccgag gatggccaag agtaggtcgt ccttggtgtt atgggcccgc 2040
agctcttccc aggtgaaggt ttttccttgg tccgttccca tggatgaatga ttcttatact 2100
cagaaggaaa tgcttaacga tttcgggtgt gagttgacaa ggagagagag aaaagaagag 2160
gaaaggtaat tcggggacgg tgggtcttga tacccttggc taaagtccca accacaaagc 2220
aaaaaaattt tcagtagtgt attttgcgtc cggcatgggt taccgggatg gccagacaaa 2280
gaaactagta caaagtctga acaagcgtag attccagact gcagtaccct acgcccttaa 2340
cggcaagtgt ggggaacggg ggaggtttga tatgtggggt gaaggggggt ctgcggggg 2400
ttgggcccgc tactgggtca atttggggtc aattggggca attggggtg ttttttggga 2460
cacaatacag ccgccaaccc ggtctctcct gaattctgca gatgggctgc aggaattccg 2520
tcgtcgctg agtcgacatc atttatttac cagttggcca caaaccttg acgatctcgt 2580
atgtccctc cgacatactc ccggccgggt ggggtacgtt cगतगगct atcgcatcg 2640
acaaggttg ggtccctagc cgataccgca ctacctgagt cacaatcttc ggaggtttag 2700
tcttcacat agcacgggca aaagtgcgtc tatatacaag agcgtttgcc agccacagat 2760
tttctactca cacaccacat cacacataca accacacaca tccacaatgg aaccgaaac 2820
taagaagacc aagactgact ccaagaagat tgtctctctc ggcggcgact tctgtggccc 2880
cgaggtgatt gccgaggccg tcaaggtgct caagtctgtt gctgaggcct ccggcaccga 2940
gtttgtgttt gaggacogac tcattggagg agctgccatt gagaaggagg gcgagcccat 3000
caccgacgtc actctcgaca tctgccgaaa ggtgactctc attatgctcg gtgctgtcgg 3060
aggcgtgccc aacaccgtat ggaccactcc cgacggacga accgacgtc gacccgagca 3120
gggtctcttc aagctcgcaa aggacctgaa cctgtacgcc aacctgcac cctgccagct 3180
gctgtcgcgc aagctcgccg atctctcccc catccgaaac gttgagggca ccgacttcat 3240
cattgtccga gagctcgctg gaggtatcta ctttggagag cgaaaggagg atgacggatc 3300
tggcgctcgt tccgacaccg agacctactc cgttcctgag gttgagcgaa ttgccgaat 3360
ggcgccttc ctggcccttc agcacaaccc cctcttccc gtgtggtctc ttgacaaggc 3420
caacgtgctg gcctctctc gactttggcg aaagactgtc actcgagtcc tcaaggacga 3480
attccccag ctcgagctca accaccagct gatcgactcg gccgccatga tctcatcaa 3540
gcagccctcc aagatgaatg gtatcatcat caccaccaac atgtttggcg atatcatctc 3600
cgacgaggcc tccgtcatcc ccggttctct gggctctgct ccctccgct ctctggcttc 3660

```

tctgccccgac acccaacgagg cggttcggtct gtacgagccc tgteacggat ctgccccga 3720
tctcgggaag cagaaggta accccattgc caccattctg tctgccgcca tgatgctcaa 3780
gttctctctt aacatgaagc cgcgcggtga cgctgttagg gctgccgtca aggagtcggt 3840
cgaggtcggt atcaactacc cgatatcgg aggcctcttc tccacctccg aggtcggaga 3900
cttgttgcca acaaggtaaa ggagctgctc aagaaggagt aagtcgtttc tacgacgcac 3960
tgatggaagg agcaaaactga cgcgcctgcg ggttggtcta ccggcagggt ccgctagtgt 4020
ataagactct ataaaaagg cctgcctctg ctaatgaaat gatgatttat aatttaccgg 4080
tgtagcaacc ttgactagaa gaagcagatt ggggtgtgtt gtagtgagg acagtggtag 4140
gttttggaag cagtcctctt gaaagtgtct tgcctacagt atattcactc ataacctcaa 4200
tagccaaggg tgtagtcggt ttattaaagg aaggaggttg tggctgatgt ggatagatat 4260
ctttaagctg gcgactgcac ccaacgagtg tgggtgtagc ttgttactgt atattcggtg 4320
agatatattt tgtggggttt tagtggtgtt taaacgtag gttagtgttt ggtatatgag 4380
ttgtaggcat gacaatttgg aaaggggtgg actttgggaa tattgtggga tttcaatacc 4440
ttagtttga cagggttaatt gttacaaatg atacaaagaa ctgtatttct tttcatttgt 4500
tttaattggt tgtatatcaa gtccgttaga cgagctcagt gccttggtct ttggcactgt 4560
atttcatttt tagaggtaca ctacattcag tgaggtatgg taaggttgag ggcataatga 4620
aggcaccttg tactgacagt cacagacctc tcaccgagaa ttttatgaga tatactcggg 4680
ttcattttag gctcatcgat tcgattcaaa ttaattaatt cgatatcata attgtcggcc 4740
gaggtctgta cggccagaac cgagatccta ttgaggaggc caagcgatac cagaaggctg 4800
gctgggaggc ttaccagaag attaaactgt agagggttaga ctatggatat gtcatttaac 4860
tgtgtatata gagagcgtgc aagtatggag cgcttgttca gctgtatga tggctagacg 4920
acctgtctga tcgagtatgt atgatactgc acaacctgtg tatccgcatg atctgtccaa 4980
tggggcatgt tgttgtgttt ctcgatacgg agatgctggg tacaagtagc taatacgatt 5040
gaactactta tacttatatg aggcctgaag aaagctgact tgtgtatgac ttattctcaa 5100
ctacatcccc agtcacaata ccaccactgc actaccacta caccaaaacc atgatcaaac 5160
caccatgga ctctctggag gcagaagaac ttgttatgga aaagctcaag agagagaa 5218

<210> 88

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL61

<400> 88

acaattccac acaacgtacg agccggaagc ata 33

<210> 89

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL62

<400> 89

tatgctccg gctcgtagt tgttggaat tgt 33

<210> 90

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL69

<400> 90

agcccatctg cagaagcttc aggagagacc ggg 33

<210> 91

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL70

<400> 91

cccggctctc cctgaagctt ctgcagatgg gct 33

<210> 92

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL77

<400> 92

tagtgagggt taattaatcg agcttggcgt aat 33

<210> 93

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL78

<400> 93

attacgcaa gctcgattaa ttaaccctca cta 33

<210> 94

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL79A

<400> 94

attctgcag cccatcgatg cagaattcag gaga 34

<210> 95

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL80A

<400> 95

tctcctgaat tctgcatcga tgggctgcag gaat 34

<210> 96

<211> 8894

<212> DNA

<213> Artificial Sequence

<220>

<223> 8894 bp fragment for integration and expression of the delta-6 and delta-5 desaturase genes and the elongase gene

<400> 96

```

tattcacatca cgctctcacc aagaatactt cttgagaacc gtggagaccg gggttcgatt    60
ccccgtatcg gagtgtttat tttttgctca accataccct ggggtgtgtt ctgtggagca    120
ttctcacttt tggtaaacga cattgcttca agtgcagcgg aatcaaaaag tataaagtgg    180
gcagcgagta tacctgtaca gactgtagcg gataactcaa tccaattacc cccacaaca    240
tgactggcca aactgatctc aagactttat tgaaatcagc aacaccgatt ctcaatgaag    300

gcacatactt cttctgcaac attcacttga cgccataagt tggtgagaaa tggaccgaca    360
agacataatt tgctatccac ggactgttgc ctgtgtcggg ggctacaata cgtgagtcag    420
aagggtgac ggtggtggtt cgtacgttgt gtggaattgt gagcggataa caatttcaca    480
caggaaacag ctatgaccat gattacgcca agctcgaat taacctcac taaagggaac    540
aaaagctgga gctccaccgc ggacacaata tctggtcaaa ttccagtctt gttacataaa    600
tcgttatgtc aaaggagtgt gggaggttaa gagaattatc accggcaaac tatctgttaa    660
ttgctaggta cctctagacg tccaccggg tgccttggcg gccgaagagg ccggaatctc    720
gggcgcgggt ggcggcgcgt tactgcaact tcttgcctt ctccttggca gcgtcggcct    780
tggcctgctt ggccaacttg gcgttcttct tgtaaaagtt gtagaagaga ccgagcatgg    840
tccacatgta gaaccaaacg agagccgtga tgaagaaggg gtatccgggg cgccaagga    900
ccttcattgg gtacatgtcc caggaaagact ggaccgacat catgcagaac tgtgtcatct    960
gcgagcgcgt gatgtagaac ttgatgaacg acacctgctt gaagcccaag gccgacaaga   1020
agtagtagcc gtacatgacg acatggatga acgagttcaa cgcagcagag aagtaggctt   1080
cacggttggg tgcaacaaaag gtgaccaacc accagatggt gaagatggag ctgtggtggt   1140
aaacgtgcaa gaaggagatc tggcggttgt tcttcttgag gaccatgac atggtgtcga   1200
caaaactccat gatcttgag aagtagaaga gccagatcat cttggccata ggaagaccct   1260
tgaaggatat atcagcagcg tcttcaaaac gtccatagtt ggctgataa gctcgtaca   1320
ggatcccacc gcacatgtag gcgctgatcg agaccagaca aaagttgtgc aggagcgaaa   1380
acgtcttgac ctggaaccgc tcaaagttct tcatgatctg catgccaca aagaccgtga   1440
ccaaataagc gagcacgac aacagcacgt ggaacggggt catcaacggc agctcacggg   1500
ccaaaggcga ctccaccgcg accaggaacc cagcgtgtg atggacaatc gtggggatgt   1560
acttctcggc ctgggccacc agcgcggcct cgagaggatc gacatagggc gcggcccggg   1620
caccgatagc ggtggcaagg tcataaaca gatcttgcgg catctttgat gggaggaatg   1680
gcgcaatcga ctccatggg ccgctctaga actagtggat cctttgaatg attcttatac   1740
tcagaaggaa atgcttaacg atttcgggtg tgagttgaca aggagagaga gaaaagaaga   1800
ggaaaggtaa ttccgggacg gtggtctttt atacccttg ctaaagtccc aaccacaaag   1860
caaaaaaatt ttacagtagc tattttgcgt ccggcatggg ttaccggat ggcagacaa   1920
agaaactagt acaaagtcg aacaagcgta gattccagac tgcagtaccc tacgccctta   1980

```

acggcaagtg tgggaaccgg gggaggtttg atatgtgggg tgaagggggc tctcgccggg	2040
gttgggcccc ctactgggtc aatttggggg caattggggc aattggggct gttttttggg	2100
acacaaatac gccccaacc cggtctctcc tgaagcttgt gagcggataa caatttcaca	2160
caggaaacag ctatgacct gattacgcca agctcgaaat taaccctcac taaagggaac	2220
aaaagctgga gctccaccgc ggacacaata tctgggtcaaa tttcagtttc gttacataaa	2280
tcgttatgtc aaaggagtggt gggaggttaa gagaattatc accggcaaac tatctgttaa	2340
ttgctaggta cctctagacg tccaccggg tgccttggcg gccgaagagg ccggaatctc	2400
gggcccgggt ggccggccgc tactcttcct tgggacggag tccaagaaca cgcaagtgtc	2460
ccaaatgtga agcaaatgct tgccaaaacg tatccttgac aagggtatga acctgtact	2520
cgctgcaggt gttcttgatg atggccagaa tatcgggata atggtgctgc gacacgttgg	2580
ggaacagatg gtgcacagcc tggtagttca agctgccagt gatgctggtc cagaggtgcg	2640
aatcgtgtgc gtaatctgc gtagtctga cctgcatagc tgcccagtc ttttgatga	2700
tcccgttctc gtcaggcaac ggccactgaa ctctctcaac aacgtggttc gcttggagg	2760
tcagcggccag ccagtaagac gacaccatgt ccgcgaccgt gaacaagagc agcaccttgc	2820
ccaggggcag atactgcagg ggaacaatca ggcgatacca gacaaagaaa gccttgccgc	2880
cccagaacat cacagtgtgc catgtcgaga tgggattgac acgaatagcg tcattggtct	2940
tgacaaagta caaaatgttg atgtcctgaa tgcgcacctt gaacgccagc agtcogtaca	3000
ggaaaggaac aaacatgtgc tgggtgatgt ggttgacaaa ccacttttgg ttgggcttga	3060
tacgacgaac atcgggctca gacgtcgaca cgtcgggac tgctccagca atgttggtgt	3120
aggggtgatg gccgagcata tgttgggtaca tccacaccag gtacgatgct ccgttgaaaa	3180
agtcgtgctg gggtcccaga atcttccaga cagtgggggt gtgggtcact gaaaagtgag	3240
acgcacatg aagaggggtg agtccgactt gtgcgcacgc aaatcccatg atgattgcaa	3300
acaccacctg aagccatgtg cgttcgacaa cgaaaggcac aaagagctgc gcgtagtagg	3360
aagcgatcaa ggatccaaag ataagagcgt atcgtcccca gatctctggt ctattcttgg	3420
gatcaatgtt ccgatccgta aagtagccct cgactctcgt cttgatggtt ttgtggaaca	3480
ccgttggtc cgggaagatg ggcagctcat tcgagaccag tgtaccgaca tagtacttct	3540
tcataatggc atctgcagcc ccaaaccggt gatacatctc aaagaccgga gtaacatctc	3600
ggccagctcc gagcaggaga gtgtccactc caccaggatg gcggctcaag aactttgtga	3660

```

catcgtacac cctgccgcgg atggccaaga gtaggtcgtc cttggtgtta tgggccgcca 3720
gctcttccca ggtgaagggt ttctcttggt ccgttcccat ggtgaatgat tcttatactc 3780
agaaggaaat gcttaacgat ttcgggtgtg agttgacaag gagagagaga aaagaagagg 3840
aaaggtaatt cggggacggg ggtcttttat acccttggct aaagtcccaa ccacaaagca 3900
aaaaaatttt cagtagtcta ttttgcgtcc ggcattgggtt acccgatgg ccagacaaag 3960
aaactagtac aaagtctgaa caagcgtaga ttccagactg cagtacccta cgccctaac 4020
ggcaagtgtg ggaaccgggg gaggtttgat atgtggggtg aagggggctc tcgccggggg 4080
tgggcccgct actgggtcaa tttgggtca attgggcaa ttggggctgt tttttggac 4140
acaaatacgc gcacaacccg gtcctctctg aattctgcag atggggtgca ggaattccgt 4200
cgtgcctga gtcacatca tttatttacc agttggccac aaaccctga cgatctcgta 4260
tgtccctcc gacatactcc cggccggctg gggtagcttc gatagccta tcggcatcga 4320
caaggtttgg gtccctagcc gataccgcac tacctgagtc acaatcttcg gaggtttagt 4380
ctccacata gcacgggcaa aagtgcgtat atatacaaga gcgtttgcca gccacagatt 4440
ttcactccac acaccacatc acacatacaa ccacacacat ccacaatgga acccgaaact 4500
aagaagacca agactgactc caagaagatt gttcttctcg gcggcgactt ctgtggcccc 4560
gaggtgattg ccgagggcgt caagggtgctc aagtctgttg ctgaggctc cggcaccgag 4620
tttgtgttg aggaccgact cattggagga gctgccattg agaaggaggg cgagcccatc 4680
accgacgcta ctctcgacat ctgccgaaag gctgactcta ttatgctcgg tgctgtcgga 4740
ggcgctgcca acaccgtatg gaccactccc gacggacgaa ccgacgtgcg acccgagcag 4800
ggctctctca agctcgcaaa ggacctgaac ctgtacgcca acctgcgacc ctgccagctg 4860
ctgtcgccca agctcgccga tctctccccc atccgaaacg ttgagggcac cgacttcac 4920
attgtccgag agctcgtcgg aggtatctac tttggagagc gaaaggagga tgacggatct 4980
ggcgtcgctt ccgacacga gacctactcc gttcctgagg ttgagcgaat tgcccgaatg 5040
gccgccttcc tggcccttca gcacaacccc cctcttcccg tgtggtctct tgacaaggcc 5100
aacgtgctgg cctcctctcg actttggcga aagactgtca ctcgagtcct caaggacgaa 5160
ttcccccagc tcgagctcaa ccaccagctg atcgactcgg ccgccatgat cctcatcaag 5220
cagccctcca agatgaatgg tatcatcatc accaccaaca tgtttggcga tatcatctcc 5280
gacgaggcct ccgtcatccc cggttctctg ggtctgctgc cctccgccto totggcttct 5340

```

```

ctgccccgaca ccaacgagggc gttcgggtctg tacgagccct gtcacggatc tgcccccgat 5400
ctcggcaagc agaagggtcaa ccccatggcc accattctgt ctgcgccat gatgctcaag 5460
ttctctctta acatgaagcc cgccgggtgac gctgttgagg ctgccgtcaa ggagtcctgc 5520
gaggctggta tcactaccgc cgatatcgga ggctcttctt ccacctccga ggtcggagac 5580
ttgttgccaa caagggtcaag gagctgctca agaaggagta agtcgtttct acgacgcatt 5640
gatggaagga gcaaaactgac gcgcctgcgg gttggtctac cggcagggtc cgctagtgtgta 5700
taagactcta taaaaagggc cctgccctgc taatgaaatg atgatttata atttaccggt 5760
gtagcaacct tgactagaag aagcagattg ggtgtgtttg tagtgaggga cagtgggtacg 5820
ttttggaac agtcttcttg aaagtgtctt gtctacagta tattactca taacctcaat 5880
agccaagggt gtagtcggtt tattaaagga agggagtgtt ggctgatgtg gatagatata 5940
tttaagctgg cgactgcacc caacgagtgt ggtggtagct tgttactgta tattecgtaa 6000
gatatatctt gtgggggttt agtgggtgtt aaacggtag ttagtgcttg gtatatgagt 6060
tgtaggcatg acaatttgga aaggggtgga ctttgggaat atttgggat ttcaatacct 6120
tagtttgtag agggtaattg ttacaaatga tacaaagaac tgtatttctt ttcatattgtt 6180
ttaattggtt gtatatcaag tccgttagac gagctcagtg ccttggtctt tggcactgta 6240
tttcattttt agagggtacac tacattcagt gaggtatggt aaggttgagg gcataatgaa 6300
ggcaccttgt actgacagtc acagacctct caccgagaat tttatgagat ataactgggt 6360
tcatttttag ctcatcgatg cagaattcag gagagaccgg gttggcggcg tatttggtgc 6420
ccaaaaaca gcccatttg ccccaattga ccccaaattg acccagtagc gggccaacc 6480
cggcgagag ccccttccac cccacatata aaacctccc cggttcccac acttgccgtt 6540
aagggcgtag ggtactgcag tctggaatct acgcttggtc agactttgta ctagtctctt 6600
tgtctggcca tccgggtaac ccatgccgga cgcaaaatag actactgaaa atttttttgc 6660
tttgtggttg ggactttagc caagggtata aaagaccacc gtccccgaat taccttctct 6720
cttcttttct ctctctctct gtcaactcac acccgaaatc gttaagcatt tccttctgag 6780
tataagaate attcaccatg cctgctgctc ccagtgtgag gacgtttact cgggccgagg 6840
ttttgaatgc cgaggctctg aatgagggca agaaggatgc cgaggcacc ttcttgatga 6900
tcatcgacaa caaggtgtac gatgtccgcg agttcgtccc tgatcatccc ggtggaagtg 6960
tgattctcac gcacgttggc aaggacggca ctgacgtctt tgacactttt caccgcgagg 7020

```

```

ctgcttggga gactcttgcc aacttttacg ttggtgatat tgacgagagc gaccgcgata 7080
tcaagaatga tgactttgcy gccgaggtcc gcaagctgcy taccttggtc cagtctcttg 7140
gttactacga ttcttccaag gcatactacg ccttcaaggt ctggttcaac ctctgcatct 7200
ggggtttgtc gacggtcatt gtggccaagt ggggccagac ctgacccctc gccaacgtgc 7260
tctcggctgc gcttttgggt ctgttctggc agcagtgccg atggttggtc cactgctttt 7320
tgcatcacca ggtcttccag gaccgtttct ggggtgatct ttccggcgcc ttcttgggag 7380
gtgtctgcca gggcttctcg tctcgtggtt ggaaggacaa gcacaacact caccacgccg 7440
cccccaacgt ccacggcgag gatcccgaca ttgacacca ccctctgttg acctggagtg 7500
agcatgcgtt ggagatgttc tcggatgtcc cagatgagga gctgacccgc atgtggtcgc 7560
gtttcatggt cctgaaccag acctgggtttt acttcccat tctctcgttt gcccgctctt 7620
cctggtgctt ccagctcatt ctcttttgtc tgctaaccg tcaggccac aagccctcgg 7680
gcgcgcgtgt gcccatctcg ttggtcgagc agctgtcgtt tgcatgcac tggacctggt 7740
acctcgccac catgttctct ttcataaagg atcccgtaa catgctggtg tacttttttg 7800
tgtcgcaggc ggtgtgcgga aacttggttg ccatcgtgtt ctgcctcaac cacaacggta 7860
tgctgtgat ctcgaggag aggcggtcga tatggatttc ttcacgaagc agatcatcac 7920
gggtcgtgat gtccaccgg gtctatttgc caactggttc acgggtgat tgaactatca 7980
gatcgagcac cacttggttc ctctgatgcc tcgccacaac ttttcaaga tccagcctgc 8040
tgtcgagacc ctgtgcaaaa agtacaatgt ccgataccac accacccgta tgatcgaggg 8100
aactgcagag gtcttttagc gtctgaacga ggtctccaag gctacctcca agatgggtaa 8160
ggcgacgtaa gcggcccgca ccgcgggccg agattccggc ctcttcggcc gccaaagcgc 8220
ccgggtggac gtctagaggt acctagcaat taacagatag ttgcccgtg ataattctct 8280
taacctccca cactccttg acataacgat ttatgtaacg aaactgaaat ttgaccagat 8340
atttgtccg cgggtggagct ccagcttttg ttccctttag tgagggttaa ttaattcgat 8400
atcataattg tcggccgagg tctgtacggc cagaaccgag atcctattga ggaggccaag 8460
cgataccaga aggtcgctg ggaggcttac cagaagatta actgttagag gttagactat 8520
ggatatgtca tttaaactgt tatatagaga gcgtgcaagt atggagcgct tgttcagctt 8580
gtatgatggt cagacgacct gtctgatcga gtatgtatga tactgcacaa cctgtgtatc 8640
cgcatgatct gtccaatggg gcattgtgtt gtgtttctcg atacggagat gctgggtaca 8700

agtagcta at acgattgaac tacttatact tatatgaggc ttgaagaaag ctgacttgtg 8760
tatgacttat tctcaactac atccccagtc acaataccac cactgacta ccactacacc 8820
aaaaccatga tcaaacacac catggacttc ctggaggcag aagaacttgt tatggaaaag 8880
ctcaagagag agaa 8894

```

<210> 97

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL101

<400> 97

gagcttggcg taatcgatgg tcatagctgt t 31

<210> 98

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL102

<400> 98

aacagctatg accatcgatt acgccaagct c 31

<210> 99

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL103

<400> 99

atgatgactc aggcgtttaa acgacggaat tctgc 36

<210> 100

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL104

<400> 100

gcaggaattc cgtcgtttaa acgcctgagt catcat 36

<210> 101

<211> 10328

<212> DNA

<213> Artificial Sequence

<220>

<223> 10328 bp fragment for integration and expression of the delta-6, delta-5, and delta-17 desaturase genes and the elongase gene

<400> 101

tatcacatca cgctctcatc aagaatactt cttgagaacc gtggagaccg gggttcgatt	60
ccccgtatcg gagtggttat tttttgctca accataccct ggggtgtgtt ctgtggagca	120
ttctcacttt tggtaaacga cattgcttca agtcgacggg aatcaaaaag tataaagtgg	180
gcagcgagta tacctgtaca gactgtaggc gataactcaa tccaattacc cccacaaca	240
tgactggcca aactgatctc aagactttat tgaatcagc aacaccgatt ctcaatgaag	300
gcacatactt cttctgcaac attcacttga cgctaaagt tgggtgagaaa tggaccgaca	360
agacatatcc tgctatccac ggactgttgc ctgtgtcggg ggctacaata cgtgagtcag	420
aagggctgac ggtggtggtt cgtacgttgt gtggaattgt gagcggataa caatttcaca	480
caggaaacag ctatgacctt gattacgcca agctcgaaat taaccctcac taaagggaac	540
aaaagctgga gotccaccgc ggacacaata tctgggtcaaa tttcagtttc gttacataaa	600
tcgttatgtc aaaggagtgt gggagggtta gagaattatc accggcaaac tatctgttaa	660
ttgctaggta cctctagacg tccaccggg tgccttgccg gccgaagagg ccggaatctc	720
gggcgcgggt ggcggccgct taactgcaact tccctgcctt ctcttgga cgcctggcct	780
tggcctgctt ggccaacttg gcgttcttct tgtaaaagtt gtagaagaga ccgagcatgg	840
tccacatgta gaaccaaagc agagccgtga tgaagaaggg gtatccgggg cggccaagga	900
ccttcattggc gtacatgtcc cagggaagact ggaccgacat catgcagaac tgtgtcatct	960
gcgagcgcgt gatgtagaac ttgatgaacg acacctgctt gaagcccaag gccgacaaga	1020
agtagtagcc gtacatgata acatggatga acgagttcaa cgcagcagag aagtaggctt	1080
caccgttggg tgcaacaaa gtagcaaac accagatggt gaagatggag ctgtggtggt	1140
aaacgtgcaa gaaggagatc tggcgggtgt tcttcttgag gaccatgac atggtgtcga	1200
caaactccat gatcttgag aagtagaaga gccagatcat cttggccata ggaagaccct	1260
tgaaggtagt atcagcagc ttctcaaaa gtccatagtt ggctgataa gcctcgtaca	1320

ggatcccacc gcacatgtag gcgctgacg agaccagaca aaagttgtgc aggagcgaaa 1380
 acgtcttgac ctggaaccgc tcaaagttct tcatgatctg catgcccaca aagaccgtga 1440
 ccaaataagc gagcacgac aacagcacgt ggaacgggtt catcaacggc agctcacggg 1500
 ccaaaggcga ctccaccgcg accaggaacc cagcgtgtg atggacaatc gtggggatgt 1560
 actctcggc ctgggccacc agcgcggcct cgagaggatc gacatagggc gcggcccgga 1620
 caccgatagc ggtggcaagg tccataaaca gatcttgcgg catctttgat gggaggaatg 1680
 gcgcaatga ctccatgcg cogctctaga actagtggat cctttgaatg attcttatac 1740
 tcagaaggaa atgcttaacg atttcgggtg tgagttgaca aggagagaga gaaaagaaga 1800
 ggaaaggtaa ttcggggacg gtggtctttt atacccttg ctaaagtccc aaccacaaag 1860
 caaaaaaatt ttcagtagtc tattttgcgt ccggcatggg ttaccgggat ggccagacaa 1920
 agaaactagt acaaagtcg aacaagcgta gattccagac tgcagtacc tacgccctta 1980
 acggcaagtg tgggaaccgg gggagggttg atatgtggg tgaagggggc tctcgcggg 2040
 gttgggcccg ctactgggtc aatttgggt caattggggc aattggggct gtttttggg 2100
 acacaaatgc gccccaacc cggctctctc tgaagcttg gagcgataa caatttcaca 2160
 caggaaacag ctatgaccat gattacgcca agctcgaaat taacctcac taaagggaac 2220
 aaaagctgga gctccaccg ggacacaata tctggtcaaa tttcagttc gttacataaa 2280
 tcgttatgtc aaaggagtgt gggagggtta gagaattatc accggcaaac tatctgttaa 2340
 ttgctaggta cctctagacg tccacccggg tcgcttggcg gccgaagagg ccggaatctc 2400
 gggccgcggt ggcggccgc tactcttctc tgggacggag tccaagaaca cgcaagtgtc 2460
 ccaaagtga agcaaatgct tgccaaaacg tatccttgac aaggtatgga acctgtact 2520
 cgctgcagg gtctctgatg atggccagaa tatcgggata atggtgctgc gacacgttg 2580
 ggaacagatg gtgcacagcc tggtagttca agctgccagt gatgctggtc cagaggtgcg 2640
 aatcgtgtgc gtaatcctgc gtagtctcga cctgcatagc tgcccagtc ttttgatga 2700
 tcccgttctc gtcaggcaac ggccactgaa ctctctcaac aacgtggtc gcctggaagg 2760
 tcagcgccag ccagtaagac gacacatgt ccgcgaccgt gaacaagagc agcaccttg 2820
 ccaggggagc atactgcagg ggaacaatca ggcgatacca gacaaagaaa gccttgccgc 2880
 ccagaacat cacagtgtgc catgtcgaga tgggattgac acgaatagcg tcattggtct 2940
 tgacaaagta caaatgttg atgtcctgaa tgcgcacctt gaacgccagc agtccgtaca 3000

```

ggaaaggaac aaacatgtgc tggttgatgt ggttgacaaa ccacttttgg ttgggcttga 3060
tacgacgaac atcgggctca gacgtcgaca cgtcgggata tgctccagca atgttggtgt 3120
aggggtgatg gccgagcata tgttggtaca tccacaccag gtacgatgct ccgttgaaaa 3180
agtcgtgcgt ggctcccaga atcttccaga cagtgggggt gtgggtcact gaaaagtgag 3240
acgcacatcg aagaggggtt agtccgactt gtgcgcacgc aaatcccatg atgattgcaa 3300
acaccacctg aagccatgtg cgttcgacaa cgaaaggcac aaagagctgc gcgtagtagg 3360
aagcgatcaa ggatccaaag ataagagcgt atcgtcccca gatctctggt ctattcttgg 3420
gatcaatgtt cogatccgta aagtagccct cgactctcgt cttgatgggt ttgtggaaca 3480
ccgttggttc cggaagatg ggcagctcat tcgagaccag tgtaccgaca tagtacttct 3540
tcataatggc atctgcagcc ccaaacgcgt gatacatctc aaagaccgga gtaacatctc 3600
ggccagctcc gagcaggaga gtgtccactc caccagatg gcggtcaag aactttgtga 3660
catcgtacac cctgccgcyg atggccaaga gtgggtcgtc cttggtgtta tgggccacca 3720
gctcttccca ggtgaagggt tttccttgggt ccgttcccat ggtgaatgat tcttatactc 3780
agaaggaaat gcttaacgat ttcgggtgtg agttgacaag gagagagaga aaagaagagg 3840
aaaggtaatt cggggacggt ggtcttttat acccttgggt aaagtcccaa ccacaaagca 3900
aaaaaatttt cagtagtcta ttttgcgtcc ggcattgggt acccgatgg ccagacaaag 3960
aaactagtac aaagtctgaa caagcgtaga ttccagactg cagtacccta cgccctaac 4020
ggcaagtgtg ggaaccgggg gaggtttgat atgtgggggt aagggggctc tcgccggggt 4080
tgggcccgct actgggtcaa tttgggtca attggggcaa ttggggctgt tttttgggac 4140
acaaatacgc cgccaacccg gtctctcctg aattctgcag atgggctgca ggaattccgt 4200
cgtcgcctga gtcgacatca tttatttacc agttggccac aaacccttga cgatctcgta 4260
tgtcccctcc gacatactcc cggccggctg gggtagcttc gatagcgcta tcggcatcga 4320
caaggtttgg gtccctagcc gataccgcac tacctgagtc acaatcttcg gaggtttagt 4380
cttcacata gcacgggcaa aagtgcgtat atatacaaga gcgtttgcca gccacagatt 4440
ttcactccac acaccacato acacatacaa ccacacacat coacaatgga acccgaaact 4500
aagaagacca agactgactc caagaagatt gttctttctg gcggcgactt ctgtggcccc 4560
gaggtgattg ccgaggccgt caaggctgctc aagtctgttg ctgaggcctc cggaaccgag 4620
tttgtgttg aggaccgact cattggagga gctgccattg agaaggaggg cgagcccatc 4680

```

```

accgacgcta ctctcgacat ctgccgaaag gctgactcta ttatgctcgg tgctgtcgga 4740
ggcgctgcca acaccgtatg gaccactccc gacggacgaa cggacgtgcy acccgagcag 4800
ggctctctca agctgcgaaa ggacctgaac ctgtacgcca acctgcgacc ctgccagctg 4860
ctgtcgccca agctcgccga tctctccccc atccgaaaag ttgagggcac cgacttcate 4920
attgtccgag agctcgtcgg aggtatctac tttggagagc gaaaggagga tgacggatct 4980
ggcgctcgtt ccgacaccca gacctactcc gttcctgagg ttgagcgaat tgcccgaatg 5040
gccgccttcc tggcccttca gcacaacccc cctcttcccg tgtggtctct tgacaaggcc 5100
aacgtgctgg cctcctctcg actttggcga aagactgtca ctcgagtcct caaggacgaa 5160
ttccccagc tcgagctcaa ccaccagctg atcgactcgg ccgccatgat cctcatcaag 5220
cagccctcca agatgaatgg tatcatcatc accaccaaca tgtttggcga tatcatctcc 5280
gacgagccct ccgcatcccc cggttctctg ggtctgtgc cctcgcctc tetggttct 5340
ctgcccga caaacgagcg gttcggctg tacgagccct gtcacggatc tgccccgat 5400
ctcggcaagc agaaggctcaa cccattgcc accattctgt ctgcgccat gatgctcaag 5460
ttctctctta acatgaagcc cgccgggtgac gctgttgagg ctgccgtcaa ggagtcgctc 5520
gaggctggta tcactaccgc cgatatcgga ggctcttct ccacctcca ggctggagac 5580
ttgttgccaa caaggctcaag gagctgctca agaaggagta agtcgtttct acgacgcatt 5640
gatggaagga gcaaaactgac gcgcctgcgg gttggtctac cggcagggtc cgctagtgt 5700
taagactcta taaaaagggc cctgccctgc taatgaaatg atgatttata atttaccggt 5760
gtagcaacct tgactagaag aagcagattg ggtgtgtttg tagtgaggga cagtggtagc 5820
ttttggaac agtcttcttg aaagtgtctt gtctacagta tattactca taacctcaat 5880
agccaagggt gtagtcggtt tattaaagga agggagttgt ggctgatgtg gatagatata 5940
tttaagctgg cgactgcacc caacgagtggt ggtggtagct tgttactgta tattcggtaa 6000
gataatattt gtggggtttt agtggtgttt aaacgacgga attcctgcag cccatctgca 6060
gaattcagga gagaccgggt tggcggtgta tttgtgtccc aaaaaacagc cccaattgcc 6120
ccaattgacc ccaaatgac ccagtagcgg gcccaacccc ggcgagagcc ccttcaccc 6180
cacatatcaa acctccccg gttcccacac ttgccgttaa gggcgtaggg tactgcagtc 6240
tggaatctac gcttgttcag actttgtact agtttctttg tctggccatc cgggtaacct 6300
atgccggacg caaaatagac tactgaaaat ttttttgctt tgtggttggg actttagcca 6360

```

```

aggggtataaa agaccaccgt ccccgaaatta cctttcctct tcttttctct ctctccttgt 6420
caactcacac ccgaaatcgt taagcatttc cttctgagta taagaatcat tcaccatggc 6480
tgaggataag accaaggtcg agttccctac cctgactgag ctgaagcact ctatccctaa 6540
cgcttgcttt gagtccaaac tcggactctc gctctactac actgcccgag cgatcttcaa 6600
cgcactctgcc tctgctctc tgctctacgc tgcccgatct actccctca ttgccgataa 6660
cgttctgctc cagctcttgg ttgcccac ctacatctac gtgcagggtg tcattctctg 6720
gggtttcttt accgtcggtc acgactgttg tcaactctgc ttctccgat accactccgt 6780
caacttcac attggctgca tcactgactc tgccattctg actccctcg agtcctggcg 6840
agtgaccac cgacaccac acaagaacac tggcaacatt gataaggacg agatcttcta 6900
ccctcatcg tccgtcaag accctcagga cgtgcgacaa tgggtctaca cctcggagg 6960
tgcttggttt gtctacatga aggtcggata tgctcctga accatgtccc actttgacct 7020
ctgggacct ctctgcttc gacgagctc cgctgtcatc gtgtccctcg gagtctgggc 7080
tgcttcttc gctgcctacg cctacctcac ataactgctc ggctttgccg tcattggcct 7140
ctactactat gctcctctct ttgtctttgc ttcttctc gtcattacta ccttcttgca 7200
tcacaacgac gaagctactc cctggtacgg tgactcggag tggacctacg tcaagggcaa 7260
cctgagctcc gtcgaccgat cgtacggagc ttctgtggac aacctgtctc accacattgg 7320
caccaccag gtccatcact tgttccctat cattcccac tacaagctca acgaagccac 7380
caagcacttt gctgccgctt accctcacct cgtgagacgt aacgacgagc ccatcattac 7440
tgcttcttc aagaccgctc acctctttgt caactacgga gctgtgccg agactgtctc 7500
gattttcacc ctcaaagagt ctgccgctgc agccaaggcc aagagcgacc accaccatca 7560
ccaccattaa gcggccgcca ccgcccgcg agattccggc ctcttcggcc gccaaagcgac 7620
ccgggtggac gtctagaggt acctagcaat taacagatag tttgccggtg ataattctct 7680
taacctcca cactccttg acataacgat ttatgtaacg aaactgaaat ttgaccagat 7740
attgtgtccg cgggtggagct ccagcttttg ttcccttag tgagggttaa ttctgagctt 7800
ggcgtaatcg atgcagaatt caggagagac cgggttggcg gcgtatttgt gtcccaaaaa 7860
acagcccaaa ttgcccgaat tgaccccaaa ttgaccagat agcgggcca accccggcga 7920
gagcccccct caccacacat atcaaacctc ccccggttcc cacacttgcg gttaagggcg 7980
tagggactg cagtctggaa tctacgcttg ttcagacttt gtactagttt ctttgtctgg 8040

```

```

ccatccgggt aacctatgcc ggacgcaaaa tagactactg aaaatttttt tgctttgtgg 8100
tggggacttt agccaagggt ataaaagacc accgtccccg aattaccttt cctcttcttt 8160
tctctctctc cttgtcaact cacaccgaa atcgttaagc atttcttctt gagtataaga 8220
atcattcacc atggctgctg ctcccagtggt gaggacgttt actcgggcgg aggttttgaa 8280
tgccgaggct ctgaatgagg gcaagaagga tgccgaggca ccttcttga tgatcatoga 8340
caacaagggt tacgatgtcc gcgagttcgt cctgatcat cccggtggaa gtgtgattct 8400
cacgcacgtt ggcaaggacg gcactgacgt ctttgacact ttccaccccg aggtgcttg 8460
gggagactctt gccaaacttt acgttgggtga tattgacgag agcgaccgcg atatcaagaa 8520
tgatgacttt gcggccgagg tcgcgaagct gcgtaccttg ttccagtcct ttggttacta 8580
cgattcttcc aaggcatact acgccttcaa ggtctcgttc aacctctgca tctggggttt 8640
gtcgacggtc atttgggcca agtggggcca gacctcgacc ctgcacaacg tgctctcggc 8700
tgcgcttttg ggtctgttct ggcagcagtg cggatggttg gctcacgact ttttgcata 8760
ccaggctctc caggaccgtt tctgggggtga tcttttcggc gccttcttgg gaggtgtctg 8820
ccagggcttc tcgtcctcgt ggtggaagga caagcacaac actcaccacg ccgcccccaa 8880
cgtccacggc gaggatcccc acattgacac ccacctctg ttgacctgga gtgagcatgc 8940
gttgagatg ttctcggatg tccagatga ggagctgacc cgcatgtggt cgcgtttcat 9000
ggctctgaac cagacctggt ttacttccc cattctctcg ttgcccgtc tctcctgggtg 9060
cctccagtc cttctctttg tgetgcctaa cggtcaggcc cacaagccct cgggcgcgcy 9120
tgtgcccatc tcgttggctg agcagctgtc gcttgcgatg cactggacct ggtacctcgc 9180
caccatgttc ctgttcatca aggatccccg caacatgctg gtgtactttt tgggtgtcgca 9240
ggcgggtgtc ggaacttgtt tggccatcgt gttctcgtc aaccacaacg gtatgcctgt 9300
gatctcgaag gaggaggcgg tcgatatgga ttcttcacg aagcagatca tcacgggtcg 9360
tgatgtccac ccgggtctat ttgccaactg gttcacgggt ggattgaact atcagatcga 9420
gcaccacttg ttcccttoga tgcttcgcca caacttttca aagatccagc ctgctgtcga 9480
gacctgtgac aaaagtaca atgtccgata ccacaccacc ggtatgatcg agggaaactgc 9540
agaggctctt agccgtctga acgaggtctc caaggctacc tccaagatgg gtaaggcgca 9600
gtaagcgggc gccaccgcyg ccgagatcc cggcctcttc ggcgcgaag gcaccgggt 9660
ggacgtctag aggtacctag caattaacag atagtgtgcc ggtgataatt ctcttaacct 9720

cccacactcc ttgacataa cgatttatgt aacgaaactg aaatttgacc agatattgtg 9780
tcccggtggt agctccagct ttgttccct ttagtgaggg ttaattaatt cgatatcata 9840
attgtcggcc gaggtctgta cggccagaac cgagatccta ttgaggaggc caagcgatac 9900
cagaaggctg gctgggaggc ttaccagaag attaaactgt agagggtaga ctatggatat 9960
gtcatttaac tgtgtatata gagagcgtgc aagtatggag cgcttgttca gcttgtatga 10020
tggtcagacg acctgtctga tcgagtatgt atgatactgc acaacctgtg tatccgcatg 10080
atctgtccaa tggggcatgt tgttgtgttt ctcgatacgg agatgctggg tacaagtagc 10140
taatacgatt gaactactta tacttatatg aggcctgaag aaagctgact tgtgtatgac 10200
ttattctcaa ctacatcccc agtcacaata ccaccactgc actaccacta caccaaaacc 10260
atgatcaaac caccatgga cttcctggag gcagaagaac ttgttatgga aaagctcaag 10320
agagagaa 10328

```

<210> 102

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL1

<400> 102

cagtgccaaa agccaaggca ctgagctcgt 30

<210> 103
 <211> 31
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL2

 <400> 103
 gacgagctca gtccttggc ttggcact g 31

 <210> 104
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL3

 <400> 104
 gtataagaat cattccatc ggatccacta gttcta 36

 <210> 105
 <211> 36
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL4

 <400> 105
 tagaactagt ggatccatgg tgaatgattc ttatac 36

 <210> 106
 <211> 39
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL5

 <400> 106
 cccccctcga ggctgatggg gtcgataagc ttgatatcg 39

 <210> 107
 <211> 39
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL6

 <400> 107
 cgatatcaag ctatcgaca ccatcgacct cgagggggg 39

 <210> 108
 <211> 37
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Primer YL7

<400> 108
caaccgattt cgacagttta ttaataattt gaatcga 37

<210> 109
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer YL8

<400> 109
tcgattcaaa ttattaatta actgtcgaaa tcggttg 37

<210> 110
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer YL9

<400> 110
tggtaaataa atgatgtcga ctcaggcgac gacgg 35

<210> 111
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer YL10

<400> 111
ccgtgtcgc ctgagtcgac atcatttatt tacca 35

<210> 112
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer YL23

<400> 112
atggatccac tagttaatta actagagcgg ccgcca 36

<210> 113
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer YL24

<400> 113
tggcggccgc tctagtaaat taactagtgg atccat 36

<210> 114
<211> 1413
<212> DNA
<213> Saprolegnia diclina

<400> 114

```

atggccccgc agacggagct ccgccagcgc cagcccgccg tcgccgagac gccggtggcc      60
ggcaagaagg cctttacatg gcaggaggtc gcgcagcaca acacggcggc ctcggcctgg      120
atcattatcc gcggaaggt ctacgacgtg accgagtggg ccaacaagca ccccgcgggc      180
cgcgagatgg tgctgctgca cgcgggtcgc gaggccaccg acacgttcga ctctgtaccac      240
ccgttcagcg acaaggccga gtcgatcttg aacaagtatg agattggcac gttcacgggc      300
ccgtccgagt ttccgacctt caagccggac acgggcttct acaaggagtg ccgcaagcgc      360
gttggcgagt acttcaagaa gaacaacctc catccgcagg acggcttccc gggcctctgg      420
cgcatgatgg tcgtgtttgc ggtcgccggc ctgccttgt acggcatgca cttttcgact      480
atctttgcgc tgcagctcgc ggcgcggcg ctctttggcg tctgccaggc gctgccgctg      540
ctccacgtca tgcacgactc gtcgcacgcg tcgtacacca acatgccgtt ctccattac      600
gtcgtcgggc gctttgccat ggactggttt gccggcggtc cgatggtgta atggtcaac      660
cagcaagtcg tgggccacca catctacacg aacgtcgcg gctcggacc ggatcttccg      720
gtcaaatg acggcgacat ccgccgcac gtgaaccgcc aggtgttcca gcccatgtac      780
gcattccagc acatctacct tccgccgctc tatggcgtgc ttggcctcaa gttccgcac      840
caggacttca ccgacagctt cggctcgac acgaacggcc cgatcccggt caaccgcac      900
gcgctctcga cgtggatggc catgatcagc tccaagtcgt tctgggctt ctaccgcgtg      960
taccttcgc ttgccgtgct ccagatgcc atcaagcgt accttgcat cttcttctc      1020
gccgagttg tcacgggctg gtacctcgcg ttcaacttcc aagtaagcca tgtctcgacc      1080
gagtgcggct acccatgcg gcgacaggcc aagatggcgc tccaggagca gtgggcagtc      1140
tcgcaggta agacgtcgt cgactacgcc catggctcgt ggatgacgac gttccttgcc      1200
ggcgcgctca actaccaggt cgtgcaccac ttgttccca cgtgtcgca gtaccactac      1260
ccggcgatcg cgcccatcat cgtcgacgtc tgcaaggagt acaacatcaa gtacgccac      1320
ttgccggact ttacggcggc gttcgttgcc cacttgaagc acctccgaa catgggcccag      1380
cagggcatcg ccgccacgat ccacatgggc taa                                     1413

```

<210> 115

<211> 470

<212> PRT

<213> Saprolegnia diclina

<400> 115

Met Ala Pro Gln Thr Glu Leu Arg Gln Arg His Ala Ala Val Ala Glu
 1 5 10 15
 Thr Pro Val Ala Gly Lys Lys Ala Phe Thr Trp Gln Glu Val Ala Gln
 20 25 30
 His Asn Thr Ala Ala Ser Ala Trp Ile Ile Ile Arg Gly Lys Val Tyr
 35 40 45
 Asp Val Thr Glu Trp Ala Asn Lys His Pro Gly Gly Arg Glu Met Val
 50 55 60
 Leu Leu His Ala Gly Arg Glu Ala Thr Asp Thr Phe Asp Ser Tyr His
 65 70 75 80
 Pro Phe Ser Asp Lys Ala Glu Ser Ile Leu Asn Lys Tyr Glu Ile Gly
 85 90 95
 Thr Phe Thr Gly Pro Ser Glu Phe Pro Thr Phe Lys Pro Asp Thr Gly
 100 105 110
 Phe Tyr Lys Glu Cys Arg Lys Arg Val Gly Glu Tyr Phe Lys Lys Asn
 115 120 125
 Asn Leu His Pro Gln Asp Gly Phe Pro Gly Leu Trp Arg Met Met Val
 130 135 140
 Val Phe Ala Val Ala Gly Leu Ala Leu Tyr Gly Met His Phe Ser Thr
 145 150 155 160
 Ile Phe Ala Leu Gln Leu Ala Ala Ala Ala Leu Phe Gly Val Cys Gln
 165 170 175
 Ala Leu Pro Leu Leu His Val Met His Asp Ser Ser His Ala Ser Tyr
 180 185 190
 Thr Asn Met Pro Phe Phe His Tyr Val Val Gly Arg Phe Ala Met Asp
 195 200 205

Trp Phe Ala Gly Gly Ser Met Val Ser Trp Leu Asn Gln His Val Val
 210 215 220
 Gly His His Ile Tyr Thr Asn Val Ala Gly Ser Asp Pro Asp Leu Pro
 225 230 235 240
 Val Asn Met Asp Gly Asp Ile Arg Arg Ile Val Asn Arg Gln Val Phe
 245 250 255
 Gln Pro Met Tyr Ala Phe Gln His Ile Tyr Leu Pro Pro Leu Tyr Gly
 260 265 270
 Val Leu Gly Leu Lys Phe Arg Ile Gln Asp Phe Thr Asp Thr Phe Gly
 275 280 285
 Ser His Thr Asn Gly Pro Ile Arg Val Asn Pro His Ala Leu Ser Thr
 290 295 300
 Trp Met Ala Met Ile Ser Ser Lys Ser Phe Trp Ala Phe Tyr Arg Val
 305 310 315 320
 Tyr Leu Pro Leu Ala Val Leu Gln Met Pro Ile Lys Thr Tyr Leu Ala
 325 330 335
 Ile Phe Phe Leu Ala Glu Phe Val Thr Gly Trp Tyr Leu Ala Phe Asn
 340 345 350
 Phe Gln Val Ser His Val Ser Thr Glu Cys Gly Tyr Pro Cys Gly Asp
 355 360 365
 Glu Ala Lys Met Ala Leu Gln Asp Glu Trp Ala Val Ser Gln Val Lys
 370 375 380
 Thr Ser Val Asp Tyr Ala His Gly Ser Trp Met Thr Thr Phe Leu Ala
 385 390 395 400
 Gly Ala Leu Asn Tyr Gln Val Val His His Leu Phe Pro Ser Val Ser
 405 410 415
 Gln Tyr His Tyr Pro Ala Ile Ala Pro Ile Ile Val Asp Val Cys Lys
 420 425 430
 Glu Tyr Asn Ile Lys Tyr Ala Ile Leu Pro Asp Phe Thr Ala Ala Phe
 435 440 445
 Val Ala His Leu Lys His Leu Arg Asn Met Gly Gln Gln Gly Ile Ala
 450 455 460
 Ala Thr Ile His Met Gly
 465 470

<210> 116

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL13A

<400> 116

ttggatccgc agacggagct ccgccagcgc 30

<210> 117

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL14

<400> 117

cccttaatta aattagccca tgtggatcgt ggcggc 36

<210> 118

<211> 1329

<212> DNA

<213> Isochrysis galbana

<400> 118

```

atggtggcag gcaaatcagg cgctgcggcg cacgtgactc acagctcgac attgccccgt    60
gagtaccatg gcgcgaccaa cgactcgcgc tctgaggcgg ccgacgtcac cgtctctagc    120
atcgatgctg aaaaggagat gatcatcaac ggccgcgtgt atgacgtgtc gtcatttgtg    180
aagcggcacc caggtggctc ggtgatcaag ttccagctgg gcgccgacgc gagcgacgcg    240
tacaacaact ttcacgtccg ctccaagaag gcggacaaga tgctgtattc gctcccgtcc    300
cggccggccg aggccggcta cgcccaggac gacatctccc gcgactttga gaagctgcgc    360
ctcgagctga agggaggagg ctacttcgag cccaacctgg tgcacgtgag ctacaggtgt    420

gtggaggttc ttgccatgta ctgggtggc gtccagctca tctggtccgg gtactggttc    480
ctcggcgcca tcgtggccgg cattgcgcag ggccgctgcg gctggctcca gcatgagggt    540
gggcactact cgctcaccgg caacatcaag atcgaccggc atctgcagat ggccatctat    600
gggcttggtc gcggcatgtc gggctgctac tggcgcaacc agcacaacaa gcaccacgcc    660
acgccgcaga agctcgggac cgaccccgac ctgcagacga tgccgctggt ggccttcac    720
aagatcgctc gcgccaaggc gcgaggcaag ggcaaggcgt ggctggcgtg gcaggcgccg    780
ctcttctttt gcgggatcat ctgctcgctc gtctcttttc gctggcagtt cgtgctccac    840
cccaaccacg cgctgcgcgt gcacaatcac ctggagctcg cgtacatggg cctgcggtac    900
gtgctgtggc acctggcctt tggccacctc gggctgctga gctcgctccg cctgtacgcc    960
ttttacgtgg ccgtggggcg cacctacatc ttaccaact tcgccgtctc gcacacccac   1020
aaggacgtcg tcccggccac caagcacatc tcgtgggcac tctactcggc caaccacacg   1080
accaactgct ccgactcgcc ctttgtcaac tggtaggatg cctacctcaa cttccagatc   1140
gagcaccacc tcttcccgct gatgccgag tacaaccacc ccaagatcgc ccccggggtg   1200
cgcgcgctct tcgagaagca cggggtcgag tatgacgtcc ggccatacct ggagtgtttt   1260
cgggtcacgt acgtcaacct gctcgccgta ggcaacccgg agcactocta ccacgagcac   1320
acgcactag                                     1329

```

<210> 119

<211> 442

<212> PRT

<213> Isochrysis galbana

<400> 119

```

Met Val Ala Gly Lys Ser Gly Ala Ala Ala His Val Thr His Ser Ser
1           5           10           15

Thr Leu Pro Arg Glu Tyr His Gly Ala Thr Asn Asp Ser Arg Ser Glu
                20           25           30

Ala Ala Asp Val Thr Val Ser Ser Ile Asp Ala Glu Lys Glu Met Ile
35           40           45

Ile Asn Gly Arg Val Tyr Asp Val Ser Ser Phe Val Lys Arg His Pro
50           55           60

```

Gly Gly Ser Val Ile Lys Phe Gln Leu Gly Ala Asp Ala Ser Asp Ala
 65 70 75 80
 Tyr Asn Asn Phe His Val Arg Ser Lys Lys Ala Asp Lys Met Leu Tyr
 85 90 95
 Ser Leu Pro Ser Arg Pro Ala Glu Ala Gly Tyr Ala Gln Asp Asp Ile
 100 105 110
 Ser Arg Asp Phe Glu Lys Leu Arg Leu Glu Leu Lys Glu Glu Gly Tyr
 115 120 125
 Phe Glu Pro Asn Leu Val His Val Ser Tyr Arg Cys Val Glu Val Leu
 130 135 140
 Ala Met Tyr Trp Ala Gly Val Gln Leu Ile Trp Ser Gly Tyr Trp Phe
 145 150 155 160
 Leu Gly Ala Ile Val Ala Gly Ile Ala Gln Gly Arg Cys Gly Trp Leu
 165 170 175
 Gln His Glu Gly Gly His Tyr Ser Leu Thr Gly Asn Ile Lys Ile Asp
 180 185 190
 Arg His Leu Gln Met Ala Ile Tyr Gly Leu Gly Cys Gly Met Ser Gly
 195 200 205
 Cys Tyr Trp Arg Asn Gln His Asn Lys His His Ala Thr Pro Gln Lys
 210 215 220
 Leu Gly Thr Asp Pro Asp Leu Gln Thr Met Pro Leu Val Ala Phe His
 225 230 235 240
 Lys Ile Val Gly Ala Lys Ala Arg Gly Lys Gly Lys Ala Trp Leu Ala
 245 250 255
 Trp Gln Ala Pro Leu Phe Phe Gly Gly Ile Ile Cys Ser Leu Val Ser
 260 265 270
 Phe Gly Trp Gln Phe Val Leu His Pro Asn His Ala Leu Arg Val His
 275 280 285
 Asn His Leu Glu Leu Ala Tyr Met Gly Leu Arg Tyr Val Leu Trp His
 290 295 300
 Leu Ala Phe Gly His Leu Gly Leu Leu Ser Ser Leu Arg Leu Tyr Ala
 305 310 315 320
 Phe Tyr Val Ala Val Gly Gly Thr Tyr Ile Phe Thr Asn Phe Ala Val
 325 330 335
 Ser His Thr His Lys Asp Val Val Pro Pro Thr Lys His Ile Ser Trp
 340 345 350
 Ala Leu Tyr Ser Ala Asn His Thr Thr Asn Cys Ser Asp Ser Pro Phe
 355 360 365
 Val Asn Trp Trp Met Ala Tyr Leu Asn Phe Gln Ile Glu His His Leu
 370 375 380
 Phe Pro Ser Met Pro Gln Tyr Asn His Pro Lys Ile Ala Pro Arg Val
 385 390 395 400
 Arg Ala Leu Phe Glu Lys His Gly Val Glu Tyr Asp Val Arg Pro Tyr
 405 410 415
 Leu Glu Cys Phe Arg Val Thr Tyr Val Asn Leu Leu Ala Val Gly Asn
 420 425 430
 Pro Glu His Ser Tyr His Glu His Thr His
 435 440

<210> 120
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer YL19A

<400> 120
 ttggatccg gcaggcaaat caggcgctgc ggcgca 36

<210> 121
 <211> 36
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Primer YL20

<400> 121
 ccttaattaa ctatgctgtg tgctcgtgtg aggagt 36

<210> 122
 <211> 1320
 <212> DNA
 <213> Thraustochytrium aureum

<400> 122
 atgggacgcg gcggcgaagg tcaggtgaac agcgcgcagg tggcacaagg cgggtgcggga 60
 acgcgaaaga cgatcctgat cgagggcgag gtctacgatg tcaccaactt taggcacccc 120
 ggcgggtcga tcatacaagtt totcacgacc gacggcaccc aggcctgtgga cgcgacgaac 180
 gcgttttcgcg agtttcaact cgggtcgggc aaggcggaaa agtacctcaa gagcctgccc 240
 aagctcggcg cgccgagcaa gatgaagttt gacgccaaag agcaggcccg gcgcgacgcg 300
 atcacgcgag actacgtcaa gctgcgcgag gagatggtgg ccgagggcct cttcaagccc 360
 gcgcccctcc acattgtcta caggtttgcg gagatcgag cctgttctgc ggcctcgttc 420
 tacctgtttt cgatgcgcg aaacgtgttc gccacgctcg cgccatcgc agtcgggggc 480
 atcgcgcagg gccgcgcg ctggtctatg cagagtgcg gacattctc gatgaccggg 540
 tacatccgc ttgactgctg cctgcaggag ctggtgtacg gcgtgggggtg ctgatgtcg 600
 gcgagctggt ggcgcgttca gcacaacaag caccacgcga ccccgagaa actcaagcac 660
 gacgtgcaga tcgacaccc cgcgcctcgt gcgttcaac agaagatcg cgccaagggtg 720
 cgccccggct cgttcacgca caagtggctc toggcgcagg cgtacatttt tgcgccgggtg 780
 tctgtcttc tggttggtct cttctggacc ctgtttctgc acccgccca catgccgcgc 840
 acgagccact ttgctgagat ggcgcgcgtc gcggtgcgcg tcgtgggctg ggcggcgctc 900
 atgcactcgt tcgggtacag cgggagcgac tcgttcggtc totacatggc cacctttggc 960
 tttggtgca cctacatctt caccaacttt gcggtcagcc acacgcacct cgacgtcacc 1020
 gagccggacg agttcctgca ctgggtcgag tacgccgcgc tgcacacgac caacgtgtcc 1080
 aacgactcgt ggttcacac ctggtggatg tcgtacctca actttcagat cgagaccac 1140
 ctctttccgt cgtgcacca gctcaacgcc ccgcgcgtcg cccgcgcgt ccgcgcctc 1200
 ttcgagaagc acggcatggc ttacgacgag cgcccgctacc ttaccgcgt tggcgacacg 1260
 tttgccaacc tgcacgcctt gggccaaaac gcgggccaagg cggcgcccaa ggcgccttag 1320

<210> 123
 <211> 439
 <212> PRT
 <213> Thraustochytrium aureum

<400> 123

Met Gly Arg Gly Gly Glu Gly Gln Val Asn Ser Ala Gln Val Ala Gln
 1 5 10 15

Gly Gly Ala Gly Thr Arg Lys Thr Ile Leu Ile Glu Gly Glu Val Tyr
 20 25 30

Asp Val Thr Asn Phe Arg His Pro Gly Gly Ser Ile Ile Lys Phe Leu
 35 40 45

Thr Thr Asp Gly Thr Glu Ala Val Asp Ala Thr Asn Ala Phe Arg Glu
 50 55 60

Phe His Cys Arg Ser Gly Lys Ala Glu Lys Tyr Leu Lys Ser Leu Pro
 65 70 75 80

Lys Leu Gly Ala Pro Ser Lys Met Lys Phe Asp Ala Lys Glu Gln Ala
 85 90 95

Arg Arg Asp Ala Ile Thr Arg Asp Tyr Val Lys Leu Arg Glu Glu Met
 100 105 110

Val Ala Glu Gly Leu Phe Lys Pro Ala Pro Leu His Ile Val Tyr Arg
 115 120 125

Phe Ala Glu Ile Ala Ala Leu Phe Ala Ala Ser Phe Tyr Leu Phe Ser
 130 135 140

Met Arg Gly Asn Val Phe Ala Thr Leu Ala Ala Ile Ala Val Gly Gly
 145 150 155 160

Ile Ala Gln Gly Arg Cys Gly Trp Leu Met His Glu Cys Gly His Phe
 165 170 175

Ser Met Thr Gly Tyr Ile Pro Leu Asp Val Arg Leu Gln Glu Leu Val

180 185 190
 Tyr Gly Val Gly Cys Ser Met Ser Ala Ser Trp Trp Arg Val Gln His
 195 200 205
 Asn Lys His His Ala Thr Pro Gln Lys Leu Lys His Asp Val Asp Leu
 210 215 220
 Asp Thr Leu Pro Leu Val Ala Phe Asn Glu Lys Ile Ala Ala Lys Val
 225 230 235 240
 Arg Pro Gly Ser Phe Gln Ala Lys Trp Leu Ser Ala Gln Ala Tyr Ile
 245 250 255
 Phe Ala Pro Val Ser Cys Phe Leu Val Gly Leu Phe Trp Thr Leu Phe
 260 265 270
 Leu His Pro Arg His Met Pro Arg Thr Ser His Phe Ala Glu Met Ala
 275 280 285
 Ala Val Ala Val Arg Val Val Gly Trp Ala Ala Leu Met His Ser Phe
 290 295 300
 Gly Tyr Ser Gly Ser Asp Ser Phe Gly Leu Tyr Met Ala Thr Phe Gly
 305 310 315 320
 Phe Gly Cys Thr Tyr Ile Phe Thr Asn Phe Ala Val Ser His Thr His
 325 330 335
 Leu Asp Val Thr Glu Pro Asp Glu Phe Leu His Trp Val Glu Tyr Ala
 340 345 350
 Ala Leu His Thr Thr Asn Val Ser Asn Asp Ser Trp Phe Ile Thr Trp
 355 360 365
 Trp Met Ser Tyr Leu Asn Phe Gln Ile Glu His His Leu Phe Pro Ser
 370 375 380
 Leu Pro Gln Leu Asn Ala Pro Arg Val Ala Pro Arg Val Arg Ala Leu
 385 390 395 400
 Phe Glu Lys His Gly Met Ala Tyr Asp Glu Arg Pro Tyr Leu Thr Ala
 405 410 415
 Leu Gly Asp Thr Phe Ala Asn Leu His Ala Val Gly Gln Asn Ala Gly
 420 425 430
 Gln Ala Ala Ala Lys Ala Ala
 435

<210> 124

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL15

<400> 124

ttttcatgg gacgcggcgg cgaaggtcag 30

<210> 125

<211> 37

<212> DNA

<213> Artificial Sequence

<220>

<223> Primer YL16B

<400> 125
 ttttgcggcc gctaagcggc cttggccgcc gcctggc 37

<210> 126
 <211> 10
 <212> DNA
 <213> Yarrowia lipolytica

<220>
 <221> misc_feature
 <222> (8)..(8)
 <223> n is a, c, g, or t

<400> 126
 mammatgnhs 10

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US46867703P \[0001\]](#)
- [US4666701A \[0004\]](#)
- [US4758592A \[0004\]](#)
- [US5116871A \[0004\]](#)
- [US4826877A \[0004\]](#)
- [US5658767A \[0006\]](#)
- [US5244921A \[0007\]](#)
- [US5492938A \[0007\]](#)
- [US5407957A \[0007\]](#)
- [US6136574A \[0010\]](#)
- [EP0005277B1 \[0012\]](#)
- [WO0012720A \[0074\] \[0103\] \[0192\]](#)
- [US5107065A \[0088\]](#)
- [WO9928508A \[0088\]](#)
- [WO0208401A \[0102\]](#)
- [US5968809A \[0103\] \[0186\]](#)
- [US5972664A \[0103\]](#)
- [US6075183A \[0103\] \[0187\]](#)
- [WO9113972A \[0103\]](#)
- [US5057419A \[0103\]](#)
- [WO9311245A \[0103\]](#)
- [WO9411516A \[0103\]](#)
- [US5443974A \[0103\]](#)
- [WO03099216A \[0103\]](#)
- [US20030136217A1 \[0103\] \[0191\]](#)
- [WO02090493A \[0103\]](#)
- [US20020139974A1 \[0103\]](#)
- [US468718P \[0117\]](#)
- [US482263P \[0128\] \[0128\]](#)

- [US519971P \[0128\]](#)
- [US6265185B \[0128\] \[0128\]](#)
- [US4880741A \[0134\]](#)
- [US5971764A \[0134\]](#)
- [US4778630A \[0139\]](#)
- [US484209P \[0140\]](#)
- [US4910141A \[0142\]](#)
- [DD259637 \[0151\]](#)
- [SU1454852 \[0151\]](#)
- [WO2001083773A \[0151\]](#)
- [DD279267 \[0151\]](#)
- [WO2001088144A \[0151\]](#)
- [RU2096461 \[0151\]](#)
- [RU2090611 \[0151\]](#)
- [DD285372 \[0151\]](#)
- [DD285370 \[0151\]](#)
- [DD275480 \[0151\]](#)
- [DD227448 \[0151\]](#)
- [PL160027 \[0151\]](#)
- [EP770683A \[0151\]](#)
- [DD267999 \[0151\]](#)
- [US6451565B \[0151\]](#)
- [FR2734843 \[0151\]](#)
- [EP578388A \[0151\]](#)
- [JP09252790B \[0151\]](#)
- [US5366860A \[0174\]](#)
- [EP272007A \[0174\]](#)
- [WO02081668A \[0188\]](#)
- [WO02081668A2 \[0189\] \[0190\]](#)
- [CL2233W \[0239\]](#)
- [EP04751769A \[0239\]](#)
- [US60468677B \[0239\]](#)

Non-patent literature cited in the description

- DYERBERG, J. et al. Amer. J. Clin Nutr., 1975, vol. 28, 958-966 [0004]
- DYERBERG, J. et al. Lancet, 1978, vol. 2, 8081117-119 [0004]
- SHIMOKAWA, H. World Rev Nutr Diet, 2001, vol. 88, 100-108 [0004]
- SCHACKY, C. DYERBERG, J. World Rev Nutr Diet, 2001, vol. 88, 90-99 [0004]
- BRENNER et al. Adv. Exp. Med. Biol., 1976, vol. 83, 85-101 [0004]
- HORROBIN et al. Am. J. Clin. Nutr., 1993, vol. 57, 732S-737S [0004]
- KRIS-ETHERTON, P.M. et al. Am. J. Clin. Nutr., 2000, vol. 71, 1179S-88S [0005]
- SIMOPOULOS, A. P. et al. Ann. Nutr. Metab., 1999, vol. 43, 127-130 [0005]
- KRAUSS, R. M. et al. AHA Circulation, 2000, vol. 102, 2284-2299 [0005]
- DOMERGUE, F. et al. Eur. J. Biochem., 2002, vol. 269, 4105-4113 [0010]
- BEAUDOIN F. et al. Proc. Natl. Acad. Sci. U.S.A., 2000, vol. 97, 126421-6 [0010]
- DYER, J.M. et al. Appl. Environ. Microbiol., 2002, vol. 59, 224-230 [0010]
- RATLEDGE, C. Prog. Ind. Microbiol., 1982, vol. 16, 119-206 [0012]
- LASSNER et al. The Plant Cell, 1996, vol. 8, 281-292 [0073]
- WEETE In: Fungal Lipid Biochemistry Plenum 1980 0000 [0076]
- YONGMANITCHAIWARD Appl. Environ. Microbiol., 1991, vol. 57, 419-25 [0076] [0157]
- ALTSCHUL, S. F. et al. J. Mol. Biol., 1993, vol. 215, 403-410 [0080]
- ALTSCHUL et al. J. Mol. Biol., 1990, vol. 215, 403-410 [0093] [0109]
- Comput. Methods Genome Res. W. R. PEARSON Proc. Int. Symp. Plenum 1992 0000 111-20 [0093] [0109]

- **SAMBROOK, J. FRITSCH, E. F. MANIATIS, T.** Molecular Cloning: A Laboratory Manual Cold Spring Harbor Laboratory 19890000 [0094] [0170]
- **SILHAVY, T. J. BENNAN, M. L. ENQUIST, L. W.** Experiments with Gene Fusions Cold Spring Harbor Laboratory 19840000 [0094]
- **AUSUBEL, F. M. et al.** Current Protocols in Molecular Biology Greene Publishing Assoc. and Wiley-Interscience 19870000 [0094] [0170]
- **SMITH, S.** FASEB J., 1994, vol. 8, 151248-59 [0096]
- **KYTEDOOLITTLE J.** Mol. Biol., 1982, vol. 157, 105-132 [0110]
- **CHOUFASMAN** Adv. Enzymol., 1978, vol. 47, 45-148 [0110]
- **MELNIKOV et al.** Nucleic Acids Research, 1999, vol. 27, 41056-1062 [0116]
- **Methods in Enzymology**, 1991, vol. 194, 186-187 [0134]
- **CHEN, D. C. et al.** Appl Microbiol Biotechnol., 1997, vol. 48, 2232-235 [0134] [0193]
- **HAMILTON et al.** J. Bacteriol., 1989, vol. 171, 4617-4622 [0143]
- **BALBAS et al.** Gene, 1993, vol. 136, 211-213 [0143]
- **GUELDERNER et al.** Nucleic Acids Res., 1996, vol. 24, 2519-2524 [0143]
- **SMITH et al.** Methods Mol. Cell. Biol., 1996, vol. 5, 270-277 [0143]
- **THOMAS D. BROCK** Biotechnology: A Textbook of Industrial Microbiology Sinauer Associates 19890000 [0145] [0159] [0171]
- **DESHPANDE, MUKUND V.** Appl. Biochem. Biotechnol., 1992, vol. 36, 227- [0145] [0159]
- **PAPANIKOLAOU S. AGGELIS G.** Bioresour. Technol, 2002, vol. 82, 143-9 [0150]
- **NAKAHARA, T. et al.** Ind. Appl. Single Cell Oils 1992000061-97 [0154]
- **Critical Reviews in Biotechnology**, 1992, vol. 12, 5/6463-491 [0161]
- **A. SINGHO. WARD** Adv. Appl. Microbiol., 1997, vol. 45, 271-312 [0161]
- **E. G. BLIGH W. J. DYER** Can. J. Biochem. Physiol., 1959, vol. 37, 911-917 [0162]
- **T. J. SILHAVY M. L. BENNAN L. W. ENQUIST** Experiments with Gene Fusions Cold Spring Harbor Laboratory 19840000 [0170]
- **Manual of Methods for General Bacteriology** American Society for Microbiology 19940000 [0171]
- **BLIGH, E. G. DYER, W. J.** Can. J. Biochem. Physiol., 1959, vol. 37, 911-917 [0177]
- **ROUGHAN, G. NISHIDA I.** Arch Biochem Biophys., 1990, vol. 276, 138-46 [0177]
- **MULLER S. et al.** Yeast, 1998, vol. 14, 1267-1283 [0180]
- **GUHANIYOGI, G. J. BREWER** Gene, 2001, vol. 265, 1-211-23 [0201]
- **KASTER, K. R. et al.** Nucleic Acids Res., 1983, vol. 11, 6895-6911 [0221]

FREMSTILLING AF POLYUMÆTTEDE FEDTSYRER I OLIEHOLDIG GÆR

PATENTKRAV

1. Transformeret olieholdig gær, som omfatter heterologe gener, der koder for enzymer af den biosyntetiske ω -3-fedtsyrebane, hvor gæren er en olieholdig *Yarrowia lipolytica*, der akkumulerer mindst
5 25 % af sin tørvægt som olie, hvor de heterologe gener koder for Δ 17-desaturase-, Δ 5-desaturase- og elongaseenzymer af den biosyntetiske ω -3-fedtsyrebane, hvor den olieholdige *Yarrowia lipolytica* fremstiller substrater til enzymerne, og hvor gæren er i stand til at fremstille ω -3-polyumættede fedtsyrer, der ikke naturligt fremstilles af gæren.
2. Transformeret olieholdig gær ifølge krav 1, hvor de heterologe gener, der koder for enzymer af den
10 biosyntetiske ω -3-fedtsyrebane, endvidere indbefatter ét eller flere gener, der er udvalgt fra gruppen bestående af: Δ 12-desaturase, Δ 6-desaturase, Δ 15-desaturase, Δ 9-desaturase og Δ 4-desaturase.
3. Transformeret olieholdig gær ifølge krav 2, hvor genet, der koder for et Δ 6-desaturasepolypeptid, er udvalgt fra gruppen bestående af:
 - (a) et isoleret nukleinsyremolekyle, der koder for aminosyresekvensen som vist i SEQ ID
15 NO: 2; og
 - (b) et isoleret nukleinsyremolekyle, der koder for et polypeptid med Δ 6-desaturase-aktivitet, og som hybridiserer med (a) under følgende hybridiseringsforhold: 0,1 X SSC, 0,1 % SDS, 65 °C og vasket med 2 X SSC, 0,1 % SDS efterfulgt af 0,1 X SSC, 0,1 % SDS.
4. Transformeret olieholdig gær ifølge krav 1, hvor genet, der koder for et elongasepolypeptid, er
20 udvalgt fra gruppen bestående af:
 - (a) et isoleret nukleinsyremolekyle, der koder for aminosyresekvensen som vist i SEQ ID NO: 8; og
 - (b) et isoleret nukleinsyremolekyle, der koder for et polypeptid med elongaseaktivitet, og som hybridiserer med (a) under følgende hybridiseringsforhold: 0,1 X SSC, 0,1 % SDS, 65 °C og vasket
25 med 2 X SSC, 0,1 % SDS efterfulgt af 0,1 X SSC, 0,1 % SDS.
5. Transformeret olieholdig gær ifølge krav 1, hvor genet, der koder for et Δ 5-desaturasepolypeptid, er udvalgt fra gruppen bestående af:
 - (a) et isoleret nukleinsyremolekyle, der koder for aminosyresekvensen udvalgt fra gruppen bestående af SEQ ID NO: 4, SEQ ID NO: 115, SEQ ID NO: 119 og SEQ ID NO: 123; og
 - 30 (b) et isoleret nukleinsyremolekyle, der koder for et polypeptid med Δ 5-desaturaseaktivitet, og som hybridiserer med (a) under følgende hybridiseringsforhold: 0,1 X SSC, 0,1 % SDS, 65 °C og vasket med 2 X SSC, 0,1 % SDS efterfulgt af 0,1 X SSC, 0,1 % SDS.
6. Transformeret olieholdig gær ifølge krav 1, hvor genet, der koder for et Δ 17-desaturasepolypeptid, er udvalgt fra gruppen bestående af:
 - 35 (a) et isoleret nukleinsyremolekyle, der koder for aminosyresekvensen som vist i SEQ ID NO: 6; og
 - (b) et isoleret nukleinsyremolekyle, der koder for et polypeptid med Δ 17-desaturaseaktivitet, og som hybridiserer med (a) under følgende hybridiseringsforhold: 0,1 X SSC, 0,1 % SDS, 65 °C og vasket med 2 X SSC, 0,1 % SDS efterfulgt af 0,1 X SSC, 0,1 % SDS.

-2-

7. Transformeret olieholdig gær ifølge et hvilket som helst af kravene 1 til 3, hvor gæren er i stand til at fremstille eicosapentaensyre.
8. Transformeret olieholdig gær ifølge et hvilket som helst af kravene 1 til 3, hvor gæren er i stand til at fremstille docosahexaensyre.
- 5 9. Transformeret olieholdig gær ifølge krav 8, hvor gæren endvidere omfatter et heterologt gen, der koder for et $\Delta 4$ -desaturaseenzym.
10. Transformeret olieholdig gær ifølge et hvilket som helst af kravene 1 til 9, hvor mindst ét af de heterologe gener omfatter et translationsinitieringssted som vist i SEQ ID NO: 126.

DRAWINGS

Figure 1




Figure 2




Figure 4




Figure 5




Figure 6A

(SEQ ID NO:5) 70
(SEQ ID NO:6) 140
210
280
350
420
490
560
630

CTCACATACTCGCTCGGCTTGGCCGTCAATGGGCTCTACTACTATGCGCGCTCTTTGCTTTGCTTCGTT
L T Y S L G F A V M G L Y Y A P L F V F A S 700

TCCTCGTCAATTACGACCTTCTTGGCACCAACGACGACGCGGTGGTACGCGACTCGGAGTGGAC
F L V I T T F L H H N D E A T P W Y G D S E W T 770

C GAGCTC A A T TCT
GTACGTCAAGGCAACCTCTCGAGCGTCGACCGCTCGTACGCGCGTTCGTGGACAACCTGAGCCACAC
Y V K G N L S S V D R S Y G A F V D N L S H H 840

AFTGGCAGCACCCAGGTCCACCACTTGTTCGCGATCATTCGCGACTACAAGCTCAACGAAGCCACCAAGC
I G T H Q V H H L F P I I P H Y K L N E A T K 910

ACTTTGCGGCCGCGTACCGCACTCGTGTGCGAGGAACGACGAGCCCATCATCAGGCGCTTCTTCAAGAC
H F A A A Y P H L V R R N D E P I I T A F F K T 980

CGCGACCTCTTTGTCACTAGGCGCTGTGCCGAGACGCGCGAGATCTTCACGCTCAAAGAGTCGGCC
A H L F V N Y G A V P E T A Q I F T L K E S A 1050

T A AGC
GCGGCCGCCAAGGCCAAGTCGGACTAA 1077
A A A K A K S D .

127/1077

Figure 8




Figure 9




Figure 10




Figure 11





Figure 13






Figure 15




Figure 16